View Filing Data for SEC filing 0001477932-22-005454 (2022)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2022

CURE PHARMACEUTICAL HOLDING CORP.

(Exact name of registrant as specified in its charter)

Delaware

000-55908

37-1765151

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

1620 Beacon Place

Oxnard, California 93033

(Address of principal executive offices) (Zip Code)

(805) 824-0410

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry Into a Material Definitive Agreement.

Asset Purchase Agreement and Promissory Note

On July 22, 2022, CURE Pharmaceutical Corporation, a California corporation ("CURE Pharmaceutical”), a wholly-owned subsidiary of CURE Pharmaceutical Holding Corp. (the "Company”), entered into an Asset Purchase Agreement (the "APA”) by and between CURE Pharmaceutical and TF Tech Ventures, Inc., a Delaware corporation (the "Buyer”), pursuant to which Buyer purchased certain assets of CURE Pharmaceutical (the "Asset Sale”), including certain patents which the Company assigned to CURE Pharmaceutical prior to the closing of the Asset Sale. The Asset Sale closed simultaneously with the execution of the APA on July 22, 2022 (the "Closing”). Detailed information regarding the terms of the Asset Sale, including the particular assets sold to the Buyer, is set forth in the APA and the additional documents described in this Item 1.01.

The total consideration paid to CURE Pharmaceutical in connection with the Asset Sale was $20,000,000, which consisted of (i) the cancellation of indebtedness owed by Cure Pharmaceutical to the Buyer in an amount equal to $4,150,000, (iii) $2,000,000 payable in the form of a secured promissory note (the "Promissory Note”), and (iii) the remainder in cash (the "Closing Cash Consideration”). The Closing Cash Consideration was reduced by approximately (i) $18,000 of accrued PTO that Buyer assumed as a liability, and (ii) $23,000 in assumed liabilities under a purchase order that was transferred to Buyer at Closing.

The Promissory Note was issued by Buyer for the benefit of CURE Pharmaceutical in the principal amount of $2,000,000 and has a maturity date of July 22, 2023. The Promissory Note is subject to offset for indemnity claims made by Buyer under the APA. If there is a pending indemnity claim on July 22, 2023, the amount subject to the claim will not be paid to Cure Pharmaceutical, but will remain outstanding under the Promissory Note until the claim is resolved.

The APA contains customary indemnification provisions and customary representations, warranties and covenants by CURE Pharmaceutical and Buyer for transactions of this type. It also contains a three-year non-compete and non-solicitation provision applicable to CURE Pharmaceutical, and its affiliates, including the Company, in favor of Buyer.

Side Letter

Also on July 22, 2022, in connection with the Closing of the Asset Sale, the Company and Buyer entered into a side letter agreement (the "Side Letter”), pursuant to which the Company (i) made certain limited representations and warranties for the benefit of the Buyer, (ii) made covenants regarding the use of certain trademarks, tradenames, and brand names and logos related to the business of CURE Pharmaceutical (the "Purchased Marks”), including but not limited to the use of the "CURE” name and trademarks, as agreed by CURE Pharmaceutical in the APA, and (iii) made a covenant not to sue with respect to the patents identified in the Side Letter.

Guaranty

On July 22, 2022, in connection with the Closing, the Company made an absolute guaranty (the "Guaranty”) to and for the benefit of Buyer, and other Buyer Indemnitees (as defined therein), of full and timely payment when due of all amounts payable by CURE Pharmaceutical under the APA, which is only terminable upon indefeasible payment in full of the Obligations (as defined therein), which was completed at Closing.

Transition Services Agreement

On July 22, 2022, in connection with the Closing, CURE Pharmaceutical and Buyer entered into a transition services agreement (the "Transition Services Agreement”), pursuant to which CURE Pharmaceutical agreed to provide Buyer certain transition services until the earlier of January 20, 2023 and the date on which the terms for all of the services have expired or been terminated (the "Transition Period”).

2

Trademark License Agreement

On July 22, 2022, in connection with the Closing, the Company, CURE Pharmaceutical, and Buyer entered into a trademark license agreement (the "Trademark License Agreement”), pursuant to which Buyer agreed to allow CURE Pharmaceutical, the Company, and their affiliates to continue to use the Purchased Marks during the Transition Period to allow for both the performance of the services to be performed by CURE Pharmaceutical pursuant to the Transition Services Agreement and for an orderly wind-down of use of the Purchased Marks and rebranding by CURE Pharmaceutical, the Company, and their affiliates, including the use of "Powered by Cure” on products the Company purchased from CURE Pharmaceutical and the utilization of CURE Pharmaceutical’s technology.

The above descriptions of the APA, Promissory Note, Side Letter, Guaranty, Transition Services Agreement, and Trademark License Agreement are qualified in their entirety by reference to the APA, Promissory Note, Side Letter, Guaranty, Transition Services Agreement, and Trademark License Agreement, copies of which are filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, to this Current Report on Form 8-K, and incorporated herein by reference.

Press Release

On July 28, 2022, the Company issued a press release announcing the completion of the Asset Sale and the additional transactions described above. A copy of the press release is furnished hereto as Exhibit 99.1.

The information contained in Exhibit 99.1 is being furnished and shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Item 2.01 Completion of Acquisition or Disposition of Assets.

The information set forth in Item 1.01 above is incorporated by reference to this Item 2.01.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Directors

On July 22, 2022, John Bell resigned as a member of the Board of Directors of the Company (the "Board”), Chair of the Audit Committee, and member of the Compensation Committee. On July 22, 2022, Joshua Held resigned as a member of the Board and member of the Compensation Committee. On July 22, 2022, Ruben King-Shaw, Jr. resigned as Chair of the Board, member of the Audit Committee, and member of the Nominating and Corporate Governance Committee. The foregoing decisions to resign were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

In connection with the resignations by Messrs. Bell, Held, and King-Shaw, the Compensation Committee recommended, and the Board approved, the acceleration of the vesting of certain restricted stock units previously granted to Messrs. Bell, Held, and King-Shaw. As a result, the Board approved the acceleration of the vesting of an aggregate of 352,941 restricted stock units that were initially granted to these directors on September 23, 2021 pursuant to the Company’s non-employee director compensation policy, which were originally scheduled to vest on September 23, 2022, the one-year anniversary of the grant date.

Appointment of Director

Effective July 22, 2022, the Board appointed Gerald Bagg to serve as a member of the Board.

Mr. Bagg, 70, has over 45 years of experience in the advertising industry. In September 2002, Mr. Bagg co-founded Quigley-Simpson & Heppelwhite, Inc. ("Quigley-Simpson”), a full-service advertising agency specializing in strategic planning, marketing, media planning and buying, brand building, analytics, creative development, and production. Mr. Bagg served as Chief Executive Officer from September 2002 to July 2015, and currently serves as Co-Chairman since July 2015. Prior to establishing Quigley-Simpson, Mr. Bagg had an extensive advertising and marketing career beginning in 1976, which included senior executive positions with major global advertising agencies and retailers. Mr. Bagg received his B.A. and M.B.A. from the University of Witwatersrand, Johannesburg.

3

There are no family relationships between Mr. Bagg and any directors or executive officers of the Company. Additionally, there are no arrangements between Mr. Bagg and any other person pursuant to which he was selected to serve as a director. Finally, there are no transactions to which the Company is or was a participant and in which Mr. Bagg has a direct or indirect material interest subject to disclosure as a related party transaction under Item404(a)ofRegulation S-K.

Mr. Bagg will be compensated for his services on the Board in accordance with the Company’s standard non-employee director compensation policy.

Departure of Chief Executive Officer

On July 22, 2022, effective upon the Closing, Robert Davidson stepped down as Chief Executive Officer. Mr. Davidson will continue to serve as a member of the Board, and in connection with the Asset Sale, and pursuant to the Transition Services Agreement, Mr. Davidson shall be available to CURE Pharmaceutical for purposes of providing the Services (as defined in the Transition Services Agreement) to Buyer.

Prior to Mr. Davidson stepping down as Chief Executive Officer, on July 22, 2022, the Compensation Committee recommended, and the Board approved, a grant of 500,000 fully-vested shares of common stock pursuant to the Company’s 2017 Equity Incentive Plan (the "2017 Plan”). The grant was approved by the Board to reward Mr. Davidson for his exceptional service to the Company in connection with the completion of the Asset Sale.

Appointment of Chief Executive Officer

On July 22, 2022, the Board appointed Nancy Duitch to serve as the Company’s Chief Executive Officer and will continue to serve as a director.

Ms. Duitch, 67, has over 30 years of experience as an entrepreneur and leader in the consumer products industry.Ms. Duitch has served as a member of the Board and as the Company’s Chief Strategic Officer since October 2020. She has also served as the Chief Executive Officer of The Sera Labs, Inc., a Delaware corporation ("Sera Labs”), a wholly owned subsidiary of the Company, since July 2018. From August 2012 to October 2018, Ms. Duitch served as Chief Executive Officer of VisionWorx, LLC, a marketing agency. Ms. Duitch previously founded and served as Chief Executive Officer of Eyes Wide Open Corp and Vertical Branding, served as President and co-founder of One World Live, and served as Vice President of Sales at Kent and Spiegel. Ms. Duitch received her B.A. from Temple University.

There are no family relationships between Ms. Duitch and any directors or executive officers of the Company. Additionally, there are no arrangements between Ms. Duitch and any other person pursuant to which she was appointed as an executive officer.

In connection with the Closing, the Company repaid the following two loans made by the The Duitch Living Trust, of which Ms. Duitch is the trustee: (i) a senior secured loan with a principal amount of $42,233 issued on January 12, 2022, with an initial interest rate of 10%, a default interest rate of 12%, and an initial maturity date of April 11, 2022, which resulted in a total payoff amount of $44,554, and (ii) a junior secured loan with a principal amount of $1,052,268 issued on June 30, 2021, with an initial interest rate of 10%, a default interest rate of 12%, and an initial maturity date of April 15, 2022, which resulted in a total loan payoff amount of $1,166,374. Except as set forth above, there are no relationships involving Ms. Duitch that are required to be reported pursuant to Item404(a)ofRegulation S-K.

Departure of Chief Financial Officer

On July 22, 2022, effective upon the Closing, Michael Redard stepped down as Chief Financial Officer. In connection with the Asset Sale and pursuant to the Transition Services Agreement, Mr. Redard shall be available to CURE Pharmaceutical for purposes of providing the Services (as defined in the Transition Services Agreement) to Buyer.

4

Appointment of Chief Financial Officer

On July 22, 2022, the Board appointed Joel Bennett to serve as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer.

Mr. Bennett, 60, joined Sera Labs in May 2022 as a consultant serving asits Chief Financial Officer. Prior to that, Mr. Bennett served as the principal finance and accounting executive of Live Nation Merchandise LLC, the consumer products division of Live Nation Entertainment, Inc., a leading publicly-traded international entertainment company, from November 2019 to December 2021. From February 2019 to May 2020, Mr. Bennett served as Chief Financial Officer for Kori Capital, Inc., the related investment management and strategic advisory firm. From August 2018 to February 2019, he served as Chief Financial Officer for BlockHold Capital Corporation, an early-stage publicly-listed company providing fintech advisory services and products. Mr. Bennett was also Chief Financial Officer of JAKKS Pacific, Inc., a leading publicly-traded international designer and producer of children’s toys and related products and consumer products, from September 1995 to March 2018. Prior to that, Mr. Bennett held various financial management positions at The Walt Disney Company and Time Warner Entertainment Company. Mr. Bennett began his career at Ernst & Young LLP rising to Supervising Senior. Mr. Bennett received his B.S. in Accounting from San Diego State University and an M.B.A. in Finance from California State University, Northridge. Mr. Bennett is also a Certified Public Accountant.

There are no family relationships between Mr. Bennett and any directors or executive officers of the Company. Additionally, there are no arrangements between Mr. Bennett and any other person pursuant to which he was appointed to serve as an executive officer. Finally, there are no transactions to which the Company is or was a participant and in which Mr. Bennett has a direct or indirect material interest subject to disclosure as a related party transaction under Item404(a)ofRegulation S-K.

Mr. Bennett entered into an employment agreement (the "Employment Agreement”) with the Company, effective July 22, 2022. Pursuant to the terms of the Employment Agreement, Mr. Bennett will receive (i) an annual base salary of $220,000, and (ii) a grant of 200,000 stock options pursuant to the 2017 Plan. The term of employment under the Employment Agreement is a two-years commencing on July 22, 2022, with a one-year extension available, unless earlier terminated upon 30 days’ written notice by either the Company or Mr. Bennett. In the event Mr. Bennett’s employment is terminated by the Company without Cause (as defined in the Employment Agreement) or by Mr. Bennett for Good Reason (as defined in the Employment Agreement), Mr. Bennett will (i) receive an amount equal to one weeks’ salary for every month he has been employed by the Company, with a maximum total severance compensation equal to six months’ salary, (ii) receive accelerated vesting, full immediate vesting in the event of a Change of Control (as defined in the Employment Agreement), and one year accelerated vesting in the event of involuntary termination without Cause or voluntary termination for Good Reason, (iii) be granted a post-termination exercise period for vested stock options of one year from the anniversary of the date of the termination, (iv) receive one month of COBRA coverage for every four months of employment by the Company for a maximum of three months of COBRA premiums, and (v) be entitled to continue participating in employee welfare benefit plans for the shorter of six months or until he becomes eligible to participate in a benefit plan offered by another employer. The above description of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.7 to this Current Report on Form 8-K, and incorporated herein by reference.

Departure of Chief Accounting Officer

On July 22, 2022, effective upon the Closing, Mark Udell stepped down as Chief Accounting Officer. In connection with the Asset Sale and pursuant to the Transition Services Agreement, Mr. Udell shall be available to CURE Pharmaceutical for purposes of providing the Services (as defined in the Transition Services Agreement) to Buyer.

5

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

10.1

Asset Purchase Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer.

10.2

Promissory Note, dated July 22, 2022, issued by Buyer for the benefit of CURE Pharmaceutical.

10.3

Side Letter, dated July 22, 2022, by and between the Company and Buyer.

10.4

Guaranty, dated July 22, 2022, by and between the Company and Buyer.

10.5

Transition Services Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer.

10.6

Trademark License Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer.

10.7

Employment Agreement, dated July 22, 2022, by and between the Company and Joel Bennett.

99.1

Press Release, dated July 28, 2022, issued by the Company.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

6

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CURE PHARMACEUTICAL HOLDING CORP.

Dated: July 28, 2022

By:

/s/ Nancy Duitch

Nancy Duitch

Chief Executive Officer

7

EXHIBIT 10.1

ASSET PURCHASE AGREEMENT

between

CURE Pharmaceutical Corporation,

and

TF Tech Ventures, Inc.

dated as of

July 22, 2022

Table of Contents

Page

ARTICLE I PURCHASE AND SALE

2

Section 1.01

Purchase and Sale of Assets

2

Section 1.02

Assumption of Liabilities

2

Section 1.03

Purchase Price

2

Section 1.04

Third-Party Payments

3

Section 1.05

Loan Amount Payoff

3

Section 1.06

Allocation of Purchase Price

4

Section 1.07

Withholding Tax

4

ARTICLE II Closing

4

Section 2.01

Closing

4

Section 2.02

Closing Deliverables.

4

Section 2.03

Holdback Amount.

8

ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER

8

Section 3.01

Organization and Authority of Seller; Enforceability

8

Section 3.02

No Conflicts; Consents

9

Section 3.03

Title to Purchased Assets

9

Section 3.04

Condition and Sufficiency of Assets

9

Section 3.05

Inventory and Equipment

9

Section 3.06

Real Property.

10

Section 3.07

Intellectual Property.

11

Section 3.08

Assigned Contracts

14

Section 3.09

Permits

14

Section 3.10

Non-foreign Status

14

Section 3.11

Customers and Suppliers.

14

Section 3.12

Insurance

14

Section 3.13

Governmental Orders

15

Section 3.14

Compliance With Laws; Permits.

15

Section 3.15

Environmental Matters.

16

i

Table of Contents

(continued)

Page

Section 3.16

Employee Benefit Matters.

18

Section 3.17

Employee Matters.

21

Section 3.18

Legal Proceedings

23

Section 3.19

Taxes.

23

Section 3.20

Transaction with Related Parties

24

Section 3.21

Governmental Loan Programs.

24

Section 3.22

Regulatory Matters

25

Section 3.23

Brokers

26

Section 3.24

Full Disclosure

27

Section 3.25

Reliance

27

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER

27

Section 4.01

Organization and Authority of Buyer; Enforceability

27

Section 4.02

No Conflicts; Consents

27

Section 4.03

Brokers

27

Section 4.04

No Reliance

27

ARTICLE V COVENANTS

28

Section 5.01

Public Announcements

28

Section 5.02

Taxes.

28

Section 5.03

Non-Assignability of Assigned Contracts and Transferred Permits

28

Section 5.04

Interest in Intellectual Property; Use of Names.

29

Section 5.05

Employee Matters.

30

Section 5.06

Dissolution

32

Section 5.07

Intellectual Property Chain of Title

32

Section 5.08

Further Assurances

32

Section 5.09

Covenant Not to Sue

32

ARTICLE VI NON-COMPETITION; NON-SOLICITATION

33

Section 6.01

Non-Competition

33

Section 6.02

Non-Solicitation

33

ii

Table of Contents

(continued)

Page

Section 6.03

Power of Attorney for D.E.A. Registration

33

Section 6.04

Remedies

33

Section 6.05

Severability

34

ARTICLE VII INDEMNIFICATION

34

Section 7.01

Survival

34

Section 7.02

Taxes

34

Section 7.03

Fundamental Representations

34

Section 7.04

Indemnification By Seller

35

Section 7.05

Indemnification By Buyer

36

Section 7.06

Certain Limitations

36

Section 7.07

Indemnification Procedures.

37

Section 7.08

Tax Treatment of Indemnification Payments

38

Section 7.09

Effect of Investigation

38

Section 7.10

Cumulative Remedies

38

ARTICLE VIII MISCELLANEOUS

38

Section 8.01

Expenses

38

Section 8.02

Notices

39

Section 8.03

Headings

39

Section 8.04

Severability

39

Section 8.05

Entire Agreement

39

Section 8.06

Successors and Assigns

39

Section 8.07

No Third-party Beneficiaries

40

Section 8.08

Amendment and Modification

40

Section 8.09

Waiver

40

Section 8.10

Governing Law

40

Section 8.11

Submission to Jurisdiction

40

Section 8.12

Waiver of Jury Trial

40

Section 8.13

Specific Performance

40

Section 8.14

Counterparts

40

iii

SCHEDULES

Schedule 1.01

Purchased Assets

Schedule 1.02

Assumed Liabilities

Schedule 1.03

(a) Loan Amount

Schedule 1.03(b)

Adjustment Items and Wire Transfer Instructions

Schedule 1.04

Repaid Indebtedness

Schedule 2.02(a)(v)

Required Consents

Schedule 2.02(a)(xi)

Key Employees

Schedule 5.05(a)-1

Job Titles and Salary/Annual Pay for Active Employees

Schedule 5.05(a)-2

Job Titles and Salary/Annual Pay for Inactive Employees

Schedule 5.07

Affected Patents

Schedule 5.09

Referenced Patents

Disclosure Schedules

EXHIBITS

Exhibit A

Holdback Note

Exhibit B

Bill of Sale

Exhibit C

Assignment and Assumption Agreement

Exhibit D

Intellectual Property Assignment

Exhibit E

Employment Agreement

Exhibit F

Transition Services Agreement

Exhibit G

Trademark License Agreement

Exhibit H

Guaranty Agreement

Exhibit I

Parent Side Letter

1

ASSET PURCHASE AGREEMENT

This Asset Purchase Agreement (this "Agreement”), dated as of July 22, 2022, is entered into between CURE Pharmaceutical Corporation, a California corporation ("Seller”), and TF Tech Ventures, Inc., a Delaware corporation ("Buyer”).

RECITALS

A. Seller is engaged in the business of the developing and manufacturing of drug delivery platforms and devices, dietary supplement products and pharmaceutical products, including, without limitation, CUREcream, CUREdrops, CUREfilm, CUREform, CUREpods, and Sildenafil Citrate (the "Business”); and

B. Seller wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from Seller, the rights and obligations of Seller to the Purchased Assets and the Assumed Liabilities (as defined herein), subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE I

PURCHASE AND SALE

Section 1.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, all of Seller’s right, title and interest in the assets set forth on Schedule 1.01 attached hereto (the "Purchased Assets”), free and clear of any mortgage, pledge, lien, charge, security interest, claim or other encumbrance ("Encumbrance”).

Section 1.02 Assumption of Liabilities. Subject to the terms and conditions set forth herein, Buyer shall assume and agree to pay, perform and discharge the liabilities and obligations set forth on Schedule 1.02, but only to the extent that (i)such liabilities and obligations do not relate to any breach, default or violation by Seller on or prior to the Closing or (ii)notwithstanding execution and delivery of the Assignment and Assumption of Lease, such liabilities and obligations do not relate to any amounts due or claimed to be due under the lease referenced therein for or relating to any period before Closing (collectively, the "Assumed Liabilities”). Other than the Assumed Liabilities, Buyer shall not assume any liabilities or obligations of Seller or the Business of any kind, whether known or unknown, contingent, matured or otherwise, whether currently existing or hereinafter created (collectively, the "Excluded Liabilities”).

Section 1.03 Purchase Price. The aggregate purchase price for the Purchased Assets shall be $20,000,000 (the "Purchase Price”), which shall be paid by wire transfer to a bank account designated by Seller, by cancellation of indebtedness of the Seller to Buyer, by issuance of a secured promissory note in a principal amount not to exceed $2,000,000, or any combination of such methods in accordance with the terms of this Section 1.03. Subject to the terms and conditions of this Agreement, the Buyer shall pay the Purchase Price as follows:

(a) An amount equal to $4,150,000 of the Purchase Price shall be paid by cancellation of the indebtedness owed from Seller to Buyer set forth on Schedule 1.03(a) (the "Loan Amount”);

2

(b) A total amount equal to $15,850,000 of the Purchase Price, minus the Holdback Amount, minus the aggregate dollar amount of Rolled Vacation and the employer-portion of any payroll, employment and other similar taxes applicable thereto set forth on Schedule 1.03(b), minus $22,500 assumed by Buyer at the Closing as Assumed Liabilities related to a commercial purchase order set forth on Schedule 1.03(b), will be paid to Seller on the Closing Date in cash, by wire transfer of immediately available funds in accordance with the wire transfer instructions set forth in Schedule 1.03(b) (the "Closing Consideration”); and

(c) The issuance and delivery to Seller of a secured promissory note with a principal amount of $2,000,000 payable to Seller, in the form of Exhibit A hereto (the "Holdback Note”), duly executed by Buyer.

Section 1.04 Third-Party Payments. Immediately following receipt of the Closing Consideration, Seller will initiate wires to make payment, by wire transfer of immediately available funds, of (i) the "Payoff Amounts” due pursuant to the payoff letters which Seller delivered to Buyer prior to the date hereof, in accordance with the wire instructions set forth in such payoff letters, for each item of indebtedness set forth on Schedule 1.04(i), (ii) Seller’s pro rata portion of the first months’ (i.e., July 2022) rent due at Closing under the Assignment and Assumption of Lease, which amount is set forth on Schedule 1.04(ii) to the Landlord, (iii) any overdue rent, overage, interest, fine and penalty set forth in Section 3.06(b)(ii) of the Disclosure Schedules to the Landlord, and (iv) the equipment lease buyout amount set forth in Schedule 1.04(iv) to VideoJet Technologies LTD. Immediately following receipt of the Buyer Lease Payments, Seller will initiate a wire to make payment, by wire transfer of immediately available funds, of the total amount of Buyer Lease Payments to the Landlord.

Section 1.05 Loan Amount Payoff. Buyer hereby (a) acknowledges and agrees that at the Closing the Loan Amount shall be automatically cancelled by Buyer, and such cancellation will constitute payment in full and complete satisfaction of all of the Company’s indebtedness and obligations to Buyer of any amounts advanced to Seller by Buyer prior to the Closing (the "Cancelled Indebtedness”), and (b) agree that, effective upon the Closing, (i) all of the Cancelled Indebtedness shall be automatically satisfied in full and irrevocably and automatically discharged, terminated and released, (ii) all the security interests, mortgages, liens, pledges, charges and other encumbrances, if any, in Buyer’s or any of its Affiliate’s favor to secure the Cancelled Indebtedness shall be automatically released with no further action on Seller’s part, and (iii) if any Uniform Commercial Code ("UCC”) statements were filed in connection with the Cancelled Indebtedness, Buyer, on its and its Affiliates’ behalf, hereby authorizes the Seller, or any other party on behalf of the Seller, to prepare and file any UCC termination statements or other documents necessary to evidence the release of any lien in any of the Seller’s properties or assets (and to do so without Buyer’s or its Affiliates’ signatures or further consent). Buyer further agree to procure, execute and deliver to the Seller, from time to time, all further releases, termination statements, certificates, instruments, and documents, and to take any other actions, in each case as may be reasonably requested by the Seller or which are required to evidence the consummation of the payoff, discharge, release, termination or any other actions contemplated by this Section 1.04.

3

Section 1.06 Allocation of Purchase Price. Seller and Buyer agree that the Purchase Price shall be allocated among the Purchased Assets for all purposes (including tax and financial accounting) as shown on the allocation schedule (the "Allocation Schedule”). A draft of the Allocation Schedule shall be prepared by Buyer and delivered to Seller within 60 days following the Closing Date. If Seller notifies Buyer in writing that Seller objects to one or more items reflected in the Allocation Schedule, Seller and Buyer shall negotiate in good faith to resolve such dispute; provided, however, that if Seller and Buyer are unable to resolve any dispute with respect to the Allocation Schedule within 90 days following the Closing Date, such dispute shall be resolved by an impartial nationally recognized firm of independent certified public accountants other than Seller’s or Buyer’s accountants. The fees and expenses of such accounting firm shall be borne equally by Seller and Buyer. Buyer and Seller shall file all Tax Returns (including amended returns and claims for refund) and information reports in a manner consistent with the Allocation Schedule. Any adjustments to the Purchase Price shall be reported in a manner consistent with the Allocation Schedule.

Section 1.07 Withholding Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer may be required to deduct and withhold under any applicable Tax law. All such withheld amounts shall be treated as delivered to Seller hereunder.

ARTICLE II

CLOSING

Section 2.01 Closing. The closing of the transactions contemplated by this Agreement (the "Closing”) shall take place simultaneously with the execution of this Agreement on the date of this Agreement (the "Closing Date”) remotely by exchange of documents and signatures (or their electronic counterparts). The consummation of the transactions contemplated by this Agreement shall be deemed to occur at 12:01 a.m. on the Closing Date.

Section 2.02 Closing Deliverables.

(a) At the Closing, Seller shall deliver to Buyer the following:

(i) a bill of sale in the form of Exhibit B hereto (the "Bill of Sale”) and duly executed by Seller, transferring the Purchased Assets to Buyer;

(ii) an assignment and assumption agreement in the form of Exhibit C hereto (the "Assignment and Assumption Agreement”) and duly executed by Seller, effecting the assignment to and assumption by Buyer of the Purchased Assets and the Assumed Liabilities;

(iii) an assignment in the form of Exhibit D hereto (the "Intellectual Property Assignment”) and duly executed by Seller, transferring all of Seller’s right, title and interest in and to the trademark registrations and applications, patents and patent applications, copyright registrations and applications and domain name registrations included in the Purchased IP (as defined herein) to Buyer;

4

(iv) an Assignment and Assumption of Lease in form and substance satisfactory to Buyer (the "Assignment and Assumption of Lease”) and duly executed by Seller;

(v) unless waived in writing by Buyer in its sole discretion, copies of all consents, approvals, waivers and authorizations referred to on Schedule 2.02(a)(v);

(vi) a duly completed and executed IRS Form W-9 of Seller;

(vii) a good standing certificate of Seller from the California Franchise Tax Board;

(viii) a certificate of the Secretary of Seller certifying as to (A) the resolutions of the board of directors of Seller, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and the transactions contemplated hereby; and (B) the names and signatures of the officers of Seller authorized to sign this Agreement and the documents to be delivered hereunder;

(ix) such evidence as Buyer may reasonably request, to evidence that all Deferred Compensation has been paid in full or will be paid in full by Seller at the Closing;

(x) such evidence as Buyer may reasonably request, to evidence that the Purchased Assets are free and clear of all Encumbrances, including, but not limited to, UCC termination statements with respect to all UCC-1 financing statements filed with respect to any Purchased Asset, cancellation or termination of any loan guarantees, etc.;

(xi) the Key Employees shall have executed employment agreements with Buyer, in the form of Exhibit E hereto ("Employment Agreements”) and effective as of the Hire Date (as defined below). For purposes of this Agreement, "Key Employees” means those individuals listed on Schedule 2.02(a)(xi);

(xii) the active employees of Seller other than the Key Employees shall have executed offer letters with the Buyer (the "Employee Offer Letters”), effective as of the Hire Date;

(xiii) the guaranty agreement in the form of Exhibit H hereto (the "Guaranty Agreement”), duly executed by CURE Pharmaceutical Holding, Corp., a Delaware corporation (the "Parent”);

5

(xiv) such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Buyer, as may be required to give effect to this Agreement;

(xv) the transition services agreement in the form of Exhibit F hereto (the "Transition Services Agreement”), duly executed by Seller;

(xvi) the trademark license agreement in the form of Exhibit G hereto (the "Trademark License Agreement”), duly executed by Seller;

(xvii) a copy of an executed payoff letter in form and substance reasonably satisfactory to Buyer from each creditor with respect to the security interest identified in Section 3.03 of the disclosure schedules ("Disclosure Schedules”), which payoff letter shall (i) indicate the aggregate amount required to be paid to such creditor on the Closing Date (including the outstanding principal amount, accrued and unpaid interest and any premium, penalty, prepayment fee, expense, breakage cost or other payment required to be made with respect to such indebtedness) in order to fully discharge all obligations with respect to such indebtedness, and provide wire transfer information for such payment, (ii) state that upon receipt of the amount described in clause "(i)” above, the instruments evidencing such indebtedness shall be terminated and (iii) state that all liens and all guarantees in connection therewith relating to the assets and properties of Seller securing such indebtedness, if any, shall be, upon the payment of the amount described in clause "(i)” above on the Closing Date, released and terminated;

(xviii) a UCC-3 termination statement terminating the security interests of each Person holding a security interest in the assets of Seller in connection with the incurrence of the indebtedness referred to in clause "(xviii)” above;

(xix) the Power of Attorney duly executed by Seller;

(xx) the Side Letter (the "Parent Side Letter”) in the form of Exhibit I hereto, duly executed by Parent; and

(xxi) a certificate of the Secretary of Parent certifying as to the resolutions of the board of directors of Parent, duly adopted and in effect, which authorize the execution, delivery and performance of the Guaranty Agreement, the Parent Side Letter, the Trademark License Agreement by Parent and the transactions contemplated thereby and the execution, delivery and performance of this Agreement by Seller and the transactions contemplated hereby.

(b) At the Closing, Buyer shall deliver to Seller the following:

(i) the Closing Consideration by wire transfer of immediately available funds to an account designated in writing by Seller to Buyer no later than two days prior to the Closing Date;

6

(ii) the Assignment and Assumption Agreement duly executed by Buyer;

(iii) the Assignment and Assumption of Lease duly executed by Buyer;

(iv) a certificate of the Secretary or Assistant Secretary (or equivalent officer) of Buyer certifying as to (A) the resolutions of the board of directors of Buyer, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and the transactions contemplated hereby; and (B) the names and signatures of the officers of Buyer authorized to sign this Agreement and the documents to be delivered hereunder;

(v) the Parent Side Letter duly executed by Buyer;

(vi) the Employment Agreements, duly executed by Buyer;

(vii) the Employee Offer Letters, duly executed by Buyer;

(viii) the Transition Services Agreement in the form of Exhibit F hereto duly executed by Buyer; and

(ix) the Trademark License Agreement in the form of Exhibit G hereto, duly executed by Buyer.

(c) Other than any Assumed Liabilities, at the Closing, Seller shall have paid in full any and all compensation that has been earned by the employee, officer, director, independent contractor or consultant of the Business in their capacity as such, but is unpaid as of the Closing including any compensation that has been earned but deferred; but excluding regular wages earned by any employee during the then-current payroll period. For the avoidance of doubt, Seller and Buyer agree that Seller will be liable for all Liabilities of Seller with respect to the employees and independent contractors of Seller (including all Continuing Employees) to the extent arising or accruing prior to the Closing Date (or arising out of or relating to facts and circumstances existing or occurring prior to the Closing Date) including any payroll, employment and other similar Taxes imposed with respect to any payments of compensation to employees and independent contractors arising in connection with the transactions contemplated by this Agreement, regardless of whether arising on or before the Closing.

(d) At the Closing, Buyer shall pay to Seller, for prompt payment to George S. Stern and Adele R. Stern, Trustees of the Stern Living Trust Dated February 27, 1985 (the "Landlord”) in accordance with Section 1.04, by wire transfer of immediately available funds which may be made as one aggregated wire transfer together with the Closing Consideration to an account designated in writing by Seller to Buyer, an amount of (i) $72,120.00 in additional security deposit in the connection with the assignment of the Leases to Buyer, and (ii) $9,458.00 as Buyer’s pro rata portion of the first month’s (i.e. July 2022) rent (collectively, the "Buyer Lease Payments”). For the avoidance of doubt, payment of such amounts shall not result in any adjustment to the Purchase Price hereunder.

7

Section 2.03 Holdback Amount.

(a) Buyer shall deliver to Seller at the Closing the Holdback Note, in the principal amount of $2,000,000.00 (the "Holdback Amount”), to be held and disbursed in accordance with this Section 2.03.

(b) On the date that is 12 months after the Closing Date, Buyer shall pay to Seller, by wire transfer of immediately available funds to an account designated in advance by Seller, an amount from the Holdback Amount equal to (i) $2,000,000.00, minus (ii) the amount of any Losses previously deducted from the Holdback Amount pursuant to ARTICLE VII, minus (iii) the aggregate amount of any Pending Claims at such time. With respect to each such Pending Claim, if the final resolved amount of Losses recoverable in respect of such Pending Claim is less than the amount retained for such Pending Claim, Buyer shall remit to Seller the excess of the amount retained in respect of such Pending Claim over the final resolved amount due for such claim (such amount, "Retained Excess”) (provided, however, in no event shall the amount of any Retained Excess exceed the difference of the Holdback Amount at such time minus the aggregate amount of any Pending Claims at such time).

"Pending Claims” means claims made in accordance with ARTICLE VII for recovery of Losses pursuant to Section 7.04 that are pending at any time before the relevant expiration periods in Section 7.01, 7.02, and 7.03.

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF SELLER

Except as set forth in the Disclosure Schedules, Seller represents and warrants to Buyer that the statements contained in this ARTICLE III are true and correct as of the date hereof.

Section 3.01 Organization and Authority of Seller; Enforceability. Seller is a corporation duly organized, validly existing and in good standing under the laws of the state of California. Seller has full corporate power and authority to enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by Seller of this Agreement and the documents to be delivered hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of Seller. This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement and the documents to be delivered hereunder constitute legal, valid and binding obligations of Seller, enforceable against Seller in accordance with their respective terms.

8

Section 3.02 No Conflicts; Consents. The execution, delivery and performance by Seller of this Agreement and the documents to be delivered hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws or other organizational documents of Seller; (b) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Seller or the Purchased Assets; (c) conflict with, or result in (with or without notice or lapse of time or both) any violation of, or default under, or give rise to a right of termination, acceleration or modification of any obligation or loss of any benefit under any contract or other instrument to which Seller is a party or to which any of the Purchased Assets are subject; or (d) result in the creation or imposition of any Encumbrance on the Purchased Assets. No consent, approval, waiver or authorization is required to be obtained by Seller from any Person (including any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of law), or any arbitrator, court or tribunal of competent jurisdiction ("Governmental Authority”) in connection with the execution, delivery and performance by Seller of this Agreement and the consummation of the transactions contemplated hereby. "Affiliate” of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term "control” (including the terms "controlled by” and "under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For purposes of this Agreement, "Person” means an individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, unincorporated organization, association, organization or other entity or form of business enterprise or Governmental Authority.

Section 3.03 Title to Purchased Assets. Seller owns and has good title to the Purchased Assets, free and clear of Encumbrances.

Section 3.04 Condition and Sufficiency of Assets. The tangible personal property included in the Purchased Assets is in good condition and is adequate for the uses to which it is being put, and none of such tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost. Together with the services provided under the Transition Services Agreement, the Purchased Assets are sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets necessary to conduct the Business as currently conducted as of the Closing Date. None of the Excluded Assets are material to the Business as conducted by Seller on the Closing Date (which is consistent with past practice).

Section 3.05 Inventory and Equipment. All inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories included in the Purchased Assets ("Inventory”) consist of a quality and quantity usable, salable in the ordinary course of business, and Manufactured in accordance with the applicable Regulatory Submission and applicable Regulatory Laws (as such terms are defined in Section 3.22 hereof), including without limitation any applicable good manufacturing practice ("GMP”) requirements. All tangible personal property included in the Purchased Assets required for Seller’s Manufacturing operations ("Equipment”) is in good operating condition and otherwise meeting applicable cGMP standards, and adequate for the uses to which they are being put, and none of such assets is in need of maintenance or repairs except for ordinary, routine maintenance and repairs or cleaning.

9

Section 3.06 Real Property.

(a) Section 3.06 of the Disclosure Schedules sets forth each parcel of real property owned by Seller and used in or necessary for the conduct of the Business as currently conducted (together with all buildings, fixtures, structures and improvements situated thereon and all easements, rights-of-way and other rights and privileges appurtenant thereto, collectively, the "Owned Real Property”), including with respect to each property, the address location and use. Seller has delivered to Buyer copies of the deeds and other instruments (as recorded) by which Seller acquired such parcel of Owned Real Property, and copies of all title insurance policies, opinions, abstracts and surveys in the possession of Seller with respect to such parcel. With respect to each parcel of real property:

(i) Seller has good and marketable fee simple title, free and clear of all Encumbrances;

(ii) Seller has not leased or otherwise granted to any Person the right to use or occupy such Owned Real Property or any portion thereof; and

(iii) there are no unrecorded outstanding options, rights of first offer or rights of first refusal to purchase such Owned Real Property or any portion thereof or interest therein.

(b) Section 3.06(b) of the Disclosure Schedules sets forth each parcel of real property leased by Seller and used in or necessary for the conduct of the Business as currently conducted (together with all rights, title and interest of Seller in and to leasehold improvements relating thereto, including, but not limited to, security deposits, reserves or prepaid rents paid in connection therewith, collectively, the "Leased Real Property”), and a true and complete list of all leases, subleases, licenses, concessions and other agreements (whether written or oral), including all amendments, extensions renewals, guaranties and other agreements with respect thereto, pursuant to which Seller holds any Leased Real Property (collectively, the "Leases”). Seller has delivered to Buyer a true and complete copy of each Lease. With respect to each Lease:

(i) such Lease is valid, binding, enforceable and in full force and effect, and Seller enjoys peaceful and undisturbed possession of the Leased Real Property;

(ii) Seller is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, passage of time or both, would constitute such a breach or default, and Seller has paid all rent due and payable under such Lease;

10

(iii) Seller has not received nor given any notice of any default or event that with notice or lapse of time, or both, would constitute a default by Seller under any of the Leases and no other party is in default thereof, and no party to any Lease has exercised any termination rights with respect thereto;

(iv) Seller has not subleased, assigned or otherwise granted to any Person the right to use or occupy such Leased Real Property or any portion thereof; and

(v) Seller has not pledged, mortgaged or otherwise granted an Encumbrance on its leasehold interest in any Leased Real Property.

(c) Seller has not received any written notice of (i) violations of building codes and/or zoning ordinances or other governmental or regulatory laws affecting the real property, (ii) existing, pending or threatened condemnation proceedings affecting the real property, or (iii) existing, pending or threatened zoning, building code or other moratorium proceedings, or similar matters which could reasonably be expected to adversely affect the ability to operate the real property as currently operated. Neither the whole nor any portion of any real property has been damaged or destroyed by fire or other casualty.

(d) The real property is sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitutes all of the real property necessary to conduct the Business as currently conducted.

Section 3.07 Intellectual Property.

(a) "Intellectual Property” means any and all of the following in any jurisdiction throughout the world: (i) trademarks and service marks, including all applications and registrations thereof, trade names, trade dress, brand names, and other indicia of source of origin, whether or not registered, logos and the goodwill connected with the use of and symbolized by any of the foregoing; (ii) published and unpublished works of authorship, copyrights, including all applications and registrations related to the foregoing, databases, computer source code, object code, executable code, programs and other software (including machine readable code, printed listings of code, software documentation and related property and information, whether embodied in software, firmware or otherwise); (iii) trade secrets, including without limitation, rights granted under the Uniform Trade Secrets Act, and confidential know-how; (iv) inventions (whether patentable or unpatentable and whether or not reduced to practice) and all improvements thereto, technology, formulas, know-how, confidential information, tangible and intangible proprietary information or materials, including, production processes and techniques, research and development information, technology, drawings, specifications, designs, plans, proposals and technical data, patents and patent applications filed, applications to be filed, renewals, reissues, reexaminations, divisionals, continuations, and continuations in part; (v) websites and internet domain name registrations; and (vi) other intellectual property and related proprietary rights, interests and protections (including all rights to sue and recover and retain damages, costs and attorneys’ fees for past, present and future infringement and any other rights relating to any of the foregoing).

11

(b) Section 3.07(b) of the Disclosure Schedules lists all of the Registered Intellectual Property which is included in the Purchased Assets, including: (i) all United States and foreign issued design, and utility patents, all pending patent applications filed by or on behalf of Seller with a Governmental Authority relating to any inventions or designs and all renewals, reissues, divisionals, continuations, continuations-in-part and extensions of the foregoing; (ii) all registered trademarks and service marks and all trademark and service mark applications filed by or on behalf of Seller with a Governmental Authority, and all trade names, corporate business and product names, logos and unregistered trademarks and service marks; (iii) all copyrights that have been registered, and all copyright applications filed by or on behalf of Seller with a Governmental Authority, and all renewals and extensions thereof; and (iv) all rights in internet websites, internet domain name registrations, social media names and keywords. "Registered Intellectual Property” means any Intellectual Property owned by Seller that is the subject of an application or registration with any governmental authority, including any domain name registration and any application or registration for any patent, copyright, mask work or trademark.

(c) With respect to the Registered Intellectual Property listed on Section 3.07(b) of the Disclosure Schedules, (i) all such Intellectual Property is valid, subsisting and in full force and effect; Seller has obtained all assignments required to transfer ownership of such Intellectual Property to Seller; (ii) Seller has filed all documents with Governmental Authorities, including relevant assignments, to evidence Seller is the recorded owner of all such Intellectual Property; and (iii) Seller has paid all maintenance fees and made all filings required to maintain Seller’s ownership thereof. For all such Registered Intellectual Property, Section 3.07(b) of the Disclosure Schedules lists (A) the jurisdiction where the application or registration is located; (B) the application or registration number; (C) the application or registration date; (D) the record owner, and if different, the legal owner; and (E) in the case of domain name registrations, the applicable registrar and expiration date.

(d) Seller owns or has adequate, valid and enforceable rights to use, make, have made, sell, offer to sell, import, reproduce, display, perform, create derivative works, or distribute all the Purchased IP, free and clear of all Encumbrances. Seller is not bound by any outstanding judgment, injunction, order or decree restricting the use of the Purchased IP, or restricting the licensing thereof to any Person. No Seller Intellectual Property right is or has been judicially determined to be invalid or unenforceable and there is no reasonable basis for any claim that any Seller Intellectual Property right is invalid or unenforceable. "Purchased IP” means all of the Intellectual Property of the Seller which relates to, or is used or held for use primarily in connection with the Business.

12

(e) Section 3.07(e) of the Disclosure Schedules contains a correct, current and complete list of all Intellectual Property Agreements relating to the Purchased Assets, specifying for each the date, title, and parties thereto, and separately identifying the Intellectual Property Agreements: (i) under which Seller is a licensor or otherwise grants to any Person any right or interest relating to any Purchased IP; (ii) under which Seller is a licensee or otherwise granted any right or interest relating to the Intellectual Property of any Person; and (iii) which otherwise relate to Seller’s ownership or use of any Intellectual Property in the conduct of the Business as currently conducted, in each case identifying the Intellectual Property covered by such Intellectual Property Agreement. Seller has provided Buyer with true and complete copies (or in the case of any oral agreements, a complete and correct written description) of all such Intellectual Property Agreements, including all modifications, amendments and supplements thereto and waivers thereunder. Each Intellectual Property Agreement is legal, valid, binding, and enforceable on all parties thereto in accordance with its terms and is in full force and effect. Neither Seller nor any other party thereto is, or is alleged to be, in breach of or default under, or has provided or received any notice of breach of, default under, or intention to terminate (including by non-renewal), any Intellectual Property Agreement. For purposes of this Section 3.07(e), "Intellectual Property Agreements” means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to sue, waivers, releases, permissions and other contracts, whether written or oral, relating to any Purchased IP to which Seller is a party, beneficiary or otherwise bound.

(f) Section 3.07(f) of the Disclosure Schedules lists all Intellectual Property of Seller and/or used in the Business that is not included in the Purchased Assets other than commercially available, off-the-shelf licenses for executable software ("Excluded IP”). The conduct of the Business by Seller as presently conducted does not infringe, violate, dilute or misappropriate the Intellectual Property of any Person and there are no judicial, regulatory, or administrative proceedings, or claims pending or threatened by any Person with respect to the ownership, validity, enforceability, effectiveness or use of the Purchased IP.

(g) No Person is infringing, misappropriating, diluting or otherwise violating any of the Purchased IP, and neither Seller nor any Affiliate of Seller has made or asserted any claim, demand or notice against any Person alleging any such infringement, misappropriation, dilution or other violation.

(h) Seller has at all times taken commercially reasonable measures, consistent with industry practice, to protect the confidentiality of trade secrets included in Seller Intellectual Property, and all other material confidential and proprietary information of Seller, including requiring all employees and third Persons having access thereto to execute written non-disclosure agreements or otherwise validly agree to non-disclosure obligations. All current and former employees and independent contractors who have contributed to or created any portion of, or otherwise have any rights in or to, any Purchased IP have validly and effectively assigned such rights to Seller.

13

Section 3.08 Assigned Contracts. Section 3.08 of the Disclosure Schedules includes each contract included in the Purchased Assets and being assigned to and assumed by Buyer (the "Assigned Contracts”). Each Assigned Contract is valid and binding on Seller in accordance with its terms and is in full force and effect. None of Seller or any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Assigned Contract. No event or circumstance has occurred that, with or without notice or lapse of time or both, would constitute an event of default under any Assigned Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of benefit thereunder. Complete and correct copies of each Assigned Contract have been made available to Buyer. There are no disputes pending or threatened under any Assigned Contract.

Section 3.09 Permits. Section 3.09 of the Disclosure Schedules lists all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained from Governmental Authorities ("Permits”) included in the Purchased Assets (the "Transferred Permits”). The Transferred Permits are valid and in full force and effect. All fees and charges with respect to such Transferred Permits as of the date hereof have been paid in full. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse or limitation of any Transferred Permit.

Section 3.10 Non-foreign Status. Seller is not a "foreign person” as that term is used in Treasury Regulations Section 1.1445-2.

Section 3.11 Customers and Suppliers.

(a) Section 3.11(a) of the Disclosure Schedules sets forth with respect to the Business (i) each customer who has paid aggregate consideration to Seller for goods or services rendered in an amount greater than or equal to $50,000 for each of the two (2) most recent fiscal years (collectively, the "Material Customers”); and (ii) the amount of consideration paid by each Material Customer during such periods. Seller has not received any notice, and has no reason to believe, that any of the Material Customers has ceased, or intends to cease after the Closing, to use the goods or services of the Business or to otherwise terminate or materially reduce its relationship with the Business.

(b) Section 3.11(b) of the Disclosure Schedules sets forth with respect to the Business (i) each supplier to whom Seller has paid aggregate consideration for goods or services rendered in an amount greater than or equal to $50,000 for each of the two (2) most recent fiscal years (collectively, the "Material Suppliers”); and (ii) the amount of purchases from each Material Supplier during such periods. Seller has not received any notice, and has no reason to believe, that any of the Material Suppliers has ceased, or intends to cease, to supply goods or services to the Business or to otherwise terminate or materially reduce its relationship with the Business.

14

Section 3.12 Insurance. Section 3.12 of the Disclosure Schedules sets forth (a) a true and complete list of all current policies or binders of fire, liability, product liability, umbrella liability, real and personal property, workers’ compensation, vehicular, fiduciary liability and other casualty and property insurance maintained by Seller or its Affiliates and relating to the Business, the Purchased Assets or the Assumed Liabilities (collectively, the "Insurance Policies”); and (b) with respect to the Business, the Purchased Assets or the Assumed Liabilities, a list of all pending claims and the claims history for Seller during the three-year period prior to the Closing Date. There are no claims related to the Business, the Purchased Assets or the Assumed Liabilities pending under any such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. Neither Seller nor any of its Affiliates has received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such Insurance Policies. All premiums due on such Insurance Policies have either been paid or, if not yet due, accrued. All such Insurance Policies (a) are in full force and effect and enforceable in accordance with their terms; (b) are provided by carriers who are financially solvent; and (c) have not been subject to any lapse in coverage. None of Seller or any of its Affiliates is in default under, or has otherwise failed to comply with any provision contained in any such Insurance Policy. The Insurance Policies are of the type and in the amounts customarily carried by Persons conducting a business similar to the Business and are sufficient for compliance with all applicable laws and contracts to which Seller is a party or by which it is bound. True and complete copies of the Insurance Policies have been made available to Buyer.

Section 3.13 Governmental Orders. Except as set forth in Section 3.13 of the Disclosure Schedules, there are no outstanding governmental orders and no unsatisfied judgments, penalties or awards against, relating to or affecting the Business, the Purchased Assets or the Assumed Liabilities. Seller is in compliance with the terms of each governmental order set forth in Section 3.13 of the Disclosure Schedules. No event has occurred or circumstances exist that may constitute or result in (with or without notice or lapse of time) a violation of any such governmental order.

Section 3.14 Compliance With Laws; Permits.

(a) Seller has complied, and is currently complying, with all applicable federal, state and local laws and regulations applicable to ownership and use of the Purchased Assets.

(b) All Permits required for Seller to conduct the Business as currently conducted or for the ownership and use of the Purchased Assets have been obtained by Seller and are valid and in full force and effect, and not subject to an existing challenge or appeal. All fees and charges with respect to such Permits as of the date hereof have been paid in full. Section 3.14(b) of the Disclosure Schedules lists all Permits issued to Seller which are related to the conduct of the Business as currently conducted or the ownership and use of the Purchased Assets, including the names of the Permits, the issuing authority, and their respective dates of issuance and expiration. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse, termination or limitation of any Permit set forth in Section 3.14(b) of the Disclosure Schedules.

15

Section 3.15 Environmental Matters.

(a) The operations of Seller with respect to the Business and the Purchased Assets are currently and have been in compliance with all Environmental Laws. Seller has not received from any Person, with respect to the Business or the Purchased Assets, any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements as of the Closing Date.

(b) Seller has obtained and is in compliance with all Environmental Permits (each of which is disclosed in Section 3.15(b) of the Disclosure Schedules) necessary for the conduct of the Business as currently conducted or the ownership, lease, operation or use of the Purchased Assets and all such Environmental Permits are in full force and effect and shall be maintained in full force and effect by Seller through the Closing Date in accordance with Environmental Law, and Seller is not aware of any condition, event or circumstance that might prevent or impede, after the Closing Date, the conduct of the Business as currently conducted or the ownership, lease, operation or use of the Purchased Assets, or result in liability under any Environmental Law. With respect to any such Environmental Permits, Seller has undertaken, or will undertake prior to the Closing Date, all measures necessary to facilitate transferability of the same, and Seller is not aware of any condition, event or circumstance that might prevent or impede the transferability of the same, and has not received any Environmental Notice or written communication regarding any adverse change in the status or terms and conditions of the same. After the Closing Date, Seller will provide reasonable cooperation to Buyer and the issuing authority of any Environmental Permit to transfer any Environmental Permit not so transferred by the Closing Date.

(c) None of the Business or the Purchased Assets or any real property currently or formerly owned, leased or operated by Seller in connection with the Business is listed on, or has been proposed for listing on, the National Priorities List (or CERCLIS) under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq. ("CERCLA”), or any similar state list.

(d) There has been no release of Hazardous Materials except in compliance with Environmental Law with respect to the Business or the Purchased Assets or any real property currently or formerly owned, leased or operated by Seller in connection with the Business, and Seller has not received an Environmental Notice that any of the Business or the Purchased Assets or real property currently or formerly owned, leased or operated by Seller in connection with the Business (including soils, soil gas, groundwater, indoor air, surface water, buildings and other structure located thereon) has been contaminated with any Hazardous Material which could reasonably be expected to result in an Environmental Claim against, or a violation of Environmental Law or term of any Environmental Permit by, Seller.

(e) Section 3.15(e) of the Disclosure Schedules contains a complete and accurate list of all active, closed, or abandoned aboveground or underground storage tanks owned or operated by Seller in connection with the Business or the Purchased Assets.

16

(f) Section 3.15(f) of the Disclosure Schedules contains a complete and accurate list of all off-site Hazardous Materials treatment, storage, or disposal facilities or locations used by Seller and any predecessors in connection with the Business or the Purchased Assets as to which Seller may retain liability, and none of these facilities or locations has been placed or proposed for placement on the National Priorities List (or CERCLIS) under CERCLA, or any similar state list, and Seller has not received any Environmental Notice regarding potential liabilities with respect to such off-site Hazardous Materials treatment, storage, or disposal facilities or locations used by Seller.

(g) Seller has not retained or assumed, by contract or operation of law, any liabilities or obligations of third parties under Environmental Law.

(h) Seller has provided or otherwise made available to Buyer and listed in Section 3.15(h) of the Disclosure Schedules: (i) any and all environmental reports, studies, audits, records, sampling data, site assessments, risk assessments, economic models and other similar documents with respect to the Business or the Purchased Assets or any real property currently or formerly owned, leased or operated by Seller in connection with the Business which are in the possession or control of Seller related to compliance with Environmental Laws, Environmental Claims or an Environmental Notice or the release of Hazardous Materials; and (ii) any and all documents concerning planned or anticipated capital expenditures required to reduce, offset, limit or otherwise control pollution and/or emissions, manage waste or otherwise ensure compliance with current or future Environmental Laws (including, without limitation, costs of remediation, pollution control equipment and operational changes).

(i) Seller is not aware of or reasonably anticipates, as of the Closing Date, any condition, event or circumstance concerning the release or regulation of Hazardous Materials that might, after the Closing Date, prevent, impede or materially increase the costs associated with the ownership, lease, operation, performance or use of the Business or the Purchased Assets as currently carried out.

For purposes of this Agreement:

"Environmental Claim” means any Action, governmental order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility to perform or pay for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence, release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with any Environmental Law or term or condition of any Environmental Permit.

17

"Environmental Law” means any applicable law, and any governmental order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, indoor air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The term "Environmental Law” includes, without limitation, the following (including their implementing regulations and any state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean Air Act Amendments of 1990, 42 U.S.C. §§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. §§ 651 et seq.

"Environmental Notice” means any written directive, notice of violation or non-compliance or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with any Environmental Law or any term or condition of any Environmental Permit.

"Environmental Permit” means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given, authorized by or made pursuant to Environmental Law.

"Hazardous Material” means substance that any governmental entity, in accordance with applicable federal, state, or local law, has designated to be radioactive, toxic, hazardous, or otherwise a danger to health or the environment, including PCBs, PFAS compounds, friable asbestos, petroleum, urea-formaldehyde, and all substances listed as hazardous substances in accordance with the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, or defined as a hazardous waste in accordance with the United States Resource Conservation and Recovery Act of 1976, as amended, and the regulations promulgated in accordance with said laws, but excluding office and janitorial supplies lawfully used or stored for their intended purpose.

Section 3.16 Employee Benefit Matters.

(a) Section 3.16(a) of the Disclosure Schedules contains a true and complete list of each pension, benefit, retirement, compensation, employment, consulting, profit-sharing, deferred compensation, incentive, bonus, performance award, phantom equity, stock or stock-based, change in control, retention, severance, vacation, paid time off (PTO), medical, vision, dental, disability, welfare, Section 125 cafeteria of the Internal Revenue Code of 1986, as amended (the "Code”), fringe-benefit and other similar agreement, plan, policy, program or arrangement (and any amendments thereto), in each case whether or not reduced to writing and whether funded or unfunded, including each "employee benefit plan” within the meaning of Section 3(3) of Employee Retirement Income Security Act of 1974, as amended ("ERISA”), whether or not tax-qualified and whether or not subject to ERISA, which is or has been maintained, sponsored, contributed to, or required to be contributed to by Seller for the benefit of any current or former employee, officer, director, retiree, independent contractor or consultant of the Business or any spouse or dependent of such individual, or under which Seller or any of its ERISA Affiliates has or may have any liability, or with respect to which Buyer or any of its Affiliates would reasonably be expected to have any liability, contingent or otherwise (as listed on Section 3.16(a) of the Disclosure Schedules, each, a "Benefit Plan”).

18

(b) With respect to each Benefit Plan, Seller has made available to Buyer accurate, current and complete copies of each of the following: (i) where the Benefit Plan has been reduced to writing, the plan document together with all amendments; (ii) where the Benefit Plan has not been reduced to writing, a written summary of all plan terms; (iii) where applicable, copies of any trust agreements or other funding arrangements, custodial agreements, insurance policies and contracts, administration agreements and similar agreements, and investment management or investment advisory agreements, now in effect or required in the future as a result of the transactions contemplated by this Agreement or otherwise; (iv) copies of any summary plan descriptions, summaries of modifications, summaries of benefits and coverage, COBRA communications, employee handbooks and any other written communications (or a description of any oral communications) relating to any Benefit Plan; (v) in the case of any Benefit Plan that is intended to be qualified under Section 401(a) of the Code, a copy of the most recent determination, opinion or advisory letter from the Internal Revenue Service and any legal opinions issued thereafter with respect to such Benefit Plan’s continued qualification; (vi) in the case of any Benefit Plan for which a Form 5500 must be filed, a copy of the two most recently filed Forms 5500, with all corresponding schedules and financial statements attached; (vii) actuarial valuations and reports related to any Benefit Plans with respect to the most recently completed plan years; (viii) the most recent nondiscrimination tests performed under the Code; and (ix) copies of notices, letters or other correspondence from the Internal Revenue Service, Department of Labor, Department of Health and Human Services, Pension Benefit Guaranty Corporation or other Governmental Authority relating to the Benefit Plan.

(c) Each Benefit Plan and any related trust has been established, administered and maintained in accordance with its terms and in compliance with all applicable laws (including ERISA, the Code and any applicable local laws). Each Benefit Plan that is intended to be qualified within the meaning of Section 401(a) of the Code (a "Qualified Benefit Plan”) is so qualified and received a favorable and current determination letter from the Internal Revenue Service with respect to the most recent five year filing cycle, or with respect to a prototype or volume submitter plan, can rely on an opinion letter from the Internal Revenue Service to the prototype plan or volume submitter plan sponsor, to the effect that such Qualified Benefit Plan is so qualified and that the plan and the trust related thereto are exempt from federal income taxes under Sections 401(a) and 501(a), respectively, of the Code, and nothing has occurred that could reasonably be expected to adversely affect the qualified status of any Qualified Benefit Plan. Nothing has occurred with respect to any Benefit Plan that has subjected or could reasonably be expected to subject Seller or any of its ERISA Affiliates or, with respect to any period on or after the Closing Date, Buyer or any of its Affiliates, to a penalty under Section 502 of ERISA or to tax or penalty under Sections 4975 or 4980H of the Code.

19

All benefits, contributions and premiums relating to each Benefit Plan have been timely paid in accordance with the terms of such Benefit Plan and all applicable laws and accounting principles, and all benefits accrued under any unfunded Benefit Plan have been paid, accrued or otherwise adequately reserved to the extent required by, and in accordance with GAAP.

(d) Neither Seller nor any of its ERISA Affiliates has (i) incurred or reasonably expects to incur, either directly or indirectly, any liability under Title I or Title IV of ERISA or related provisions of the Code or applicable local law relating to employee benefit plans; (ii) failed to timely pay premiums to the Pension Benefit Guaranty Corporation; (iii) withdrawn from any Benefit Plan; (iv) engaged in any transaction which would give rise to liability under Section 4069 or Section 4212(c) of ERISA; (v) incurred taxes under Section 4971 of the Code with respect to any Single Employer Plan; or (vi) participated in a multiple employer welfare arrangements (MEWA).

(e) With respect to each Benefit Plan (i) no such plan is a multiemployer plan within the meaning of Section 3(37) of ERISA; (ii) no such plan is a "multiple employer plan” within the meaning of Section 413(c) of the Code; and (iii) no such plan is subject to Title IV of ERISA or the minimum funding requirements under Section 412 of the Code.

(f) Other than as required under Sections 601 to 608 of ERISA or other applicable law, no Benefit Plan or other arrangement provides post-termination or retiree health benefits to any individual for any reason.

(g) There is no pending or threatened Action relating to a Benefit Plan (other than routine claims for benefits), and no Benefit Plan has within the six (6) years prior to the date hereof been the subject of an examination or audit by a Governmental Authority or the subject of an application or filing under, or is a participant in, an amnesty, voluntary compliance, self-correction or similar program sponsored by any Governmental Authority.

(h) There has been no amendment to, announcement by Seller or any of its Affiliates relating to, or change in employee participation or coverage under, any Benefit Plan or collective bargaining agreement that would increase the annual expense of maintaining such plan above the level of the expense incurred for the most recently completed fiscal year (other than on a de minimis basis) with respect to any director, officer, employee, consultant or independent contractor of the Business, as applicable. Neither Seller nor any of its Affiliates has any commitment or obligation or has made any representations to any director, officer, employee, consultant or independent contractor of the Business, whether or not legally binding, to adopt, amend, modify or terminate any Benefit Plan or any collective bargaining agreement.

20

(i) Each Benefit Plan that is subject to Section 409A of the Code has been administered in compliance with its terms and the operational and documentary requirements of Section 409A of the Code and all applicable regulatory guidance (including, notices, rulings and proposed and final regulations) thereunder. Seller does not have any obligation to gross up, indemnify or otherwise reimburse any individual for any excise taxes, interest or penalties incurred pursuant to Section 409A of the Code.

(j) Neither the execution of this Agreement nor any of the transactions contemplated by this Agreement will (either alone or upon the occurrence of any additional or subsequent events): (i) entitle any current or former director, officer, employee, independent contractor or consultant of the Business to severance pay or any other payment; (ii) accelerate the time of payment, funding or vesting, or increase the amount of compensation (including stock-based compensation) due to any such individual; (iii) increase the amount payable under or result in any other obligation pursuant to any Benefit Plan; (iv) result in "excess parachute payments” within the meaning of Section 280G(b) of the Code; or (v) require a "gross-up” or other payment to any "disqualified individual” within the meaning of Section 280G(c) of the Code. Seller has made available to Buyer true and complete copies of any Section 280G calculations prepared (whether or not final) with respect to any disqualified individual in connection with the transactions.

Section 3.17 Employee Matters.

(a) Section 3.17(a) of the Disclosure Schedules contains a list of all persons who are employees, independent contractors or consultants of the Business as of the date hereof, including any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full-time or part-time); (iii) hire or retention date; (iv) current annual base compensation rate or contract fee; (v) commission, bonus or other incentive-based compensation; (vi) deferred compensation; and (vii) a description of the fringe benefits provided to each such individual as of the date hereof. As of the date hereof, all compensation, including wages, commissions, bonuses, fees and other compensation, payable to all employees, independent contractors or consultants of the Business for services performed on or prior to the date hereof, except for the deferred compensation set forth in Section 3.17(a) of the Disclosure Schedules (the "Deferred Compensation”) have been paid in full and there are no outstanding agreements, understandings or commitments of Seller with respect to any compensation, commissions, bonuses or fees.

(b) Except as set forth in Section 3.17(b) of the Disclosure Schedules, Seller is not, and has not been, a party to, bound by, or negotiating any collective bargaining agreement or other contract with a union, works council or labor organization (collectively, "Union”), and there is not, and has not been, any Union representing or purporting to represent any employee of Seller, and no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining. There has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting Seller or any employees of the Business. Seller has no duty to bargain with any Union.

21

(c) Seller is and has been in compliance with the terms of the collective bargaining agreements and other contracts listed on Section 3.17(b) of the Disclosure Schedules and all applicable laws pertaining to employment and employment practices to the extent they relate to employees, volunteers, interns, consultants and independent contractors of the Business, including all laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers’ compensation, leaves of absence, paid sick leave and unemployment insurance. All individuals characterized and treated by Seller as consultants or independent contractors of the Business are properly treated as independent contractors under all applicable laws. All employees of the Business classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified. Seller is in compliance with and has complied with all immigration laws, including Form I-9 requirements and any applicable mandatory E-Verify obligations. There are no Actions against Seller pending, or threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant, volunteer, intern or independent contractor of the Business, including, without limitation, any charge, investigation or claim relating to unfair labor practices, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, employee classification, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers’ compensation, leaves of absence, paid sick leave, unemployment insurance or any other employment related matter arising under applicable laws.

(d) Seller has complied with the WARN Act, and it has no plans to undertake any action in the future that would trigger the WARN Act.

(e) With respect to each government contract, Seller is and has been in compliance with Executive Order No. 11246 of 1965 ("E.O. 11246”), Section 503 of the Rehabilitation Act of 1973 ("Section 503”) and the Vietnam Era Veterans’ Readjustment Assistance Act of 1974 ("VEVRAA”), including all implementing regulations. Seller maintains and complies with affirmative action plans in compliance with E.O. 11246, Section 503 and VEVRAA, including all implementing regulations. Seller is not, and has not been for the past six (6) years, the subject of any audit, investigation or enforcement action by any Governmental Authority in connection with any government contract or related compliance with E.O. 11246, Section 503 or VEVRAA. Seller has not been debarred, suspended or otherwise made ineligible from doing business with the United States government or any government contractor. Seller is in compliance with and has complied with all immigration laws, including any applicable mandatory E-Verify obligations.

22

Section 3.18 Legal Proceedings. There is no claim, action, suit, proceeding or governmental investigation ("Action”) of any nature pending or threatened against or by Seller (a) relating to or affecting the Purchased Assets or the Assumed Liabilities; or (b) that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

Section 3.19 Taxes.

(a) All Tax Returns required to be filed by Seller have been timely filed. Such Tax Returns are true, complete, and correct in all respects. All Taxes due and owing by Seller (whether or not shown on any tax return) have been timely paid or timely withheld and remitted. For purposes of this Agreement, "Tax” means (a) any tax, duty, impost, or other similar governmental fee, levy, charge, or assessment in the nature of taxes (including net income, capital gains, gross income, gross receipts, sales, use, transfer, ad valorem, profits, capital, withholding, payroll, estimated, employment, excise, severance, occupation, premium, property, social security, alternative or add-on minimum or estimated amounts, value added, registration, windfall profits, franchise or other tax) imposed by any Governmental Authority, and any interest, addition or penalties imposed by any taxing authority with respect thereto and (b) liability for the payment of any amounts of the type described in clause (a) as a transferee or successor, by contract or from any express or implied obligation to indemnify or otherwise assume or succeed to the liability of any other Person and "Tax Return” or "Tax Returns” means any return, declaration, report, claim for refund, information return or statement (including schedules and any amendments) filed or required to be filed with, or required to be supplied in copy to, any Governmental Authority in connection with any Tax.

(b) Seller has materially complied with all information reporting and backup withholding provisions of applicable law.

(c) No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Seller.

(d) All Tax deficiencies asserted, or assessments made, against Seller as a result of any examinations by any taxing authority have been fully paid.

(e) Seller is not a party to any Action with respect to Taxes by any Governmental Authority. There are no pending or threatened Actions with respect to Taxes by any Governmental Authority.

(f) There are no Encumbrances for Taxes upon any of the Purchased Assets nor is any Governmental Authority in the process of imposing any Encumbrances for Taxes on any of the Purchased Assets (other than for current Taxes not yet due and payable).

23

(g) Seller is not, and has not been, a party to, or a promoter of, a "reportable transaction” within the meaning of Section 6707A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b).

(h) None of the Purchased Assets is (i) required to be treated as being owned by another person pursuant to the so-called "safe harbor lease” provisions of former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended, (ii) subject to Section 168(g)(1)(A) of the Code, or (iii) subject to a disqualified leaseback or long-term agreement as defined in Section 467 of the Code.

(i) None of the Purchased Assets is tax-exempt use property within the meaning of Section 168(h) of the Code.

Section 3.20 Transaction with Related Parties. No Related Party is or has been since January 1, 2019, a party to any transaction, agreement or understanding with Seller except for arrangements disclosed on Section 3.20 of the Disclosure Schedules. Section 3.20 of the Disclosure Schedules separately identifies all services that any Related Party provides to the Business and all outstanding liabilities of any Related Party that are related to the Business. No Related Party uses any of the Purchased Assets for purposes not related to the Business. No Related Party has any claim of any nature, including any inchoate claim, against any assets used in the Business (including the Purchased Assets). No Related Party, directly or indirectly, owns or is engaged in any business that competes directly or indirectly with Seller. Except as disclosed on Section 3.20 of the Disclosure Schedules or as otherwise expressly provided by this Agreement or by any other agreement: (i) no Related Party will at any time after the Closing for any reason, directly or indirectly, be or become entitled to receive any payment or transfer of money or other property of any kind from Buyer with respect to facts, circumstances or events existing or occurring on or before the Closing Date; and (ii) Buyer will not at any time after the Closing for any reason, directly or indirectly, be or become subject to any obligation to any Related Party with respect to facts, circumstances or events existing or occurring on or before the Closing Date.

For purposes of this section, "Related Party” means (i) any Affiliate of Seller; (ii) any officer, director, member, manager, partner, executor or trustee (or similar capacity) of any person identified in clause (i) preceding; (iii) any spouse, sibling, ancestor, lineal descendant of or person who resides with any natural person identified in any one of the preceding clauses and any Affiliate of any such person; and (iv) any person with respect to whom any natural person identified in any one of the preceding clauses is an officer, director, partner, executor or trustee (or similar capacity) and any Affiliate of any such person.

Section 3.21 Governmental Loan Programs.

(a) Seller obtained a loan in the amount of $399,000.00 from Midfirst Bank (the "PPP Lender”) pursuant to a Promissory Note dated April 14, 2020, under the Coronavirus Aid, Relief, and Economic Security Act, as amended (the "CARES Act”) and the Paycheck Protection Program and the rules and regulations issued in respect thereof (the "PPP Loan”), which has been forgiven in full. Other than the PPP Loan, Seller has not (i) applied for or received any loans pursuant to or under any PPP and EIDL Laws or (ii) received or applied for any other benefits under any PPP and EIDL Laws or any other laws promulgated in response to COVID-19.

24

(b) Seller has made available to Buyer a true, correct and complete copy of each governmental loan document relating to the PPP Loan. The PPP Loan was properly obtained based on accurate certifications of eligibility by Seller.

(c) For purposes of this section, "PPP and EIDL Laws” means the CARES Act, the Small Business Administration’s ("SBA”) interpretation of the CARES Act and of the Paycheck Protection Program Interim Final Rule, the Small Business Act, the rules and regulations issued by any Governmental Authority in respect of any of the foregoing, and any other laws applicable to the PPP Loan.

Section 3.22 Regulatory Matters

For purposes of this section:

"Manufacture”, "Manufactured” or "Manufacturing” means the sourcing, receipt, storage, processing, manufacturing, packaging, labeling, or holding of any Product, or any component or raw material thereof.

"Product” means any pharmaceutical, dietary supplement, or other product Manufactured by Seller that is subject to FDA regulation or any U.S. or foreign Governmental Authority with similar authority.

"Regulatory Submission” means any pending or approved submission to FDA or any other Governmental Authority held by Seller or any third party authorizing the Manufacturing of any Product, including without limitation, a New Drug Application ("NDA”), Abbreviated New Drug Application ("ANDA”), Investigational New Drug Application ("IND”), or equivalent submissions to any foreign Governmental Authority.

(a) Seller has made available complete and correct copies of all Regulatory Submissions sponsored, held, or owned by Seller ("Seller Regulatory Submissions”); all written communications from the Food and Drug Administration ("FDA”), Drug Enforcement Administration ("DEA”) or other Governmental Authority relating to Seller Regulatory Submissions, Products, Inventories, or Manufacturing; all information about adverse drug experiences obtained or otherwise received by Seller or its Affiliates from any source pertaining to any of the Products, in the United States or outside the United States. Subject to Seller and Buyer each submitting transfer letters to the FDA or other applicable Governmental Authority, the rights and benefits of each Seller Regulatory Submission will be available to Seller on the Closing Date on terms substantially identical to those enjoyed by Buyer immediately prior to the Closing Date. Neither Seller, nor its Affiliates nor any person acting on behalf of Seller or its Affiliates, has made an untrue statement of a material fact or fraudulent statement to the FDA or other Governmental Authority, or failed to make a statement or committed an act in contravention to the policies of FDA or any other Governmental Authority.

25

(b) Seller has submitted to and filed with the FDA all required notices, supplemental applications and annual or other reports or documents, including adverse event reports and field alerts, with respect to Seller Regulatory Submissions, Manufacturing, and Inventory, (ii) Seller and/or its Affiliates have paid all fees required by any Governmental Authority with respect to Seller Regulatory Submissions, including filing fees applicable to the Products and with respect to all Permits, and (iii) with respect to the Products, Inventory, and Manufacturing, Seller has acted in material compliance with all applicable laws, including, but not limited to, the Federal Food, Drug, and Cosmetic Act ("FD&C Act”), the Controlled Substances Act ("CSA”), all similar state, local, federal and foreign laws and regulations ("Regulatory Laws”) and all terms and conditions of the Regulatory Submissions and Permits.

(c) The operations of Seller at the real property included in the Purchased Assets and with respect to the Manufacturing and Inventory comply with the applicable requirements of the FDA, DEA, and all Regulatory Laws.

(d) Seller has not received from the FDA, DEA, or any other Governmental Authority any notice of adverse findings, FDA Form 483s, notices of violations, warning letters, untitled letters, clinical holds, civil or criminal proceeding notices, or notices of inspection or investigation under the FD&C Act, regarding the Purchased Assets and none of the Products have been recalled or subject to FDA or other Governmental Authority correction or removal requirements, and Seller has not received written notice from the FDA, DEA, or another Governmental Authority: of any proceeding seeking to commence a recall, or threatening a recall, removal, or seizure of any Products; the imposition of material sales, marketing, or production restrictions on any Product; or the suspension, termination, or other restriction on any preclinical or clinical research. There is no circumstance or condition that may lead to the recall, removal, or seizure of any Products.

(e) Seller has not used in any capacity the services of any person debarred, excluded, or disqualified under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or other similar law. Neither Seller nor any individual employed by Seller has been disqualified or debarred by any Governmental Authority, including but not limited to the FDA pursuant to the FD&C Act, or been convicted of any crime under any Regulatory Law or has engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment, exclusion, or disqualification under 21 U.S.C. Section 335a, 42 U.S.C. Section 1320a-7, 21 C.F.R. Section 312.70, or any similar laws, rules regulations, or engaged in any misconduct relating to the development, approval, marketing or sale of pharmaceutical products, including the Products.

Section 3.23 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller or Parent.

26

Section 3.24 Full Disclosure. No representation or warranty by Seller in this Agreement and no statement contained in the Disclosure Schedules to this Agreement or any certificate or other document furnished or to be furnished to Buyer pursuant to this Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.

Section 3.25 Reliance. Seller makes the foregoing representations and warranties with the knowledge and expectation that Buyer is placing reliance on the representations and warranties.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer represents and warrants to Seller that the statements contained in this ARTICLE IV are true and correct as of the date hereof.

Section 4.01 Organization and Authority of Buyer; Enforceability. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware. Buyer has full corporate power and authority to enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement and the documents to be delivered hereunder constitute legal, valid and binding obligations of Buyer enforceable against Buyer in accordance with their respective terms.

Section 4.02 No Conflicts; Consents. The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws or other organizational documents of Buyer; or (b) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Buyer. No consent, approval, waiver or authorization is required to be obtained by Buyer from any Person in connection with the execution, delivery and performance by Buyer of this Agreement and the consummation of the transactions contemplated hereby.

Section 4.03 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

Section 4.04 No Reliance. In connection with entering into this Agreement and the other agreements contemplated by this Agreement, Buyer hereby represents, warrants and acknowledges that Buyer is not relying upon any representations or warranties of Seller, other than the express representations and warranties made by the Seller in ARTICLE III of this Agreement and all agreements, certificate and documents signed and delivered by Seller in connection with this Agreement or the transactions contemplated hereby and Buyer specifically disclaims that it is relying upon or has relied upon any such other representations or warranties as to the Seller or the Business in connection with the subject matter of this Agreement.

27

ARTICLE V

COVENANTS

Section 5.01 Public Announcements. Unless otherwise required by applicable law or stock exchange requirements, neither party shall make any public announcements regarding this Agreement or the transactions contemplated hereby without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed).

Section 5.02 Taxes.

(a) All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the documents to be delivered hereunder shall be borne and paid by Seller when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as necessary).

(b) Buyer and Seller will cooperate, as and to the extent reasonably requested by any other party, in connection with the filing and preparation of Tax Returns related to the Purchased Assets and any Action related thereto, including providing reasonable access to the requesting party and its representatives to all relevant Tax and financial records.

(c) Each of Buyer and Seller shall be responsible for its pro rata share of the current year’s personal property, real property, ad valorem and similar Taxes with respect to the Purchased Assets, prorated on a calendar year basis as of the Closing Date. Buyer shall make timely payment in full of all such amounts to the applicable taxing authority and Seller shall pay Buyer for any Taxes that Buyer has notified Seller are the responsibility of Seller pursuant to this Section 5.02(c) promptly (and in any event within 10 days) following Buyer’s demand therefor.

Section 5.03 Non-Assignability of Assigned Contracts and Transferred Permits. This Agreement reflects Seller’s intent to assign, to the extent transferable, all of the Assigned Contracts and Transferred Permits to Buyer on the Closing Date or otherwise to use Seller’s commercially reasonable efforts to assist with the issuance of new Permits; provided, however, that Seller shall not assign to Buyer an Assigned Contract or Transferred Permit if an assignment thereof would, in the absence of any approval, consent, license, permit, order, ratification, waiver, registration, filing, application, or authorization (each a "Consent”) of a third party thereto or the expiration of a notice period to a third party thereto: (a) constitute a breach or default thereof, (b) cause or permit the acceleration or termination thereof, (c) be prohibited by applicable any law or regulation of any Governmental Authority, or (d) in any way materially and adversely affect the rights of Buyer or Seller thereunder or the right of Buyer to conduct all or any material part of the Business relating to the Purchased Assets in the manner and on the terms presently enjoyed by Seller and in accordance with all applicable laws or regulations of any Governmental Authority. In any such case where Consent of a third party thereto has not been obtained, then, until the receipt of such Consent, the interest of Seller therein and thereunder shall be maintained by Seller in trust for Buyer’s sole benefit and use, and Seller shall use commercially reasonable efforts to (i)secure such Consent and conditions for transfer as soon as reasonably possible, (ii)cooperate in any reasonable and lawful alternative arrangement designed to provide the benefits of such Purchased Asset to Buyer, and (iii) enforce, at the reasonable request of Buyer and at Buyer’s reasonable cost and expense, any rights of Seller with respect to such Purchased Asset against the other parties thereto. Upon a third party Consent being obtained, Seller shall assign to Buyer and Buyer shall assume from Seller, in each case effective as of the Closing Date, by supplemental instrument of conveyance if requested by Buyer, all of Seller’s rights, title and interest in and to, and obligations under, such Assigned Contract or Transferred Permit, without further payment or consideration, and the arrangements entered into between Seller and Buyer hereunder as to such Assigned Contract or Transferred Permit will terminate. Nothing in this Section limits Seller’s obligation to obtain any Consent required by this Agreement or waives Buyer’s right to require such Consent as a condition to its obligation to proceed with Closing.

28

Section 5.04 Interest in Intellectual Property; Use of Names.

(a) As soon as reasonably practicable after the Closing Date, but in any event within 90 days after the Closing Date (the "Transitional Period”), Seller and Parent shall, and shall cause their Affiliates to, cease and discontinue all uses of any trademarks in the Purchased IP (the "Purchased Marks”), except as provided in this Section 5.04 or as necessary to perform the transition services under the Transition Services Agreement, including by (i) changing the corporate and business names and trade names of Seller, Parent and their Affiliates to a name that does not include any Purchased Mark and is not confusingly similar thereto and otherwise cease to refer to themselves as or do business under, any Purchased Mark or any name that includes any Purchased Mark, (ii) not putting into use any items or materials that bear any Purchased Mark; (iii) not using any websites or domain names that include any reference to any Purchased Mark, except as expressly contemplated in Section 5.04(b), (iv) removing or obliterating any Purchased Mark from any and all exterior signs and other identifiers located on or attached to any property, buildings, vehicles, signs or premises used in connection with the Business, and (v) ceasing to use all letterhead, envelopes, invoices, supplies, labels, product packaging and inserts, promotional materials, marketing collateral, advertisements and other communications media or similar materials of any kind that includes any Purchased Mark (collectively, "Business Materials”). Seller, Parent, and their Affiliates (A) shall use the Purchased Marks during the Transitional Period only in the same form and manner as they were used in the Business immediately prior to the Closing, (B) shall not modify the Purchased Marks or any Business Materials containing the Purchased Marks in any respect and (C) at Buyer’s reasonable request, shall provide appropriate documentation to confirm compliance with the foregoing. Seller, Parent, and their Affiliates agree that all goodwill arising from any use of the Purchased Marks by Seller, Parent, or any of their Affiliates will inure solely to the benefit of Buyer and its Affiliates. Notwithstanding anything to the contrary in this Agreement or in any agreement ancillary hereto, nothing in this Agreement or any agreement ancillary hereto shall restrict Seller, Parent and its Affiliates’ (i) sale, promotion, marketing, or advertising of their inventory that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure”, or (ii) use of packaging that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure” on future products that they might purchase from Buyer in accordance with the relevant terms of such purchase(s).

(b) Notwithstanding anything to the contrary, Buyer shall grant to Seller, Parent and their Affiliates a non-assignable, non-transferable, and non-sublicensable license to use the Purchased Marks during the Transitional Period all as more fully set forth in a trademark agreement in the form of Exhibit G hereto.

29

(c) No later than 60 days following the Closing Date, Seller, Parent, and their Affiliates shall have arranged for new website domains to host websites of Seller, Parent, and their Affiliates, which domains shall not include any reference to Purchased Marks. No later than 60 days following the Closing Date, Seller, Parent, and their Affiliates shall operate its websites solely through such new website domain names (and any other domain names created after the Closing that does not include reference to any Purchased Marks); provided that notwithstanding the foregoing, domains with reference to Purchased Marks may remain active for 180 days after the Closing solely for the purpose of redirecting users to the new websites of Seller, Parent, and their Affiliates.

Section 5.05 Employee Matters.

(a) Prior to the Date hereof, Buyer has made offers of employment to the active employees of Seller other than the Key Employees which offer provided (i) the job title set forth on Schedule 5.05(a)-1 for each such employee, and (ii) at least the same amount of annual salary or hourly pay rate set forth on Schedule 5.05(a)-1 for each such employee. Buyer agrees to make offers of employment to the employees of Seller who are on an approved leave of absence (the "Inactive Employees”) at the same time that Buyer makes offers of employment to the active employees of Seller which offer shall provide (i) the job title set forth on Schedule 5.05(a)-2 for each such employee, and (ii) at least the same amount of annual salary or hourly pay rate set forth on Schedule 5.05(a)-2 for each such employee. Buyer shall be obligated to make any such offer of employment to each Inactive Employee in accordance with applicable Law and shall provide each such Inactive Employee with the opportunity for reinstatement in the same or comparable position for no less than the period required by applicable Law. Upon written request by Buyer during the period in which the Transition Services Agreement is in effect, Seller shall terminate, effective no later than three (3) business days following Buyer’s written request (which written request shall be made no later than 45 days after the Closing Date), all employees of Seller (the effective date of termination, the "Termination Date”) and the employment of the employees who have accepted Buyer’s offer of employment shall commence on the day immediately following the Termination Date or such other date mutually agreed to in writing by Buyer and Seller (such date, the "Hire Date”). With respect to any payroll period which is open as of the Closing Date, Seller and Buyer agree that, pursuant to the terms of the Transition Services Agreement and as an Assumed Liability hereunder that Buyer shall be responsible for all Liabilities of Seller with respect to the Key Employees and the employees of Seller set forth on Schedule 5.05(a)-1 and Schedule 5.05(a)-2, to the extent arising or accruing on or after the Closing Date, including any payroll, employment and other similar Taxes imposed with respect to any payments of compensation to such employees.

(b) Effective as of the Termination Date, (i) Seller shall cease to be a participating employer in any other employee benefit plan that is not a Benefit Plan (and any other employee benefit or compensation plan or arrangement maintained or contributed to by Seller or its Affiliates), and (ii) each employee of the Business who accepts an offer employment with Buyer or its Affiliates (each, a "Continuing Employee”) shall cease to be an active participant in such employee plans and other benefit or compensation plans and arrangements following the effective date of such employment. Other than as contemplated in the Transition Services Agreement, Parent, Seller and their Affiliates shall retain all liability associated with the employee benefit plans (other than Benefit Plans) and other employee benefit or compensation plans or arrangements maintained or contributed to by Parent, Seller or their Affiliates, whether such liability arises prior to, at or after the Closing.

30

(c) With respect to each benefit plan, program, practice, policy or arrangement maintained or set up by Buyer or an Affiliate of Buyer following the Closing and in which any of the Continuing Employees participate following the Closing, for purposes of determining eligibility to participate, vesting and accrual of and entitlement to benefits, service with Parent, Seller and their Affiliates (or predecessor employers to the extent Seller or any of its Affiliates provides past service credit) shall be treated as service with Buyer and its Affiliates; provided, however, that service shall not be credited for purposes of accruals of benefits under a defined benefit plan or retiree welfare programs or eligibility for retirement provisions under any equity compensation arrangements or to the extent such credit would result in a duplication of benefits.

(d) Prior to the Closing, Seller shall offer each Continuing Employee (including Inactive Employees) the option to choose to either have their accrued but unused vacation pay and personal time off paid out in full by Seller (all such payments "Rollover Vacation Cashout Payments”), or to have such Continuing Employee’s accrued but unused vacation pay and personal time off assumed by the Buyer (all such assumed accrued paid time off, the "Rolled Vacation”). The liability for the Rolled Vacation shall transfer to, and be honored by Buyer, to the extent that the dollar amount of such Rolled Vacation ("Rolled Vacation Amounts”, together with Rollover Vacation Cashout Payments, "Rollover Vacation”) and the employer-portion of any payroll, employment and other similar taxes applicable thereto were deducted from the Closing Consideration, subject to Buyer’s paid time off policies (to the extent compliant with applicable law), and provided that each such Continuing Employee shall request and utilize such Rolled Vacation in accordance with Buyer’s paid time off policies. Buyer shall be obligated to pay any Rolled Vacation, if and to the extent required under applicable Law. On the Termination Date, Seller shall make payment in full of the Rollover Vacation Cashout Payments to the relevant employees of Seller as set forth on Schedule 1.03(b).

31

Section 5.06 Dissolution. Seller will not dissolve until the lapse of 18 months after the Closing Date.

Section 5.07 Intellectual Property Chain of Title

. The parties hereto are aware that there are potential chain of title issues with respect to the three (3) patents identified on Schedule 5.07 (the "Affected Patents”). Seller agrees to use commercially reasonable efforts to resolve such potential chain of title issues with respect to the Affected Patents as soon as possible following Closing during the sixty (60) days from the Closing Date.

Section 5.08 Further Assurances

. Following the Closing, each of the parties hereto shall execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the documents to be delivered hereunder.

Section 5.09 Covenant Not to Sue. Seller represents that Parent possesses all or joint right, title, and interest in and to the patents listed in Schedule 5.09 attached hereto (the "Referenced Patents”). Seller unconditionally agrees, promises, and covenants that it will not sue or otherwise enforce the Referenced Patents against Buyer, its parents, subsidiaries, affiliates, or successor companies in connection with Buyer’s conduct of the Business. Based on the foregoing representations and subject to the conditions set forth herein, Seller unconditionally agrees, promises, and covenants not to sue or otherwise hold liable Buyer, its parents, subsidiaries, affiliates, or successor companies or their authorized contractors, distributors, and customers, for any and all claims that the manufacture, use, license, sublicense, sale, offer for sale, distribution, and/or importation or exportation of a product in the operation of the Business, strictly by or on behalf of, or as authorized by Buyer (or its parents, subsidiaries, affiliates, or successor-in-interest), infringes any claim of the Referenced Patents. Seller also unconditionally agrees, promises, and covenants that it will not sue or otherwise enforce the Referenced Patents against Buyer’s customers, suppliers, importers, manufacturers, licensees, distributors, or insurers in connection with the manufacture, use, license, sublicense, sale, offer for sale, or importation or exportation of Buyer’s products in the operation of the Business. The covenant not to sue set forth in this Section 5.09 expressly includes any future assignees, licensees, or successors-in-interest to the Referenced Patents, such that those entities may not sue or otherwise enforce the Referenced Patents against Buyer, its parents, subsidiaries, affiliates, or successors, or Buyer’s customers, suppliers, importers, manufacturers, distributors, or insurers in connection with the manufacture, use, offer for sale, sale, distribution, or importation of the products in the operation of the Business. Buyer further promises to impose the covenant not to sue contained in this Agreement on any assignees, licensees, or successors-in-interest to the Referenced Patents. The covenant not to sue set forth in this Section 5.09 expressly includes any successor or assignee of Buyer or any Buyer parent, subsidiaries, affiliates, or successors-in-interest that subsequently purchases substantially all of the assets of either Buyer or any Buyer parent, subsidiary, affiliate, or successor in interest and any entity that subsequently purchases Buyer’s drug products in the operation of the Business. In the event that Buyer or any of its Affiliates acquires (whether through merger, stock acquisition, asset acquisition or otherwise) any entity, product, product line or technology after the Closing Date, the releases, licenses and covenants granted by Seller in this Section 5.09 shall in no event apply to any such products, services or technology of such entity or included within such products, product lines or technology, including with respect to the post-acquisition manufacture, sale use or other exploitation of such products, services, technology or product lines by Buyer and its Affiliates.

32

ARTICLE VI

NON-COMPETITION; NON-SOLICITATION

Section 6.01 Non-Competition. For a period of 3 years commencing on the Closing Date (the "Restricted Period”), except pursuant to the Transition Services Agreement, Seller shall not, and shall not permit any of its Affiliates to, directly or indirectly, (i) engage in or assist others in engaging in the Restricted Business; (ii) except as approved in writing by Buyer, have an interest in any Person that engages directly or indirectly in the Restricted Business in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant; or (iii) cause, induce or encourage any material actual or prospective client, customer, supplier or licensor of the Business (including any existing or former client or customer of Seller and any Person that becomes a client or customer of the Business after the Closing), or any other Person who has a material business relationship with the Business, to terminate or modify any such actual or prospective relationship. Notwithstanding the foregoing, Seller may own, directly or indirectly, solely as an investment, securities of any Person traded on any national securities exchange if Seller is not a controlling Person of, or a member of a group which controls, such Person and does not, directly or indirectly, own 5% or more of any class of securities of such Person. For purposes of this Agreement, the term "Restricted Business” means the Business as conducted by the Seller as of the Closing Date.

Section 6.02 Non-Solicitation. During the Restricted Period, Seller shall not, and shall not permit any of its Affiliates to, directly or indirectly, hire or solicit any Key Employee, or encourage any such employee to leave such employment or hire any such employee who has left such employment, except pursuant to a general solicitation which is not directed specifically to any such employees; provided, that nothing in this Section 6.02 shall prevent Seller or any of its Affiliates from hiring (i) any employee whose employment has been terminated by Buyer or (ii) after 180 days from the date of termination of employment, any employee whose employment has been terminated by the employee.

Section 6.03 Power of Attorney for D.E.A. Registration. At or prior to Closing, Seller shall execute in favor of Buyer one or more Powers of Attorney for Order Forms (the "Power of Attorney”) authorizing Buyer or a representative of Buyer to execute applications for books of official order forms and to sign such order forms, under Seller’s D.E.A. Registration Number(s) as required for all necessary controlled substances on an interim basis until such time as Buyer shall receive approval of all necessary D.E.A. registration(s). Seller covenants that it shall cooperate with Buyer and provide such information as Buyer may reasonably request in making all such applications for registration or licensing.

Section 6.04 Remedies. Seller acknowledges that a breach or threatened breach of this ARTICLE VII would give rise to irreparable harm to Buyer, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by Seller of any such obligations, Buyer shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond).

33

Section 6.05 Severability. Seller acknowledges that the restrictions contained in this ARTICLE VII are reasonable and necessary to protect the legitimate interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the transactions contemplated by this Agreement. In the event that any covenant contained in this ARTICLE VII should ever be adjudicated to exceed the time, geographic, product or service or other limitations permitted by applicable law in any jurisdiction, then any court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service or other limitations permitted by applicable law. The covenants contained in this ARTICLE VII and each provision hereof are severable and distinct covenants and provisions. The invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in any other jurisdiction

ARTICLE VII

INDEMNIFICATION

Section 7.01 Survival. All representations, warranties, covenants and agreements contained herein and all related rights to indemnification shall survive the Closing. The representations and warranties of Seller in ARTICLE III will survive the Closing Date and will continue for a period of 12 months from the Closing Date.

Section 7.02 Taxes. The representations and warranties in Section 3.19 (Taxes) will survive the Closing Date and will continue for 30 days after the expiration of the applicable statute of limitations applicable to the underlying subject matter at which time such representations and warranties will expire.

Section 7.03 Fundamental Representations. The representations and warranties in Sections 3.01 (Organization and Authority of Seller; Enforceability), 3.02 (No Conflicts; Consents), 3.03 (Title to Purchased Assets), 3.15 (Environmental Matters), and 3.23 (Brokers) (the "Fundamental Representations”) will survive the Closing Date and will continue for a period of 72 months following the Closing Date at which time such Fundamental Representations will expire. Notwithstanding anything else in this Agreement, any claims for Losses asserted in accordance with this ARTICLE VII before the expiration date of the applicable survival period in Section 7.01, 7.02 or 7.03 will not thereafter be barred by the expiration of such survival period and such claims will survive until finally resolved and all obligations with respect thereto fully satisfied.

34

Section 7.04 Indemnification By Seller. Subject to the other terms and conditions of this ARTICLE VII, Seller shall indemnify and defend each of Buyer and its Affiliates and their respective directors, shareholders, members, limited or general partners, officers, employees, agents, consultants, advisors, or other representatives ("Representatives”) and collectively, the "Buyer Indemnitees”) against, and shall hold each of them harmless from and against, any and all losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees (collectively, "Losses”), incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, or with respect to any of the following:

(a) any inaccuracy in or breach of any of the representations or warranties of Seller or Parent contained in this Agreement or any other transaction document (including the Parent Side Letter), or any schedule, certificate, or exhibit related thereto, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);

(b) any breach or non-fulfillment of any covenant, agreement, or obligation to be performed by Seller pursuant to this Agreement, any other transaction document, or any schedule, certificate, or exhibit related thereto;

(c) any Excluded Liabilities and any assets of Seller or of Parent that are not Purchased Assets;

(d) (i) any Taxes of Seller for any taxable period, (ii) any Taxes imposed with respect to the Purchased Assets or the Business for all taxable periods (or portions thereof) ending before the Closing Date, and (iii) any liability of Seller for unpaid Taxes of any Person under Treasury Regulations Section 1.1502-6 (or any similar provisions of state, local or foreign law), as a transferee or successor, by contract or otherwise by operation of law;

(e) only for any portion of a Loss for which a claim cannot be made under Section 7.04(a): any Third Party Claim based upon, resulting from, or arising out of the business, operations, properties, assets, or obligations of Seller or any of its Affiliates conducted, existing, or arising on or prior to the Closing Date, including, without limitation any Third Party Claim for violation, dilution, infringement, or misappropriation of Intellectual Property, provided, however, that to the extent such Third Party Claim relates to the Purchased Assets or Assumed Liabilities, solely to the extent related to the period prior to the Closing Date. For purposes of this Agreement, "Third Party Claim” means the notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing;

(f) the release of any Hazardous Material at, on or below the Leased Real Property in violation of applicable Environmental Law prior to the Closing;

(g) the failure of Seller or its shareholders to comply with any Environmental Claim, Environmental Law, or Environmental Permit prior to the Closing;

35

(h) any liability under any fraudulent transfer law or act or the failure to comply with any bulk sales laws and similar laws, if applicable; and

(i) fraud by or on behalf of Seller.

Section 7.05 Indemnification By Buyer. Buyer shall defend, indemnify and hold harmless Seller, its Affiliates and their respective Representatives (collectively, "Seller Indemnitees”) from and against all Losses, arising from or relating to:

(a) any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or any document to be delivered hereunder; or

(b) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement or any document to be delivered hereunder.

Section 7.06 Certain Limitations. The indemnification provided for in Section 7.04 and Section 7.05 shall be subject to the following limitations:

(a) Seller shall not be liable to the Buyer Indemnitees for indemnification under Section 7.04(a) until the aggregate amount of all Losses in respect of indemnification under Section 7.04(a) exceeds $75,000.00 (the "Basket”), in which event Seller shall be required to pay or be liable only for such Losses all such Losses from the first dollar. The aggregate amount of all Losses for which Seller shall be liable pursuant to this section shall not exceed the Holdback Amount.

(b) Buyer shall not be liable to Seller Indemnitees for indemnification under Section 7.05(a) until the aggregate amount of all Losses in respect of indemnification under Section 7.05(a) exceeds the Basket, in which event Buyer shall be required to pay or be liable only for such Losses that exceed the Basket. The aggregate amount of all Losses for which Buyer shall be liable pursuant to Section 7.05(a) shall not exceed any unpaid portion of the Purchase Price, other than as to Losses for which Buyer is liable pursuant to Section 7.05(a) for breaches of Section 4.03 (Brokers), which collectively with the foregoing Losses shall not exceed the Purchase Price (whether or not paid).

(c) Notwithstanding the foregoing, the limitations set forth in Section 7.06(a) shall not apply to Losses based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of the Fundamental Representations or any representation or warranty in Section 3.19 or any breach of Seller’s obligations under Section 1.04 or Section 5.05(a); provided, however, that except in the event of fraud, willful misconduct or intentional misrepresentation or any breach of Seller’s obligations under Section 1.04 or Section 5.05(a), in no event shall the total cumulative amount of Losses for which the Seller or Parent (pursuant to the Guaranty Agreement) may be liable to the Buyer Indemnitees under this ARTICLE VIII exceed the Purchase Price.

(d) For purposes of this ARTICLE VIII, any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, material adverse effect or other similar qualification contained in or otherwise applicable to such representation or warranty).

36

Section 7.07 Indemnification Procedures.

(a) If an Indemnified Party claims a right to payment pursuant to this Agreement, such Indemnified Party shall send written notice of such claim to the Buyer, if such Indemnified Party is a Seller Indemnitee, or to the Seller, if such Indemnified Party is a Buyer Indemnitee. Such notice must be delivered prior to the expiration of the applicable survival period, if any, and shall specify the basis for such claim with reasonable specificity. Failure by an Indemnified Party to so notify the Indemnifying Party of a Third Party Claim will not relieve the Indemnifying Party from any liability it may have to such Indemnified Party as to such Third Party Claim, except to the extent that the Indemnifying Party is materially prejudiced by the failure to give such notice. If the Indemnifying Party does not notify the Indemnified Party within 30 days following its receipt of such notice that the Indemnifying Party disputes its liability to the Indemnified Party under this ARTICLE VII or the amount thereof, the claim specified by the Indemnified Party in such notice shall be conclusively deemed a Loss under this ARTICLE VII. If the Indemnifying Party has timely disputed its liability with respect to such claim as provided above, as promptly as possible, such Indemnified Party and the Indemnifying Party will establish the merits and amount of such claim by mutual agreement or, if mutual agreement has not been reached within sixty (60) days following delivery of the dispute notice, then by dispute resolution pursuant to Section 8.10.

(b) Within five business days following the final determination of any claim for Losses made by any of the Buyer Indemnitees (by mutual agreement or by dispute resolution pursuant to Section 8.10), Buyer shall deduct from the unpaid principal of the Holdback Note the amount of such finally determined Losses. In the event that the Losses exceeds the amounts then remaining of the principal amount of the Holdback Note and to the extent recovery for such Losses is not otherwise limited pursuant to Section 7.06, the Seller shall be required to promptly pay to such Buyer Indemnitee, by wire transfer of immediately available funds to an account designated in advance by such Buyer Indemnitee, the amount of such Losses.

(c) Within five business days following the final determination of any claim for Losses made by any of the Seller Indemnitees, Buyer shall be required to promptly pay to Seller, by wire transfer of immediately available funds to an account designated in advance by Seller, the amount of such Losses.

(d) In case any Third Party Claim, action or proceeding is brought against any Indemnified Party in respect of which indemnification may be sought by the Indemnified Party pursuant to this ARTICLE VII (a "Claim”), the parties shall discuss in good faith whether the Indemnifying Party or the Indemnified Party shall control the defense of such Claim; provided, that the Indemnifying Party shall not be able to control such defense without the consent of the Indemnified Party (which shall not be unreasonably withheld, conditioned or delayed). If the Indemnifying Party controls the Claim, it shall not settle or compromise such Claim without the prior written consent of the Indemnified Party (which shall not be unreasonably withheld, conditioned or delayed) unless such settlement includes as an unconditional term thereof the giving by the claimant or the plaintiff of a release of the Indemnified Party, reasonably satisfactory to the Indemnified Party, from all liability with respect to such Claim and the Indemnifying Party acknowledges that the Claim is fully indemnifiable hereunder and the amount of the Claim is less than the amounts then remaining under the Holdback Amount. Each party shall cooperate with the other parties in the defense of any Claims and keep the other parties apprised on a reasonably prompt basis of all material developments with respect to such Claims.

37

"Indemnified Party” means the Seller Indemnitees having a right to be indemnified by Buyer on the one hand, or the Buyer Indemnitees having a right to be indemnified by Seller on the other hand, as the case may be, pursuant to Section 7.04 or Section 7.05.

"Indemnifying Party” means Seller having an obligation to indemnify the Buyer Indemnitees on the one hand, or Buyer having an obligation to indemnify the Seller Indemnitees on the other hand, as the case may be, pursuant to Section 7.04 or Section 7.05.

Section 7.08 Tax Treatment of Indemnification Payments. All indemnification payments made by Seller under this Agreement shall be treated by the parties as an adjustment to the Purchase Price for tax purposes, unless otherwise required by law.

Section 7.09 Effect of Investigation. Buyer’s right to indemnification or other remedy based on the representations, warranties, covenants and agreements of Seller contained herein will not be affected by any investigation conducted by Buyer with respect to, or any knowledge acquired by Buyer at any time, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or agreement.

Section 7.10 Cumulative Remedies. The rights and remedies provided in this ARTICLE VII are cumulative and are in addition to and not in substitution for any other rights and remedies available at law or in equity or otherwise.

ARTICLE VIII

MISCELLANEOUS

Section 8.01 Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

38

Section 8.02 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a)when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 8.02):

If to Seller:

5805 Sepulveda Blvd., #801

Van Nuys, CA 91411

E-mail: nancy@theseralabs.com

Attention: CEO of The Sera Labs, Inc.

with a copy to:

Stradling Yocca Carlson & Rauth

3075 Townsgate Road, Suite 330

Westlake Village, CA 91361

Attention: Brent Reinke

Email: breinke@stradlinglaw.com

Facsimile: (805) 730-6825

If to Buyer:

TF Tech Ventures, Inc.

4000 N. Federal Highway, Suite 216

Boca Raton, FL 33431

E-mail: capreston92@gmail.com

Attention: CA Preston, CEO

with a copy to:

K&L Gates LLP

4 Embarcadero Center, Suite 1200

San Francisco, CA 94111

Facsimile: 415-882-8220

E-mail: alidad.vakili@klgates.com

Attention: Alidad Vakili

Section 8.03 Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

Section 8.04 Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

Section 8.05 Entire Agreement. This Agreement and the documents to be delivered hereunder constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and the documents to be delivered hereunder, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.

Section 8.06 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed. No assignment shall relieve the assigning party of any of its obligations hereunder.

39

Section 8.07 No Third-party Beneficiaries. Except as provided in ARTICLE VII, this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

Section 8.08 Amendment and Modification. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto.

Section 8.09 Waiver. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

Section 8.10 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of California without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

Section 8.11 Submission to Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of California in each case located in the city of Ventura and county of Ventura, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.

Section 8.12 Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may arise under this Agreement is likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the transactions contemplated hereby.

Section 8.13 Specific Performance. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.

Section 8.14 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[signature page follows]

40

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

CURE Pharmaceutical Corporation

By

/s/ Rob Davidson

Name:

Title:

Rob Davidson

CEO

TF TECH VENTURES, INC.

By

/s/ C.A. Preston

Name:

Title:

C.A. Preston

CEO & President

[Signature Page to Asset Purchase Agreement]

41

SCHEDULES

to the

ASSET PURCHASE AGREEMENT

by and between

CURE Pharmaceutical Corporation

and

TF Tech Ventures, Inc.

42

Schedule 1.01

Purchased Assets

1. The Purchased IP, including but not limited to:

The following patents:

PATENTS

Title

Serial No.

(Filing Date)

Status

Patent No.

(Issue Date)

Record Owner

(Legal Owner)

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

11/836,758

(08/09/2007)

Issued

U.S. 8,840,919

(09/23/2014)

Cure Pharmaceutical Corporation

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

14/490,959

(09/19/2014)

Issued

U.S. 9,155,698

(10/13/2015)

Cure Pharmaceutical Corporation

Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

15/666,057

(08/01/2017)

Issued

U.S. 10,398,644

(09/03/2019)

Cure Pharmaceutical Corporation

Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use

11/371,167

(03/07/2006)

Issued

U.S. 8,999,372

(04/07/2015)

Cure Pharmaceutical Corporation

Thin film with high load of active ingredient

13/890,875

(5/9/2013)

Issued

U.S. 10,413,516

(09/17/2019)

Cure Pharmaceutical Corporation

43

Thin film with high load of active ingredient

CN Filing No. 201480039313.6

(11/09/2015)

Issued

CN Patent No. ZL201480039313.6

(02/07/2020)

Cure Pharmaceutical Corporation

Thin film with high load of active ingredient

CN Filing No. 202010151541.X

(03/06/2020)

Pending

N/A

Cure Pharmaceutical Corporation

Methods and compositions for improving sleep

16/432,443

(06/05/2019)

Allowed

U.S. 11,331,309

(05/17/2022)

Cure Pharmaceutical Corporation

Methods and compositions for improving sleep

17/660,479

(04/25/2022)

Pending

N/A

Cure Pharmaceutical Corporation

OTF Containing Vitamin D3

17/038,494

(09/30/2020)

Pending

N/A

Cure Pharmaceutical Corporation

Oral soluble film containing sildenafil citrate

17/236,054

(04/21/2021)

Issued

U.S. 11,179,331

(11/23/2021)

Cure Pharmaceutical Corporation

Oral soluble film containing sildenafil citrate

17/488,610

(09/29/2021)

Pending

N/A

Cure Pharmaceutical Corporation

OTF with high load of polymeric binder

17/236,008

(04/21/2021)

Pending

N/A

Cure Pharmaceutical Corporation

Method for obtaining an extract of a plant biomass

17/193,261

(03/05/2021)

Pending

N/A

Cure Pharmaceutical Corporation

Edible films for administration of medicaments to animals

10/921,770

(08/18/2004)

Issued

U.S. 9,561,182

(02/07/2017)

Cure Pharmaceutical Corporation

Low moisture rapidly disintegrating OTF

16/508,637

(07/11/2019)

Issued

U.S. 11,344,506 (05/31/2022)

Cure Pharmaceutical Corporation

44

Rapidly disintegrating oral film matrix

PCT/US19/41328

(07/11/2019)

National Phase:

CA (Appl. No. 3106167)

SK (Appl. No. 10-2021-7004173)

EP (Appl. No. 19 745 924.1)

HK (Appl. No. 62021041213.1)

JP (Appl. No. 2021-523566)

CN (Appl. No 201980059169.5)

AU (Appl. No. 2019302664)

SG (Appl. No. 11202100241U)

ZA (Appl. No. 2021/00395)

NZ (Appl. No. 771961)

IN (Appl. No. 202117002338)

Pending

N/A

Cure Pharmaceutical Corporation

OTF with pores extending therethrough

17/331,731

(05/27/2021)

Pending

N/A

Cure Pharmaceutical Corporation

Protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol

13/444,852

(04/12/2012)

Issued

U.S. 10,470,478

(11/12/2019)

Cure Pharmaceutical Corporation

Protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol

16/559,797

(09/04/2019)

Issued

U.S. 11,160,292

(11/02/2021)

Cure Pharmaceutical Corporation

OTF and Method of Manufacturing and Using the Same

PCT/US20/067677

(12/31/2020)

Pending

N/A

Cure Pharmaceutical Corporation

45

The following registered United States Trademarks:

TRADEMARKS

Trademark

Serial No.

(Filing Date)

Registration No.

Status

Record Owner

View Filing Data for SEC filing 0001477932-22-005454 (1)

C CURE PHARMACEUTICAL

The mark consists of the word "CURE” appearing over the word "pharmaceutical.” A stylized letter C appears on the left side of the words. The two ends of the C are connected by varying shades of gray to form a circle.

88035253

(07/12/2018)

5708591

Registered

(03/26/2019)

Cure Pharmaceutical Corporation

View Filing Data for SEC filing 0001477932-22-005454 (2)

Logo

The mark consists of a stylized letter C. The two ends of the C are connected by varying shades of gray to form a circle.

88035251

(07/12/2018)

5708589

Registered

(03/26/2019)

Cure Pharmaceutical Corporation

CUREFILM

The mark consists of standard characters, without claim to any particular font style, size, or color.

88035249

(07/12/2018)

5690125

Registered

(03/05/2019)

Cure Pharmaceutical Corporation

DELIVERING THE PROMISE OF HEALTHIER LIVES

88035248

(07/12/2018)

6008699

Registered

(03/10/2020

Cure Pharmaceutical Corporation

CURE PHARMACEUTICAL

The mark consists of standard characters, without claim to any particular font style, size, or color.

88035238

(07/12/2018)

5708588

Registered

(03/26/2019)

Cure Pharmaceutical Corporation

46

The following unregistered Trademarks:

1. Powered by CURE

2. CUREdots

3. CUREcream

4. CUREpods

5. CUREdrops

The following Domain Names:

Domain Name

Jurisdiction Where the Application or Registration is Located

Application or Registration Number

Application or Registration Date

Record Owner/Registrant

Applicable Registrar and Expiration Date

curepharmaceutical.com

HostMonster.com

N/A

7/12/2008

Cure Pharmaceutical Corporation

HostMonster

6/27/2023

curepharmainc.com

HostMonster.com

N/A

6/3/2010

Cure Pharmaceutical Corporation

HostMonster

6/3/2023

curepharma.com

NameBright.com

N/A

5/31/2014

Cure Pharmaceutical Corporation

ProNamed LLC 5/31/2023

by-cure.com

GoDaddy.com

N/A

4/13/2020

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/13/2024

bycure.online

GoDaddy.com

N/A

4/13/2020

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/13/2024

curebio.net

GoDaddy.com

N/A

3/5/2019

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

3/5/2023

47

curebio.us

GoDaddy.com

N/A

3/5/2019

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

3/5/2023

curebioscience.co

GoDaddy.com

N/A

4/27/2019

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/27/2023

curebioscience.com

GoDaddy.com

N/A

4/27/2020

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/27/2024

curebioscience.net

GoDaddy.com

N/A

3/5/2019

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

3/5/2023

curebioscience.us

GoDaddy.com

N/A

3/5/2019

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

3/5/2023

curebiosciences.com

GoDaddy.com

N/A

4/30/2018

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/30/2023

poweredbycure.com

GoDaddy.com

N/A

4/13/2020

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/30/2024

wellnessbycure.com

GoDaddy.com

N/A

4/13/2020

Cure Pharmaceutical Corporation

GoDaddy.com, LLC

4/30/2024

48

KNOW-HOW

The CURE Know-How which is broadly directed to the development and manufacturing of dosage forms such as oral thin films (OTFs), for wellness products and/or pharmaceutical drug products. The CURE Know-How includes all know-how of the Company, including, but not limited to, all unpatented inventions, in-process research and development, technologies, methods, materials, know-how, studies, pre-clinical and clinical data (including toxicology and safety data), tests and assays, reports, manufacturing processes, regulatory filings (including drafts), product selection, quality systems, and other information controlled by Seller.

OTHER PURCHASED ASSETS

Any other Intellectual Property of the Seller actually used in the Business.

Inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories of the Business.

Furniture, fixtures, equipment, hardware, supplies and other tangible personal property of the Business, excluding personal effects of the Seller employees, if any.

Deposits and prepaid expenses of the Business, which had the following balances as of March 31, 2022:

· Inventory deposits in the amount of $5,444.95

· Building lease security deposit in the amount of $34,500.00

· Utility deposits in the amount of $855.00

· Equipment deposits in the amount of $66,982.50

· Prepaid software license in the amount of $13,500

Originals, or where not available, electronic copies, of books and records, including books of account, ledgers and general, financial and accounting records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, research and development files, records and data (including all correspondence with any Governmental Authority), sales material and records, strategic plans, internal financial statements and marketing and promotional surveys, material and research, emails and other correspondence, that exclusively relate to the Business.

All telephone numbers, websites, URLs and e-mail addresses owned, licensed or otherwise used by Seller in connection with, or otherwise relating to, any of the Business and/or the Purchased Assets.

49

All Web 2.0 (including but not limited to Facebook or Twitter, LinkedIn, TikTok, Instagram) or similar social media accounts maintained or established by Seller or otherwise relating to the Business, including the following:

Social Media Names and Keywords

Site

Social Media Name

Keywords/Hashtags

Facebook.com

CURE Pharmaceutical

@CUREPharmaceutical

LinkedIn.com

CURE Pharmaceutical

#Drugdelivery

#Cannabinoids

#Patientexperience

Instram.com

curepharma

#PoweredByCURE

Twitter.com

CURE Pharmaceutical

@Cure_Pharma_

#PoweredByCURE

The goodwill associated with any of the Purchased Assets

The Assigned Contracts set forth on Section 3.08 of the Disclosure Schedule.

The Permits of the Business to the extent transferable, including but not limited to the Permits set forth in Section 3.09 of the Disclosure Schedule, to the extent transferable.

All of Seller’s rights under warranties, indemnities, and all similar rights against third parties to the extent related to any Purchased Assets.

All insurance benefits, including rights and proceeds, arising from or relating to the Business, the Purchased Assets, or the Assumed Liabilities.

50

Schedule 1.02

Assumed Liabilities

1. The Rolled Vacation attributable to the Continuing Employees pursuant to Section 5.05(d) of the Agreement, which shall be honored by Buyer in accordance with the terms of the Agreement and in compliance with applicable Law to the extent the dollar value of such Rolled Vacation was deducted from the Closing Consideration, which Rolled Vacation is set forth below:

Rolled Vacation Amounts

Employee

Vacation Amount

Personal Time Off Amount

Cheryl Baumgart

$2,259.78

$115.00

Jose Bernardo

-

$576.92

Sandy Garate

$1,964.92

$122.20

Adrienne Grashaw

$1,878.95

$480.00

Tim Habeck

$3,726.10

-

Katherine Landas

-

$480.00

Courtney Lasley

$3,468.16

-

Karina Sierra

$20.19

$320.00

Sarahi Zuniga

$42.55

$368.00

2. The following employer-portion of any payroll, employment and other similar taxes applicable to the Rollover Vacation:

Social security: $981.01

Medicare: $229.43

FUTA: $94.94

SUI: $537.97

ETT: $15.82

3. Liabilities arising under the Assigned Contracts but only to the extent that such liabilities thereunder are required to be performed after the Closing Date (even if accruing prior to the Closing Date), including Liabilities for the following deferred revenue associated with customer deposits made under Assigned Contracts, which customer deposits shall be retained by the Seller, but which shall not reduce the Closing Cash Consideration:

a. $215,000 deposited in connection with the Collaboration and Joint Development Agreement, dated February 1, 2021, by and between Seller and Medolife Rx.

b. $25,000 under the Development Agreement, dated May 10, 2022, by and between Seller and Robell Research, Inc., d/b/a Supersmile.

4. All liabilities of Seller with respect to the Key Employees and the employees of Seller set forth on Schedule 5.05(a)-1 and Schedule 5.05(a)-2 of these Schedules, arising from the employment of such employees after the Closing, including wages, cash or equity incentive compensation, accrued personal time off, accrued vacation accrued payroll, accrued unpaid commissions, accrued bonuses, accrued sick leave or vacation, accrued bereavement time, accrued floating holidays or other similar accrued paid time off, business expense reimbursements, and related Taxes.

51

Schedule 1.03(a)

Loan Amount

Unsecured Buyer Deposits

Invisiguard, Inc. (C.A. Preston)

10/15/21

$250,000

Invisiguard, Inc. (C.A. Preston)

12/13/21

$60,000

Invisiguard, Inc. (C.A. Preston)

12/15/21

$138,000

Raymond J. Vanaria (Drew Cervasio)

1/31/22

$250,000

Invisiguard, Inc. (C.A. Preston)

2/11/22

$52,000

Raymond J. Vanaria (Drew Cervasio)

2/28/22

$250,000

Raymond J. Vanaria (Drew Cervasio)

3/4/22

$300,000

Raymond J. Vanaria (Drew Cervasio)

3/9/22

$1,200,000

Raymond J. Vanaria (Drew Cervasio)

4/27/22

$500,000

Raymond J. Vanaria (Drew Cervasio)

5/18/22

$250,000

Raymond J. Vanaria (Drew Cervasio)

5/31/22

$250,000

Andrew F. Cervasio

6/10/22

$300,000

Raymond J. Vanaria (Drew Cervasio)

7/5/22

$300,000

52

Schedule 1.03(b)

Closing Consideration

1. Rollover Vacation Cashout Payments, which does not reduce the Closing Consideration:

Rollover Vacation Cashout Payments

Employee

Vacation Amount

Personal Time Off Amount

Jose Bernardo

7,200.44

-

Robert Davidson

25,000.00

2,000.00

Lina Galeano

192.03

156.00

Katherine Landas

6,000.00

-

Michael Redard

23,076.92

1,846.15

Mark Udell

15,384.62

1,230.77

2. Rolled Vacation Amounts:

Rolled Vacation Amounts

Employee

Vacation Amount

Personal Time Off Amount

Cheryl Baumgart

$2,259.78

$115.00

Jose Bernardo

-

$576.92

Sandy Garate

$1,964.92

$122.20

Adrienne Grashaw

$1,878.95

$480.00

Tim Habeck

$3,726.10

-

Katherine Landas

-

$480.00

Courtney Lasley

$3,468.16

-

Karina Sierra

$20.19

$320.00

Sarahi Zuniga

$42.55

$368.00

3. The following employer-portion of any payroll, employment and other similar taxes applicable to the Rolled Vacation: $1,859.18

4. Purchase Order #060222-A issued by Robell Research, Inc., d/b/a Supersmile to Seller on June 2, 2022.

5. Wire Instructions:

Wire Transfer Instructions

Bank:

ABA Routing #

Beneficiary Name:

Cure Pharmaceutical Corporation

Bank Account #:

SWIFT #

(International Wires Only)

53

Schedule 1.04

Third-Party Payments

(i)

1. $178,886.13 Settlement Agreement, dated April 29, 2022, by and between Cure Pharmaceutical Corporation and Settle, Inc.

2. $122,378 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated November 18, 2021, by and between Cure Pharmaceutical Holding Corp. and Fourth Street Fund, LP.

3. $1,168,738 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated June 30, 2021, by and between Cure Pharmaceutical Holding Corp. and The Duitch Living Trust dated January 9, 1989.

4. $44,649 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note and Security Agreement, dated January 12, 2022, by and between Cure Pharmaceutical Holding Corp. And The Duitch Living Trust dated January 9, 1989.

5. $177,881 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated August 6, 2021, by and between Cure Pharmaceutical Holding Corp. and Onbelay Capital Inc.

6. $53,504 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated November 16, 2021, by and between Cure Pharmaceutical Holding Corp. and Onbelay Capital Inc.

7. $218,788 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated October 16, 2021, by and between Cure Pharmaceutical Holding Corp. and Cresco Capital Partners II, LLC.

8. $21,571 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated October 16, 2021, by and between Cure Pharmaceutical Holding Corp. and Mac F&F Spe, LLC.

9. $267,589 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated November 15, 2021, by and between Cure Pharmaceutical Holding Corp. and Macarthur Investments, LLC.

10. $26,465 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated December 28, 2021, by and between Cure Pharmaceutical Holding Corp. and Maci Molecule SPV, LLC.

54

11. $54,052 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated October 7, 2021, by and between Cure Pharmaceutical Holding Corp. and Maci Molecule SPV, LLC.

12. $224,811 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note, dated May 3, 2021, by and between Cure Pharmaceutical Holding Corp. and Maci Molecule SPV, LLC.

13. $210,564 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note and Security Agreement, dated January 18, 2022, by and between Cure Pharmaceutical Holding Corp. and Interplaza Development Company, LLC and Amendment to Secured Promissory Note, dated April 11, 2022, by and between Cure Pharmaceutical Holding Corp. and Interplaza Development Company, LLC.

14. $21,100 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note and Security Agreement, dated January 10, 2022, by and between Cure Pharmaceutical Holding Corp. and Mac F&F Spe, LLC.

15. $73,851 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note and Security Agreement, dated January 10, 2022, by and between Cure Pharmaceutical Holding Corp. and MacArthur Investments, LLC.

16. $105,501 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Cure Pharmaceutical Holding Corp. Secured Promissory Note and Security Agreement, dated January 10, 2022, by and between Cure Pharmaceutical Holding Corp. and Cresco Capital Partners II, LLC.

17. $361,655 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated October 27, 2021, by and between Cure Pharmaceutical Holding Corp. and EROP Enterprises, LLC.

18. $270,391 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated October 30, 2021, by and between Cure Pharmaceutical Holding Corp. and Fromar Investments LP.

19. $212,044 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated December 16, 2021, by and between Cure Pharmaceutical Holding Corp. and Fromar Investments LP.

20. $302,163 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated May 18, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

55

21. $591,603 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated August 12, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

22. $288,343 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated January 13, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

23. $285,398 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated February 25, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

24. $113,008 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated April 8, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

25. $169,307 and the Per Diem Amount (as defined in the relevant Payoff Letter) under Secured Promissory Note, dated April 13, 2021, by and between Cure Pharmaceutical Holding Corp. and Ross Equity Partners.

(ii)

Seller’s portion of July pro rata rent: $14,957.

(iii)

Overdue rent in the amount of $92,730.16 and property tax and insurance overages in the total amount of $20,263.

(iv)

Buyout payment in the amount of $58,510.22 under VideoJet Equipment Lease Proposal Q-118450, dated June 26, 2019 by and between Seller and Videojet Technologies LTD.

56

Schedule 5.07

Affected Patents

Assignments Status (per PTO assignment database)

Appln. No. (Serial No.)

Carlson Caspers Matter No.

1.Innozen->Cure Pharm Corp

2.Cure Pharm Corp->Cure Pharm Holding Corp

No inventor assignment filed

11/836,758

1351.015US1

1.Zengen->Innozen

2.Inventors->Zengen

3.Innozen->Cure Pharm Corp

4.Cure Pharm Corp->Cure Pharm Holding Corp

15/666,057

1351.003US1

1.Zengen->Innozen

2.Innozen->Zengen

3.Innozen->Cure Pharma Corp

4.Innozen->Cure Pharma Corp

5.Inventor->Cure Pharma Corp

6. Cure Pharma Corp->Cure Pharma Holding Corp

10/921,770

1351.018US1

1.Cure Pharma Corp->Cure Pharm Holding Corp

2.Inventor->Chemistry Holding

3.Chemistry Holding->Cure Pharma Corp

4.Chemistry Holdings->Cure Pharma Corp

13/444,852

1351.016US

57

Schedule 5.09

Referenced Patents

PATENTS

Title

Serial No.

Filing Date

Status

Patent No.

(Issue Date)

Oral dissolvable film that includes plant extract

14/810,595

07/28/2015

Issued

U.S. 10,307,397

(06/04/2019)

Oral dissolvable film that includes plant extract

16/394,413

04/25/2019

Issued

U.S. 11,266,625 (03/08/2022)

Oral dissolvable film containing psychedelic compound

16/947,005

07/14/2020

Pending

N/A

Oral soft gel capsule containing psychedelic compound

16/947,003

07/14/2020

Pending

N/A

Pharmaceutical composition and method of manufacturing

14/255,296

04/17/2014

Issued

U.S. 9,044,390 (06/02/2015)

Pharmaceutical composition and method of manufacturing

14/723,980

05/28/2015

Issued

U.S. 9,186,386 (11/17/2015)

Pharmaceutical composition and method of manufacturing

14/694,303

04/23/2015

Issued

US 9,980,996 (05/29/2018)

Pharmaceutical composition and method of manufacturing

15/988,484

05/24/2018

Issued

U.S. 10,092,611 (10/09/2018)

Pharmaceutical composition and method of manufacturing

14/934,940

11/06/2015

Issued

US 10,238,705 (03/26/2019)

Pharmaceutical composition and method of manufacturing

16/151,436

10/04/2018

Issued

U.S. 10,639,339 (05/05/2020)

Pharmaceutical composition and method of manufacturing

16/359,579

03/20/2019

Issued

U.S. 10,624,940 (04/21/2020)

Pharmaceutical composition and method of manufacturing

16/809,958

03/05/2020

Issued

11,266,702 (03/08/2022)

Pharmaceutical composition and method of manufacturing

16/809,700

03/05/2020

Allowed

Pharmaceutical composition and method of manufacturing

16/856,492

04/23/2020

Issued

U.S. 11,344,591

(05/11/2022)

Pharmaceutical composition and method of manufacturing

16/856,609

04/23/2020

Issued

U.S. 11,331,358 (05/17/2022)

58

EXHIBIT 10.2

SECURED PROMISSORY NOTE FROM

TF TECH VENTURES, INC.

$2,000,000

Oxnard, California

July 22, 2022

FOR VALUE RECEIVED, TF Tech Ventures, Inc., a Delaware corporation (the "Borrower”) hereby unconditionally promises to pay to the order of CURE Pharmaceutical Corp. a California corporation (the "Noteholder”), with its principal address at 5805 Sepulveda Blvd., #801, Van Nuys, CA 91411, the principal amount of $2,000,000 (the "Loan”), together with all accrued interest thereon, as provided in this Secured Promissory Note (this "Note”).

1. Payment Dates.

(a) Payment Date. The aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note shall be due and payable on July 22, 2023 ("Maturity Date”), other than with respect to any Pending Claim Amount for which portion of the Loan the Maturity Date is extended as set forth in Section 5 below.

(b) Prepayment. The Borrower may prepay the Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment.

2. Interest.

(a) Interest Rate. Except as provided in Section 2(b), principal amounts outstanding under this Note shall bear interest at a rate per annum (the "Interest Rate”) equal to 2.37%.

(b) Default Interest. If any amount payable hereunder is not paid when due (without regard to any applicable grace period), whether at stated maturity, by acceleration, or otherwise, such overdue amount shall bear interest at the Interest Rate plus 2.63% (the "Default Rate”).

(c) Computation of Interest. All computations of interest hereunder shall be made on the basis of a year of 365 days and the actual number of days elapsed. Interest shall begin to accrue on the Loan on the date of this Note. On any portion of the Loan that is repaid, interest shall not accrue on the date on which such payment is made.

(a) Interest Rate Limitation. If at any time the Interest Rate or Default Rate, as the case may be, payable on the Loan shall exceed the maximum rate of interest permitted under applicable law, such Interest Rate or Default Rate, as the case may be, shall be reduced automatically to the maximum rate permitted.

3. Payment Mechanics.

(a) Manner of Payment. All payments of principal and interest shall be made in US dollars on the date on which such payment is due and shall be made to Noteholder at 5805 Sepulveda Blvd., #801, Van Nuys, CA 91411, or at such other place as Noteholder may, from time to time, designate in writing. Such payments shall be made by cashier’s check, certified check, or wire transfer of immediately available funds to the Noteholder’s account at a bank specified by the Noteholder in writing to the Borrower from time to time.

(b) Application of Payments. All payments shall be applied, first, to fees or charges outstanding under this Note, second, to accrued interest, and, third, to principal outstanding under this Note.

(c) Business Day. Whenever any payment hereunder is due on a day that is not a Business Day, such payment shall be made on the next succeeding Business Day, and interest shall be calculated to include such extension. "Business Day” means a day other than Saturday, Sunday, or other day on which commercial banks in Los Angeles, California are authorized or required by law to close.

(d) Evidence of Debt. The Borrower authorizes the Noteholder to record on the grid attached as Exhibit A the Loan made to the Borrower and the date and amount of each payment or prepayment of the Loan. The entries made by the Noteholder shall be prima facie evidence of the existence and amount of the obligations of the Borrower recorded therein in the absence of manifest error. No failure to make any such record, nor any errors in making any such records, shall affect the validity of the Borrower’s obligation to repay the unpaid principal of the Loan with interest in accordance with the terms of this Note.

4. Grant of Security Interest.

(a) Borrower hereby unconditionally grants, assigns, and pledges to Noteholder to secure the Borrower’s obligations to make any payments under the terms of this Note, (the "Obligations”), a first priority continuing security interest (hereinafter referred to as the "Security Interest”) in all of Maker’s right, title, and interest in and to the following (as each such capitalized term is defined in the California Uniform Commercial Code, the "Code”) or the Purchase Agreement, as applicable), whether now owned or hereafter acquired or arising and wherever located (collectively, the "Collateral”): (i) fixed assets to the extent included in the Purchased Assets, (ii) all inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories, (iii) accounts receivable (iv) all substitutions for, additions to, replacements for, improvements to, and accessions to the foregoing (i) – (iii), and (v) all of the proceeds (as such term is defined in the Code) and products, whether tangible or intangible, of any of the foregoing clauses (i), (ii), and (iv), and any and all Accounts, Books, money, or other tangible or intangible property resulting from the sale, or other disposition of any of the foregoing. Borrower hereby authorizes Noteholder to file with the California Secretary of State’s Office a UCC-1 Financing Statement with respect to Noteholder’s Security Interest in the Collateral, and to execute, acknowledge, deliver, file and record, as the case may be, with the proper filing and recording agencies in any jurisdiction, all such instruments, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by the Noteholder, to perfect the Security Interest granted hereunder and otherwise to carry out the intent and purposes of this Note, or for assuring and confirming to the Noteholder the grant or perfection of a perfected first priority security interest in all the Collateral under the UCC.

2

(b) Upon the occurrence of an Event of Default and the expiration of any applicable notice or cure periods hereunder, Noteholder, at its option, may (i) exercise any one or more of the cumulative rights and remedies hereinafter set forth and any other right or remedy provided for in this Note or available at law or in equity, and any one or more of such rights and remedies may be exercised simultaneously or successively, and the initiation or completion of any such exercise shall not constitute an election and shall not estop or prevent the pursuit of any other right or remedy; (ii) dispose of the Collateral in any manner allowed by law, in whole or in part, at one or more public or private sales, in its then condition or following any commercially reasonable action; and (iii) incur expenses, including reasonable attorneys’ fees and related costs, in the exercise of any right or remedy under or in connection with this Note, and Borrower agrees to pay or reimburse Noteholder for all such expenses and all such expenses shall become a part of the Secured Obligations hereunder. Noteholder is hereby vested with full power and authority to deliver to the purchaser or purchasers any and all of the Collateral disposed of in accordance herewith, and to execute and deliver any and all instruments or documents necessary to vest full title thereto in such purchaser or purchasers. Borrower hereby waives all demands of performance, notices of sale, advertisements and presence of the Collateral at any disposition thereof, except that Borrower shall be given thirty (30) days written notice of any disposition, which notice shall include the time and place of any public sale or the place where, and the time on or after which, any other disposition is to be made. Such sale may be conducted by an auctioneer or by any agent of Noteholder.

(c) Borrower hereby waives any right to require Noteholder (i) to proceed against any other person, firm or corporation liable on, or in connection with, any of the Secured Obligations; (ii) to proceed against or exhaust the Collateral, whether now held or hereafter acquired, or any specific part thereof; or (iii) to pursue any other right or remedy within Noteholder’s power.

(d) The proceeds of any disposition of all or any part of the Collateral shall be applied as follows: (i) first, to the payment of any and all reasonable expenses, including actual costs and reasonable attorneys’ fees, incurred or paid by Noteholder in enforcing this Agreement, or in obtaining possession of, dealing with or disposing of the Collateral; (ii) second, to the payment of the unpaid balance of the Loan, including accrued interest; and (iii) thereafter, any surplus shall be paid to Borrower.

(e) When the unpaid balance of the Loan is paid, and all of the Secured Obligations have been fully satisfied and discharged, Noteholder shall release its Security Interest in and to the Collateral, and this Note shall terminate and be of no further force or effect. Upon the termination of this Note pursuant to this Section 4(e), Noteholder shall, at the expense of Borrower, take all actions reasonably necessary or desirable to release any security interest then existing pursuant to this Note.

3

5. Representations and Warranties. The Borrower represents and warrants to the Noteholder as follows:

(a) Existence. The Borrower is a corporation duly incorporated, validly existing, and in good standing under the laws of the state of its organization. The Borrower has the requisite power and authority to own, lease, and operate its property, and to carry on its business.

(b) Power and Authority. The Borrower has the requisite power and authority to execute, deliver, and perform its obligations under this Note.

(c) Authorization; Execution and Delivery. The execution and delivery of this Note by the Borrower and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with applicable law. The Borrower has duly executed and delivered this Note.

6. Offset Right. This Note is being delivered by Borrower as consideration for Borrower’s purchase of certain assets of Noteholder pursuant to that certain Asset Purchase Agreement between Borrower, as purchaser, and Noteholder, as seller, dated as of the date hereof (the "Purchase Agreement”). Any terms not otherwise defined herein shall have the meaning given to such term in the Purchase Agreement. Borrower shall have the right to offset the principal amount of the Loan by the amount of any Losses finally determined to be due from Seller to any Buyer Indemnitee in accordance with the terms of Section 7.07(a) of the Purchase Agreement. If Borrower provides Noteholder with notice of an indemnification claim in accordance with the Purchase Agreement prior to the Maturity Date, then the Maturity Date will be extended with respect to the amount of such Pending Claim until the fifth (5th) Business Day following the final determination of such indemnifiable claim. For the avoidance of doubt, Buyer shall make payment on the Maturity Date of the aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note minus the Pending Claim Amount, if any. Reductions to the principal amount of the Loan as provided for in this Section 6 shall be treated and reported for all federal tax purposes as adjustments to the Purchase Price, unless otherwise required by law.

7. Events of Default. The occurrence and continuance of any of the following shall constitute an "Event of Default” hereunder:

(a) Failure to Pay. The Borrower fails to pay (i) any principal amount of the Loan when due or (ii) any other amount due hereunder within ten (10) days after such amount is due.

(b) Breach of Representations and Warranties. Any representation or warranty made by the Borrower to the Noteholder herein contains an untrue or misleading statement of a material fact as of the date made; provided, however, no Event of Default shall be deemed to have occurred pursuant to this Section 7(b) if, within thirty (30) days of the date on which the Borrower receives notice (from any source) of such untrue or misleading statement, Borrower shall have addressed the adverse effects of such untrue or misleading statement to the reasonable satisfaction of the Noteholder.

4

(c) Bankruptcy; Insolvency.

(i) The Borrower institutes a voluntary case seeking relief under any law relating to bankruptcy, insolvency, reorganization, or other relief for debtors.

(ii) An involuntary case is commenced seeking the liquidation or reorganization of the Borrower under any law relating to bankruptcy or insolvency, and such case is not dismissed or vacated within sixty (60) days of its filing.

(iii) The Borrower makes a general assignment for the benefit of its creditors.

(iv) A case is commenced against the Borrower or its assets seeking attachment, execution, or similar process against all or a substantial part of its assets, and such case is not dismissed or vacated within sixty (60) days of its filing.

8. Notice of Event of Default. As soon as possible after it becomes aware that an Event of Default has occurred, and in any event within two (2) Business Days, the Borrower shall notify the Noteholder in writing of the nature and extent of such Event of Default and the action, if any, it has taken or proposes to take with respect to such Event of Default.

9. Remedies. Upon the occurrence and during the continuance of an Event of Default, the Noteholder may, at its option, by written notice to the Borrower declare the outstanding principal amount of the Loan, accrued and unpaid interest thereon, and all other amounts payable hereunder immediately due and payable and shall have all the rights and remedies available to it under this Note and the Security Agreement.

10. Expenses. The Borrower shall reimburse the Noteholder on demand for all reasonable and documented out-of-pocket costs, expenses, and fees, including the reasonable fees and expenses of counsel, incurred by the Noteholder in connection with the enforcement of the Noteholder’s rights hereunder.

5

11. Notices. All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (x) deposit with the United States Postal Service or overnight courier service, properly addressed and postage prepaid; (y) transmittal by facsimile or e-mail properly addressed (with confirmation of transmission); or (z) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party shall specify in writing:

If to Seller:

5805 Sepulveda Blvd., #801

Van Nuys, CA 91411

E-mail: nancy@theseralabs.com

Attention: CEO of The Sera Labs, Inc.

with a copy to:

Stradling Yocca Carlson & Rauth

3075 Townsgate Road, Suite 330

Westlake Village, CA 91361

Attention: Brent Reinke

Email: breinke@stradlinglaw.com

Facsimile: (805) 730-6825

If to Buyer:

TF Tech Ventures, Inc.

4000 N. Federal Highway, Suite 216

Boca Raton, FL 33431

Facsimile: ____________________

E-mail: capreston92@gmail.com

Attention: CA Preston, CEO

with a copy to:

K&L Gates LLP

4 Embarcadero Center, Suite 1200

San Francisco, CA 94111

Facsimile: 415-882-8220

E-mail: alidad.vakili@klgates.com

Attention: Alidad Vakili

12. Governing Law. This Note and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based on, arising out of, or relating to this Note and the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of California.

13. Disputes.

(a) Submission to Jurisdiction.

(i) The Borrower irrevocably and unconditionally (A) agrees that any action, suit, or proceeding arising from or relating to this Note may be brought in the courts of the State of California sitting in Ventura County, and in the United States District Court for the Central District of California, and (B) submits to the jurisdiction of such courts in any such action, suit, or proceeding. Final judgment against the Borrower in any such action, suit, or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

(ii) Nothing in this Section 13(a) shall affect the right of the Noteholder to bring any action, suit, or proceeding relating to this Note against the Borrower or its properties in the courts of any other jurisdiction.

(iii) Nothing in this Section 13(a) shall affect the right of the Noteholder to serve process upon the Borrower in any manner authorized by the laws of any such jurisdiction.

(b) Venue. The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by law, (i) any objection that it may now or hereafter have to the laying of venue in any action, suit, or proceeding relating to this Note in any court referred to in Section 13(a), and (ii) the defense of inconvenient forum to the maintenance of such action, suit, or proceeding in any such court.

6

(c) Waiver of Jury Trial. THE BORROWER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY.

14. Successors and Assigns. This Note may not be assigned or transferred by the Noteholder without the prior written consent of the Borrower in its sole discretion.

15. Integration. This Note constitutes the entire contract between the Borrower and the Noteholder with respect to the subject matter hereof and supersedes all previous agreements and understandings, oral or written, with respect thereto.

16. Amendments and Waivers. No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Noteholder. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.

17. No Waiver; Cumulative Remedies. No failure by the Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power. The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.

18. Severability. If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.

19. Counterparts. This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Note by facsimile or in electronic ("pdf” or "tif”) format shall be as effective as delivery of a manually executed counterpart of this Note.

20. Electronic Execution. The words "execution,” "signed,” "signature,” and words of similar import in this Note shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15 U.S.C. § 7001 et seq.) and any other similar state laws based on the Uniform Electronic Transactions Act.

[signature page follows]

7

IN WITNESS WHEREOF, the Borrower has executed this Note as of July 22, 2022.

BORROWER:

TF Tech Ventures, Inc.

By: /s/ C.A. Preston
Name: C.A. Preston
Title: CEO & President

ACKNOWLEDGED AND ACCEPTED BY:

NOTEHOLDER:

CURE Pharmaceutical Corporation

By

/s/ Rob Davidson

Name: Rob Davidson

Title: CEO

8

EXHIBIT 10.3

July 22, 2022

TF Tech Ventures, Inc.

4000 N. Federal Highway, Suite 216

Boca Raton, FL 33431

Re: Asset Purchase

Ladies and Gentlemen:

This letter confirms the agreement (this "Agreement”), entered into as of July 22, 2022, by and between CURE Pharmaceutical Holding Corp., a Delaware corporation ("Parent”) and TF Tech Ventures, Inc., a Delaware corporation ("Buyer”), in consideration of Buyer’s purchase of certain assets of CURE Pharmaceutical Corporation, a California corporation and wholly-owned subsidiary of Parent ("Seller”) pursuant to that certain Asset Purchase Agreement, dated as of the date hereof, by and between Buyer and Seller (the "APA”). Capitalized terms used herein but not defined herein will have the meaning ascribed thereto in the APA.

WHEREAS, concurrently herewith, Seller and Buyer are entering into the APA, pursuant to which Buyer is purchasing the Purchased Assets from Seller, and Parent will directly or indirectly obtain substantial benefit from the consummation of the transactions contemplated by the Purchase Agreement; and

WHEREAS, Parent’s execution and delivery of this Agreement is a condition to the obligation of Buyer to consummate the transactions contemplated by the Purchase Agreement.

NOW, THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Representations and Warranties.

Parent represents and warrants to and for the benefit of Buyer as follows:

a. Organization and Authority of Parent; Enforceability. Parent is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware. Parent has full corporate power and authority to enter into this Agreement and the other documents to be entered into by Parent and delivered under the APA, to carry out its obligations thereunder and to consummate the transactions contemplated thereby. The execution, delivery and performance by Parent of this Agreement and the documents to be entered into by Parent and delivered under the APA and the consummation of the transactions contemplated thereby have been duly authorized by all requisite corporate action on the part of Parent. This Agreement and the documents to be entered into by Parent and delivered under the APA have been duly executed and delivered by Parent, and (assuming due authorization, execution and delivery by Buyer) this Agreement and the documents to be entered into by Parent and delivered under the APA constitute legal, valid and binding obligations of Parent, enforceable against Parent in accordance with their respective terms.

b. No Conflicts; Consents. The execution, delivery and performance by Parent of this Agreement and the documents to be entered into by Parent and delivered under the APA, and the consummation of the transactions contemplated thereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws or other organizational documents of Parent; (b) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Parent. No consent, approval, waiver or authorization is required to be obtained by Parent from any Governmental Authority in connection with the execution, delivery and performance by Parent of this Agreement and the consummation of the transactions contemplated under the APA.

c. Legal Proceedings. There is no Action of any nature pending or threatened against or by Parent (a) with respect to the execution, delivery and performance by Parent of this Agreement and the documents to be entered into by Parent and delivered under the APA, or the consummation of the transactions contemplated thereby; or (b) that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement and the APA. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

d. Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement and the APA based upon arrangements made by or on behalf of Parent.

2. Interest in Intellectual Property; Use of Names.

a. As soon as reasonably practicable after the Closing Date, but in any event within the Transitional Period, Parent shall, and shall cause its Affiliates to, cease and discontinue all uses of any Purchased Marks, except as provided in this Agreement, the Transition Services Agreement, the APA and the Trademark License Agreement including by (i) changing the corporate and business names and trade names of Seller, Parent and their Affiliates to a name that does not include any Purchased Mark and is not confusingly similar thereto and otherwise cease to refer to themselves as or do business under, any Purchased Mark or any name that includes any Purchased Mark, (ii) not putting into use any items or materials that bear any Purchased Mark; (iii) not using any websites or domain names that include any reference to any Purchased Mark, except as expressly contemplated in the APA, (iv) removing or obliterating any Purchased Mark from any and all exterior signs and other identifiers located on or attached to any property, buildings, vehicles, signs or premises used in connection with the Business, and (v) ceasing to use all Business Materials. Seller, Parent, and their Affiliates (A) shall use the Purchased Marks during the Transitional Period only in the same form and manner as they were used in the Business immediately prior to the Closing, (B) shall not modify the Purchased Marks or any Business Materials containing the Purchased Marks in any respect and (C) at Buyer’s reasonable request, shall provide appropriate documentation to confirm compliance with the foregoing. Seller, Parent, and their Affiliates agree that all goodwill arising from any use of the Purchased Marks by Seller, Parent, or any of their Affiliates will inure solely to the benefit of Buyer and its Affiliates. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement or the APA shall restrict Parent and its Affiliates’ (i) sale, promotion, marketing, or advertising of their inventory that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure”, or (ii) use of packaging that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure” on future products that they might purchase form Buyer in accordance with the relevant terms of such purchase(s).

2

b. No later than 60 days following the Closing Date, Parent and its Affiliates shall have arranged for new website domains to host websites of Parent and its Affiliates, which domains shall not include any reference to Purchased Marks. No later than 60 days following the Closing Date, Parent and its Affiliates shall operate its websites solely through such new website domain names (and any other domain names created after the Closing that does not include reference to any Purchased Marks); provided that notwithstanding the foregoing, domains with reference to Purchased Marks may remain active for 180 days after the Closing solely for the purpose of redirecting users to the new websites of Parent and its Affiliates.

3. Covenant Not to Sue.

a. Parent represents that it possesses all or joint right, title, and interest in and to the patents listed in Schedule A attached hereto (the "Referenced Patents”). Parent further represents that as of the date of this Agreement, other than the patents listed on Schedule A of this Agreement and the Registered Intellectual Property listed on Section 1.01 of the APA, neither Parent nor Seller owns any other any Intellectual Property that is the subject of an application or registration with any governmental authority, including any domain name registration and any application or registration for any patent, copyright, mask work or trademark.

b. Parent unconditionally agrees, promises, and covenants that it will not sue or otherwise enforce the Referenced Patents against Buyer, its parents, subsidiaries, affiliates, or successor companies in connection with Buyer’s conduct of the Business.

c. Based on the foregoing representations and subject to the conditions set forth herein, Parent unconditionally agrees, promises, and covenants not to sue or otherwise hold liable Buyer, its parents, subsidiaries, affiliates, or successor companies or their authorized contractors, distributors, and customers, for any and all claims that the manufacture, use, license, sublicense, sale, offer for sale, distribution, and/or importation or exportation of a product in the operation of the Business, strictly by or on behalf of, or as authorized by Buyer (or its parents, subsidiaries, affiliates, or successor-in-interest), infringes any claim of the Referenced Patents.

3

d. Parent also unconditionally agrees, promises, and covenants that it will not sue or otherwise enforce the Referenced Patents against Buyer’s customers, suppliers, importers, manufacturers, licensees, distributors, or insurers in connection with the manufacture, use, license, sublicense, sale, offer for sale, or importation or exportation of Buyer’s products in the operation of the Business.

e. This Agreement and the covenant not to sue set forth herein expressly includes any future assignees, licensees, or successors-in-interest to the Referenced Patents, such that those entities may not sue or otherwise enforce the Referenced Patents against Buyer, its parents, subsidiaries, affiliates, or successors, or Buyer’s customers, suppliers, importers, manufacturers, distributors, or insurers in connection with the manufacture, use, offer for sale, sale, distribution, or importation of the products in the operation of the Business. Buyer further promises to impose the covenant not to sue contained in this Agreement on any assignees, licensees, or successors-in-interest to the Referenced Patents.

f. This Agreement and the covenant not to sue set forth herein expressly includes any successor or assignee of Buyer or any Buyer parent, subsidiaries, affiliates, or successors-in-interest that subsequently purchases substantially all of the assets of either Buyer or any Buyer parent, subsidiary, affiliate, or successor in interest and any entity that subsequently purchases Buyer’s drug products in the operation of the Business.

g. The parties hereto agree that this Agreement and the covenant not to sue set forth herein shall not operate as a waiver or admission of any fact not set forth herein.

h. In the event that Buyer or any of its Affiliates acquires (whether through merger, stock acquisition, asset acquisition or otherwise) any entity, product, product line or technology after the Closing Date, the releases, licenses and covenants granted by Parent hereunder shall in no event apply to any such products, services, or technology of such entity or included within such products, product lines or technology, including with respect to the post-acquisition manufacture, sale, use or other exploitation of such products, services, technology or product lines by Buyer and its Affiliates.

4. Miscellaneous.

a. General Provisions. Section 9.02 (Notices), Section 9.04 (Severability), Section 9.05 (Entire Agreement), Section 9.06 (Successors and Assigns), Section 9.08 (Amendment and Modification), Section 9.09 (Waiver), Section 9.10 (Governing Law), Section 9.11 (Submission to Jurisdiction), Section 9.12 (Waiver of Jury Trial), Section 9.13 (Specific Performance), and Section 9.14 (Counterparts) of the Purchase Agreement are each hereby incorporated by reference mutatis mutandis; provided, that Parent’s notice information is set forth below its signature on the signature page hereto.

b. Attorney’s Fees. In the event any party breaches any of the terms of this Agreement and the Party not in default employs attorneys to protect or enforce its rights hereunder and prevails, then the defaulting party agrees to pay reasonable attorney’s fees and costs incurred by the prevailing party.

Signature page follows

4

IN WITNESS WHEREOF, the parties hereto have executed this letter agreement as of the date first above written.

Very truly yours,

CURE Pharmaceutical Holding Corp.
By: /s/ Robert Davidson

Name:

Robert Davidson

Title:

CEO

Address for Notices:

5805 Sepulveda Blvd., #801

Van Nuys, CA 91411

E-Mail: rdavidson@curepharma.com

AGREED AND ACCEPTED:

TF TECH VENTURES, INC.

By

/s/ C.A. Preston

Name: C.A. Preston

Title: CEO & President

5

Schedule A

Referenced Patents

PATENTS

Title

Serial No.

Filing Date

Status

Patent No.

(Issue Date)

Oral dissolvable film that includes plant extract

14/810,595

07/28/2015

Issued

U.S. 10,307,397

(06/04/2019)

Oral dissolvable film that includes plant extract

16/394,413

04/25/2019

Issued

U.S. 11,266,625 (03/08/2022)

Oral dissolvable film containing psychedelic compound

16/947,005

07/14/2020

Pending

N/A

Oral soft gel capsule containing psychedelic compound

16/947,003

07/14/2020

Pending

N/A

Pharmaceutical composition and method of manufacturing

14/255,296

04/17/2014

Issued

U.S. 9,044,390 (06/02/2015)

Pharmaceutical composition and method of manufacturing

14/723,980

05/28/2015

Issued

U.S. 9,186,386 (11/17/2015)

Pharmaceutical composition and method of manufacturing

14/694,303

04/23/2015

Issued

US 9,980,996 (05/29/2018)

Pharmaceutical composition and method of manufacturing

15/988,484

05/24/2018

Issued

U.S. 10,092,611 (10/09/2018)

Pharmaceutical composition and method of manufacturing

14/934,940

11/06/2015

Issued

US 10,238,705 (03/26/2019)

Pharmaceutical composition and method of manufacturing

16/151,436

10/04/2018

Issued

U.S. 10,639,339 (05/05/2020)

Pharmaceutical composition and method of manufacturing

16/359,579

03/20/2019

Issued

U.S. 10,624,940 (04/21/2020)

Pharmaceutical composition and method of manufacturing

16/809,958

03/05/2020

Issued

11,266,702 (03/08/2022)

Pharmaceutical composition and method of manufacturing

16/809,700

03/05/2020

Allowed

Pharmaceutical composition and method of manufacturing

16/856,492

04/23/2020

Issued

U.S. 11,344,591

(05/11/2022)

Pharmaceutical composition and method of manufacturing

16/856,609

04/23/2020

Issued

U.S. 11,331,358 (05/17/2022)

6

EXHIBIT 10.4

PARENT GUARANTY

THIS GUARANTY ("Guaranty”), effective as of July 22, 2022, is made by CURE Pharmaceutical Holding Corp., a Delaware corporation ("Guarantor”), to and for the benefit of TF Tech Ventures, Inc., a Delaware corporation ("Buyer”) and other Buyer Indemnitees (together with Buyer, "Beneficiaries”, and each of them, a "Beneficiary”) (each of Guarantor and Beneficiaries, a "Party” and collectively, the "Parties”). Capitalized terms not otherwise defined herein shall have the meaning given such terms in the Purchase Agreement (as such term is defined below).

W I T N E S S E T H:

WHEREAS, Buyer and CURE Pharmaceutical Corporation, a California corporation ("Seller”), entered into that certain Asset Purchase Agreement on July 22, 2022 (as such agreement may be amended, modified or supplemented from time to time, the "Purchase Agreement”) pursuant to which Buyer is purchasing certain assets of Seller;

WHEREAS, Seller is a wholly owned subsidiary of Guarantor.

NOW THEREFORE, for valuable consideration and as an inducement to Buyer to enter into the Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Guarantor covenants with Buyer Indemnitees as follows:

1. Guaranty. Subject to the provisions hereof, Guarantor hereby irrevocably and unconditionally guarantees to each of the Beneficiaries the full and timely payment (and not merely collection) when due of all amounts payable by Seller under the Purchase Agreement (such obligations of Seller, collectively, the "Obligations”).

2. Covenant of Guarantor. This is a continuing guarantee of payment and not of collection. Guarantor covenants with Beneficiaries that if at any time Seller should default in the payment when due, or should commit a breach of any of the Obligations, Guarantor shall, promptly upon written notice by any Beneficiary, pay in Seller’s stead, or cause the payment of, such Obligations.

3. Payments. Any payments owed by Guarantor to any Beneficiary shall be made in United States Dollars via wire transfer to an account designated in writing by such Beneficiary in immediately available funds, and shall be paid within five (5) Business Days after receipt by Guarantor from such Beneficiary of written demand for such payment. A single written demand shall be effective as to any default of Seller under the Purchase Agreement during the continuance of such default.

4. Guaranty Absolute. The obligations of Guarantor under this Guaranty shall be irrevocable, absolute and unconditional, and shall remain in full force and effect until such time as set forth in Section 10 hereof, and until such time, the obligations of Guarantor shall not be affected, modified or impaired or prejudiced (x) by any other security now or hereafter held by any Beneficiary as security for the Obligations; or (y) upon the happening from time to time of any one or more of the following whether or not with notice to or consent of Seller (except to the extent that Seller’s consent may be required to effectuate a modification of the Purchase Agreement) or Guarantor:

(a) the compromise, settlement, release, change, modification, or termination of any of the Obligations;

(b) the waiver by any Beneficiary of the payment of any of the Obligations;

(c) the extension of time for payment of any amounts due or of the time for payment of any of the Obligations;

(d) the modification or amendment (whether material or otherwise) of any of the Obligations;

(e) the failure, omission, delay or lack on the part of any Beneficiary to enforce, ascertain or exercise any right, power or remedy under or pursuant to the terms of the Purchase Agreement or this Guaranty;

(f) the fact that Guarantor may at any time in the future dispose of all or any part of its interest in Seller, or otherwise alter its investment in Seller in any manner;

(g) the voluntary or involuntary bankruptcy, insolvency, winding up, dissolution, liquidation, administration, reorganization or other similar or dissimilar failure or financial disability of Seller or Guarantor or any legal limitation, disability, incapacity or other circumstances relating to Seller or Guarantor;

(h) the addition, substitution or partial or entire release of any guarantor, maker or other party (including Seller) primarily or secondarily liable or responsible for the payment of any of the Obligations or by any extension, waiver, amendment or thing whatsoever which may release a guarantor (other than payment of Obligations in accordance with the terms and conditions hereunder);

(i) the invalidity, nonbinding effect or unenforceability (other than as a result of any breach by any Beneficiary of any of its obligations under the Purchase Agreement) of (x) any of the Obligations or (y) the Purchase Agreement in its entirety; or

(j) the taking, variation, renewal, addition, substitution, subordination, or partial or entire release of any security for the payment of any of the Obligations or the enforcement or neglect to perfect or enforce any such security.

5. Waiver of Subrogation. Guarantor irrevocably and absolutely waives any and all right of subrogation, contribution, indemnification, reimbursement or similar rights against Seller with respect to this Guaranty until the payment or satisfaction of the Obligations indefeasibly in full, it being the intention of the Parties that Guarantor shall not be deemed to be a "creditor” (as defined in Section 101 of the U.S. Bankruptcy Code (the "Bankruptcy Code”) or any other applicable law) of Seller by reason of the existence of this Guaranty in the event that Seller becomes a debtor in any proceeding under the U.S. Bankruptcy Code or any other applicable law. In addition, Guarantor will not exercise any rights which it may acquire by way of subrogation under this Guaranty by any payment made hereunder or otherwise.

2

6. Continuing Guaranty. This Guaranty is a continuing guarantee, and shall apply to all Obligations whenever arising. Each and every default or failure by Seller in making a payment set forth in the Purchase Agreement shall give rise to a separate liability of Seller to Beneficiaries and a separate cause of action hereunder and a separate suit may be brought hereunder as each liability or cause of action arises. Each Beneficiary shall have the right, in its sole judgment and discretion, from time to time, to make demand for payment and to proceed against Guarantor for the recovery of the total of any and all amounts then due to such Beneficiary pursuant to this Guaranty as and when the same are due under the terms hereof, or to proceed from time to time against Guarantor for such portion of any and all such amounts as such Beneficiary may determine.

7. Bankruptcy.

(a) The obligations of Guarantor under this Guaranty shall not be altered, limited or affected by any proceeding, voluntary or involuntary, involving the winding up, dissolution, administration, bankruptcy, reorganization, insolvency, receivership, liquidation or arrangement or similar proceeding of Seller, or by any defense which Seller may have by reason of any order, decree or decision of any court or administrative body resulting from any such proceeding.

(b) Should the Purchase Agreement be disaffirmed by a trustee in bankruptcy for Seller, Guarantor shall, at the option of Beneficiaries, make and enter into a new agreement pursuant to which Guarantor shall pay or cause to be paid the balance of the Obligations.

8. Certain Waivers. Guarantor agrees not to assert or take advantage of:

(a) any right to require any Beneficiary to institute suit against Seller or exhaust any security held by such Beneficiary before proceeding against Guarantor;

(b) any defense that may arise by reason of the incapacity, lack of authority, death or disability of any other person or the failure of any Beneficiary to file or enforce a claim against the estate (in administration, bankruptcy or any other similar proceeding) of any other person;

(c) demand, presentment, protest and notice of any kind, including without limitation notice of the existence, creation or incurring of any new or additional obligation or of any action or non-action on the part of Seller or any Beneficiary (other than a breach by such Beneficiary of any of its obligations under the Purchase Agreement);

(d) any defense based upon an election of remedies by any Beneficiary which destroys or otherwise impairs the subrogation rights of Guarantor, the right of Guarantor to proceed against Seller for reimbursement, or both;

3

(e) any duty on the part of any Beneficiary to disclose to Guarantor any facts such Beneficiary may now or hereafter know about Seller, regardless of whether such Beneficiary has reason to believe that any such facts materially increase the risk beyond that which Guarantor intends to assume, or has reason to believe that such facts are unknown to Guarantor, or has a reasonable opportunity to communicate such facts to Guarantor, since Guarantor acknowledges that Guarantor is fully responsible for being and keeping informed of the financial condition of Seller and of all circumstances bearing on the risk of non-payment of any Obligations hereby guaranteed;

(f) any defense arising because of any Beneficiary’s election, in any proceeding instituted under the Bankruptcy Code, of the application of Section 1111(b)(2) of the Bankruptcy Code; and

(g) any defense based upon any borrowing or grant of a security interest under Section 364 of the Bankruptcy Code.

Guarantor hereby unconditionally and irrevocably further waives (i) any right to require any Beneficiary to proceed against Guarantor or any other person or any security now or later held by any Beneficiary or to pursue any other remedy whatsoever, including any such right or any other right set forth in California Civil Code Section 2845 or Section 2850; (ii) all rights of subrogation, reimbursement, indemnity, contribution, any other rights that may become available to Guarantor under California Civil Code Sections 2787–2856, inclusive, all rights to enforce any remedy that any Beneficiary may have against Guarantor or any other person, and all rights to participate in any security held by any Beneficiary for the indebtedness secured hereby, including any such right or any other right set forth in California Civil Code Section 1845, Section 2848, or Section 2849, until the indebtedness secured hereby has been performed in full, and any defense based on the impairment of any subrogation rights that Guarantor may have; (iii) any defense to recovery by any Beneficiary of a deficiency after a nonjudicial sale of real or personal property, any defense based on the unavailability to any Beneficiary of recovery of a deficiency judgment after nonjudicial sale of real or personal property, and any defense based on or arising from California Code of Civil Procedure Section 580a, Section 580b, Section 580d, or Section 726 (including any fair value limitations under Section 726 of that Code) or based on or arising from Division 9 or any other applicable division of the California Commercial Code; (iv) any defense based on California Civil Code Section 2809;

Guarantor hereby unconditionally and irrevocably further waives all rights and defenses that Guarantor may have because Guarantor’s obligations and debt are secured by real property. This means, among other things, that (i) any Beneficiary may collect from Guarantor without first foreclosing on any real or personal property collateral pledged by any person; and (ii) if any Beneficiary forecloses on any real property collateral, then (1) the amount of the debt may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral is worth more than the sale price, and (2) any Beneficiary may collect from Guarantor even if such Beneficiary, by foreclosing on the real property collateral, has destroyed any right Guarantor may have to collect from any other person. This is an unconditional and irrevocable waiver of any rights and defenses Guarantor may have because the Guaranteed Obligations are secured by real property. These rights and defenses include any rights or defenses based on California Code of Civil Procedure Sections 580a, 580b, 580d, or 726.

4

Without limiting the foregoing, (i) Guarantor waives all rights and defenses arising out of an election of remedies by any Beneficiary, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed obligation, has destroyed Guarantor’s rights of subrogation and reimbursement against the principal by the operation of Section 580d of the California Code of Civil Procedure or otherwise; and (ii) Guarantor hereby unconditionally and irrevocably further waives and relinquishes, and agrees not to assert or take advantage of, all rights, defenses or benefits arising directly or indirectly under 2899 and 3433 of the California Civil Code, and all other rights and remedies of sureties or guarantors under California law.

9. Representations and Warranties. Guarantor represents and warrants to Beneficiaries that, as of the date of this Guaranty:

(a) the execution and delivery of this Guaranty and its performance have been duly authorized by all necessary corporate action on the part of Guarantor;

(b) this Guaranty is the legal, valid and binding obligation of Guarantor, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights generally and by general equitable principles;

(c) the execution, delivery and performance of this Guaranty will not violate any material law or any material provision of any security issued by the Guarantor or of any material agreement to which the Guarantor is a party or by which it or any of its property is bound, and do not require any license, consent or approval of any governmental authority; and

(d) no litigation, investigation or proceeding of or before any arbitrator or governmental authority is pending or, to Guarantor’s knowledge, threatened against the Guarantor which, if adversely determined, would be reasonably likely to affect, impair or diminish the validity or enforceability of this Guaranty.

10. Termination; Reinstatement of Guaranty.

(a) Subject to the provisions of Section 10(b) and to the proviso set forth in this Section 10(a), this Guaranty shall terminate upon the indefeasible payment in full of the Obligations.

(b) Notwithstanding the provisions of Section 10(a), this Guaranty shall be reinstated if at any time following the termination of this Guaranty under Section 10(a), any payment prior to such termination by Guarantor or Seller under this Guaranty or the Purchase Agreement or pursuant hereto or thereto is rescinded or must otherwise be returned by any Beneficiary upon the insolvency, bankruptcy, reorganization, dissolution, liquidation, or similar occurrence of Seller or Guarantor all as though such payment had not been made. Such period of reinstatement shall continue until satisfaction of the conditions contained in, and shall continue to be subject to, the provisions of this Section10.

11. Benefit of Guaranty. This Guaranty shall inure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns; provided, that neither Party may make any assignment of this Guaranty unless it has obtained the prior written consent of the other Party (which consent shall not be unreasonably conditioned, withheld or delayed), except that Buyer may assign this Guaranty, without consent of Guarantor, to any person to whom Buyer has rightfully assigned the Purchase Agreement pursuant to the terms thereof. Any attempted assignment in violation of this Section 11 shall be null and void ab initio.

5

12. Notices. All notices or other communications under or respecting this Guaranty shall be in writing and shall be served by (i) personal delivery, (ii) mailing copies thereof by registered or certified United States mail, postage prepaid, (iii) nationally recognized courier service, or (iv) electronic mail, followed by confirmation in one of the other accepted methods in parts (i), (ii), or (iii) of this sentence, and shall be addressed as follows:

If to Guarantor:

CURE Pharmaceutical Holding Corp.

5805 Sepulveda Blvd., #801

Van Nuys, CA 91411

with a copy to:

Stradling Yocca Carlson & Rauth

3075 Townsgate Road, Suite 330

Westlake Village, CA 91361

Email: breinke@stradlinglaw.com

Facsimile: (805) 730-6825

Attention: Brent Reinke

If to Buyer:

TF Tech Ventures, Inc.

4000 N. Federal Highway, Suite 216

Boca Raton, FL 33431

E-mail: capreston92@gmail.com

Attention: CA Preston, CEO

with a copy to:

K&L Gates LLP

4 Embarcadero Center, Suite 1200

San Francisco, CA 94111

E-mail: alidad.vakili@klgates.com

Facsimile: 415-882-8220

Attention: Alidad Vakili

or at such other address such Party may from time to time designate in writing. All notices shall be effective upon actual receipt.

13. Governing Law; Consent to Jurisdiction; Waiver of Jury Trial.

(a) This Guaranty shall in all respects be interpreted, and construed and governed by and in accordance with, the internal, substantive laws of the State of California without regard to the principles of conflicts of laws thereof that would direct the application of the law of another jurisdiction.

6

(b) Any action, suit or proceeding by or between the Parties under or relating to this Guaranty shall be brought exclusively in whichever of the state or federal courts located in the County of Ventura, State of California that has subject matter jurisdiction over the dispute (or, if such courts do not accept jurisdiction, then in any federal or state court in the United States of competent jurisdiction). Each of the Parties hereby (i) waives any objection which Guarantor may now or hereafter have regarding the choice of forum whether on personal jurisdiction, venue, forum non conveniens or on any other ground, (ii) irrevocably consents that it is subject to the personal jurisdiction of the state or federal courts located in the County of Ventura, State of California, and (iii) irrevocably consents to the service of process outside of the territorial jurisdiction of such courts by nationally recognized courier service or by mailing copies thereof by registered or certified United States mail, postage prepaid, to Guarantor’s last designated address pursuant to Section 12 with the same effect as if Guarantor were a resident of the State of California and had been lawfully served in such state. Nothing in this Guaranty shall affect the right to service of process in any other manner permitted by law.

(c) EACH OF THE PARTIES TO THIS GUARANTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS GUARANTY.

14. Severability. Any invalid or unenforceable provisions in this Guaranty shall be deemed severed herefrom, and such whole or partial invalidity shall not affect the enforceability or validity of the balance of this Guaranty.

15. Waiver; Amendment. No failure on the part of either Party to exercise, and no delay in exercising, any right, remedy or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by either Party of any right, remedy or power hereunder preclude any other or future exercise of any right, remedy or power. This Guaranty may not be amended, supplemented, waived, or modified except by an instrument in writing signed by each Party.

16. Entire Agreement. This Guaranty constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the Parties with respect to the subject matter hereof.

17. Headings. The headings of this Guaranty are for convenience only, and shall be deemed not to be a part of this Guaranty not to affect the interpretation hereof.

18. Counterparts. This Guaranty may be executed and delivered in counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. This Guaranty may be delivered by electronic transmission, including as a .pdf file.

[signature page follows]

7

IN WITNESS WHEREOF, Guarantor has caused this Guaranty to be executed as of the date first above written.

CURE Pharmaceutical Holding Corp.

By: /s/ Robert Davidson

Name: Robert Davidson

Title: CEO

ACCEPTED BY BUYER: Buyer acknowledges and accepts the above Guaranty as of the date first above written.

TF TECH VENTURES, INC.

By: /s/ C.A. Preston

Name: C.A. Preston

Title: CEO & President

[Parent Guaranty]

8

EXHIBIT 10.5

TRANSITION SERVICES AGREEMENT

This TRANSITION SERVICES AGREEMENT (this "Agreement”) is made this 22nd day of July, 2022, by and between CURE Pharmaceutical Corporation, a California corporation ("Seller”) and TF Tech Ventures, Inc., a Delaware corporation ("Buyer”).

W I T N E S S E T H:

WHEREAS, Seller and Buyer are parties to that certain Asset Purchase Agreement, dated as of the date hereof, by and between Buyer and Seller (as amended or otherwise modified from time to time in accordance with its terms, the "Purchase Agreement”). Capitalized terms used but not defined herein shall have the respective meanings given to them in the Purchase Agreement; and

WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, Seller has agreed to provide to Buyer certain transitional services for the periods and on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual agreements and covenants set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound hereby, the parties agree:

1. SERVICES

1.1 Services. During the term of this Agreement and subject to the terms and conditions set forth herein, Seller shall provide to Buyer, or cause an Affiliate or Affiliates of Seller designated by Seller for this purpose (each, a "Service Provider”) to provide to Buyer, and Buyer agrees to purchase from the Service Providers, the services set forth in Schedule A attached hereto (each, a "Service”, and collectively, the "Services”).

1.2 Level of Services. Except as set forth specifically in Schedule A or otherwise specifically agreed to in writing by the parties, Seller shall provide, or cause its Affiliate or third parties to provide, each Service with a degree of care with the same standard of care it exercised in the twelve (12) month period prior to the date hereof in the conduct of similar activities for itself. In providing the Services, Seller shall use the Business Employees so long as they are personnel of Seller, and following the Termination Date, Buyer shall make the Business Employees available to Seller for purposes of providing the Services, in accordance with Section 1.7 .

1.3 Additional Services. Notwithstanding the contents of Schedule A, Seller agrees to consider in good faith any reasonable request by Buyer for access to any additional services that was historically provided by Seller to or in connection with the Business and are necessary for the operation of the Business and which are not currently contemplated in Schedule A, at a price and for a term to be agreed upon after good faith negotiations between the parties. Any such additional services so provided by Seller shall constitute Services under this Agreement and be reflected in an amendment to Schedule A and subject in all respect to the provisions of this Agreement as if fully set forth on Schedule A as of the date hereof.

1.4 Third Parties. At its option, Seller may cause any Service it is required to provide hereunder to be provided by any third party (a "Third Party Service”) so long as such third party provider (each, a "Third Party Provider”) is (i) a provider that has historically been used by Seller and its Affiliates for provision of similar services, (ii) is a provider historically used by Buyer and its Affiliates for provision of similar services or (iii) is a provider able to provide such Services in all material respects in a manner consistent in scope, quality and nature with those provided by Seller and its Affiliates (or on their respective behalf) to Buyer. In the event of a Third Party Service, Seller shall obtain prior written consent of Buyer; provided that the foregoing shall not relieve Seller from its responsibility for its obligations hereunder. The provision of any Third Party Services or any other Services provided by a third party shall be subject to the terms and provisions of the underlying contract with such third party for such Services, including restrictions on use and confidentiality obligations. Buyer agrees that it shall sign any confidentiality agreement reasonably required by a third party providing, or enabling the provision of, any Services.

1.5 Employees Matters.

(a) Seller is providing the employees of Seller set forth on Schedule B (the "Business Employees”) merely as an accommodation to Buyer and shall have no liability to Buyer in the event that any Business Employee terminates his or her work status with the Seller during the term of this Agreement and Seller shall be under no obligation to replace such Business Employee. Buyer acknowledges and agrees that, as an accommodation to Buyer, the Business Employees shall remain employees of Seller and on the payroll of Seller for a transition period in order to facilitate Buyer establishing its own payroll services and operational readiness to employ such employees directly. It is the intention of the Seller and Buyer that (i) such employees who remain employed by Seller will become Buyer’s employees as soon as possible following the Closing, and (ii) for so long as such employees remain employees of and on the payroll of Seller, absent gross negligence, willful misconduct or fraud by Seller, Buyer will be responsible for and shall pay to Seller all wages and salaries and other documented out-of-pocket costs actually paid by Seller for such employees pursuant to this Agreement and will indemnify and hold harmless Seller and the other Seller Indemnitees from and against any Damages (as defined in Section 4(a)) resulting from or arising out of the retention of such employees during the term of this Agreement. During the term of this Agreement, Seller shall not increase the wages, bonus opportunities, vacation pay or other benefits afforded to any Business Employee from levels paid and/or provided to such Business Employee immediately prior to the Closing.

(b) Seller shall terminate the employment of each Business Employee who has accepted Buyer’s offer of employment and whose employment with Seller has not terminated (the "Continuing Employees”) effective as of the Termination Date. On the Termination Date or on any date that a Business Employee otherwise terminates employment with Seller prior to the Termination Date (each such employee, a "Terminated Employee” and each such date, a "Separation Date”), Seller shall make payment to each Continuing Employee and each Terminated Employee of all accrued wages, salaries and earned but unused vacation time or personal time off and any other amounts due under applicable law for all periods from the date hereof through the Termination Date or Separation Date (as applicable). Seller shall provide Buyer with a Payroll Notice (as defined below) with respect to the amounts due to the Business Employees on the Termination Date, and Buyer shall make payment in accordance with the terms of Section 1.6(a) of the amounts set forth in such Payroll Notice. Following any Separation Date, Seller shall promptly provide to Buyer the amounts paid by Seller to such Terminated Employee on such date, including all related employment Taxes paid with respect thereto, and Buyer shall pay such amount to Seller within five (5) Business Days of receipt of an invoice for such amount from Seller.

(c) Notwithstanding anything to the contrary, Buyer shall not be responsible for any wages, salaries, vacations, expenses, costs, fees, severances, or benefits arising out of or relating to the employment of Business Employees by Seller prior to the date hereof other than the Rollover Vacation liability expressly assumed by Buyer pursuant to the Purchase Agreement in accordance with the terms thereof.

1.6 Funding of Payroll and Benefits. Not less than four (4) Business Days prior to any payroll date (the "Applicable Payroll Date”), Seller shall provide the Buyer with written notice (the "Payroll Notice”) of all amounts required to be paid by the Buyer to Seller with respect to the Applicable Payroll Date, and not less than two (2) Business Days prior to such Applicable Payroll Date, Buyer shall fund by wire transfer of immediately available funds all amounts set forth in such Payroll Notice from Seller. Each Payroll Notice shall be accompanied by supporting documentation of the gross wages, employer paid taxes, employer paid employee benefits and any other Business Employee payroll related fees and charges due on such Applicable Payroll Date. All such wire transfers by Buyer to Seller shall be to the account of Seller set forth on Appendix I to Schedule A. For the avoidance of doubt, Seller shall pay all necessary employment Taxes as required by Law with respect to the Business Employees for the period from the date of this Agreement until the Termination Date and Buyer shall reimburse Seller in full for the employer portion of such employment Taxes paid or payable by Seller with respect thereto.

2

1.7 Cooperation and Access. The Parties acknowledge and agree that, effective as of the Closing, among other things, (a) substantially all of the Seller’s assets related to the Business will transfer to Buyer, (b) all of the Continuing Employees will transfer employment to the Buyer following the Termination Date, and (c) such assets, and after the Termination Date, employees, are contemplated to be used in the provision of the Services. Accordingly, subject to the limitations set forth in this Agreement, (i) Buyer shall cause its employees to reasonably cooperate with employees of the Service Provider in providing a Service to Buyer, to the extent required for effective delivery of the Services and to minimize the disruption to, or additional recordkeeping required by, the Service Provider and (ii) Buyer shall give the Service Provider full access to the properties, assets and networks environments of Buyer (the "Facilities”) as is reasonably necessary for the Service Provider to provide the Services. From the date hereof until the Termination Date, Seller shall direct the Business Employees to follow and comply with the instructions and policies provided by Buyer and Buyer or its designee will supervise and direct the Business Employees with respect to day-to-day responsibilities. For the avoidance of doubt, Seller shall not be required to hire any employees or purchase or otherwise obtain any assets in connection with the performance of the Services, it being expressly acknowledged and agreed that Seller’s obligation to provide the Services shall be wholly dependent on Buyer’s making available (at Buyer’s sole cost and expense) any such assets or, after the Termination Date, employees, as Seller deems necessary to perform the Services.

1.8 Limitation of Liability; Disclaimer.

(a) The parties hereto acknowledge and agree that the Services are being provided by Seller: (i) at the request of the Buyer in order to accommodate it following the Closing, (ii) at the costs set forth in Section 1.5, Section 1.6, Section 2.1 and Schedule A hereto and with no expectation of profit being made by Seller thereon, and (iii) with the expectation that Seller is not assuming any financial or operational risks, including those usually assumed by a service provider, except for those risks explicitly set forth herein. Accordingly, subject to Section 4 of this Agreement, each party agrees that, absent gross negligence or willful misconduct, Seller, its Affiliates, and their directors, officers, employees, representatives, consultants and agents shall not be liable for any direct, indirect, special, incidental or consequential damages, including lost profits or savings, whether or not such damages are foreseeable, or for any third party claims relating to the Services or Seller’s performance under this Agreement. Notwithstanding anything to the contrary contained herein, in the event that Seller commits an error with respect to or incorrectly performs or fails to perform any Service in any material respect, at the Buyer’s request, Seller shall use reasonable efforts and in good faith attempt to correct such error, re-perform or perform such Service at no additional cost to Buyer; provided, that, absent gross negligence or willful misconduct, Seller shall have no obligation to recreate any lost or destroyed data to the extent the same connect be cured by re-performance of the Service in question.

(b) EXCEPT AS EXPRESSLY SET FORTH HEREIN, SELLER MAKES NO REPRESENTATIONS OR WARRANTIES IN RESPECT OF THE SERVICES, EXPRESS OR IMPLIED.

2. PAYMENTS

2.1 Services Pricing.

(a) Buyer shall pay Seller, or its applicable Affiliate, (i) the fees for the Services on the basis and in the manner described in Section 1.5, Section 1.6 and in Schedule A, and (ii) any reasonably out-of-pocket costs and expenses that Seller incurs in providing the Services, provided, that with respect to clause (ii) hereof, that Buyer has approved in writing any such costs and expenses in excess of $2,500 in advance (collectively, the "Fees”). Seller or its agents shall keep and maintain such books and records as may be reasonably necessary to make any applicable allocations. Seller shall make copies of the relevant portion of such books and records available to Buyer for inspection upon request and with reasonable notice. The Fees shall not be increased during the term of this Agreement except as contemplated by this Section 2.1.

2.2 Invoicing. Except for those charges with alternate invoicing and payment terms specifically set forth in Section 1.5, Section 1.6 or in Schedule A, within 10 Business Days following the end of each calendar month during the term hereof, Seller shall provide to Buyer a single invoice in form, format and media reasonably acceptable to Buyer totaling all charges during such month for the Services incurred by Buyer hereunder (each, an "Invoice”). Each Invoice shall contain a brief description of each Service giving rise to such charge in reasonable detail, with such supporting documentation as Buyer may reasonably request. Notwithstanding the foregoing, Seller shall be permitted to direct Buyer to make payment to third parties directly for Services hereunder (including, without limitation, making payment of the utilities costs for the Facilities) and Buyer shall make timely payment of such amounts in accordance with the applicable payment terms therefor.

3

2.3 Payment. Buyer shall pay all amounts due under each Invoice no later than 5 days following receipt of such Invoice. Buyer shall pay all amounts due with respect to those charges with alternate invoicing and payment terms specifically set forth in Section 1.6 or in Schedule A hereto in accordance with the relevant payment terms set forth in Section 1.6 or Schedule A, as the case may be.

3. TERM AND TERMINATION

3.1 Term. Unless earlier terminated in accordance with Section 3.2 below, this Agreement shall be in effect from the date of this Agreement until the earlier of (i) January 20, 2023 and (ii) the date on which the terms for all of the Services have expired or been terminated, which term may be extended by mutual written agreement of the parties; provided that the term with respect to any specific Service may be shorter if such shorter term is set forth on Schedule A or this Agreement is otherwise terminated with respect to such Service hereunder.

3.2 Termination.

(a) If a party (the "Defaulting Party”) has materially breached its obligations under this Agreement (including a failure to make timely payment of any amount due under this Agreement) and has not cured such default within 30 days following the date on which the other party (the "Notifying Party”) has given written notice to the Defaulting Party specifying the facts constituting the default, the Notifying Party may, in its sole discretion, (i) suspend or terminate (or any combination thereof) providing or receiving any or all of the Services, in whole or in part, or (ii) terminate this Agreement. Notwithstanding the foregoing sentence, neither this Agreement nor any Service shall be terminated due to a default by the Defaulting Party if such default is directly attributable to a breach of this Agreement by the Notifying Party.

(b) Buyer will have no obligation to continue to use any of the Services and shall be permitted to terminate this Agreement with respect to any particular or all of the Services to be provided by a Service Provider, by giving Seller written notice of its desire to terminate any particular Service, in whole or in part (a "Termination Notice”), which Termination Notice shall take effect on the date set forth therein, which date shall be not less than 30 days after delivery of such Termination Notice or such earlier date as may be mutually agreed upon by Seller and Buyer (the "Effective Date”). Upon such termination, Buyer’s obligation to pay any fees applicable to the provision of such terminated Services (or part thereof) following the Effective Date (if applicable), and the Service Provider’s obligation to provide such terminated Services (or part thereof) following the Effective Date, will terminate; provided that no termination shall relieve Buyer of its obligation to pay for Services provided prior to the Effective Date. Once Buyer has terminated any of the Services, Buyer may request any such Services to be resumed pursuant hereto, but Seller shall not be required to resume any such terminated Services.

(c) Upon termination of this Agreement for any reason, all rights and obligations of the parties under this Agreement shall cease and be of no further force or effect, except that the provisions of Sections 1.5, 1.6, 1.8, 2.3, 3, 4 and 5 of this Agreement shall survive any such termination or expiration.

4. INDEMNITY

(a) Buyer agrees to indemnify, defend and hold Seller and its Affiliates and persons serving as officers, directors, partners or employees thereof (collectively "Seller Indemnitees”) harmless from and against any damages, liabilities, losses, taxes, fines, penalties, costs and expenses (each, a "Damage” and, collectively, the "Damages”) (including, without limitation, reasonable fees of counsel) of any kind or nature whatsoever (whether or not arising out of third-party claims and including all amounts paid in investigation, defense or settlement of the foregoing) which may be sustained or suffered by any of them arising out of or based on (i) the provision of the Services (other than as a result of the gross negligence or willful misconduct of Seller), (ii) any breach of this Agreement by Buyer, (iii) violation of law by Buyer, or (iv) willful misconduct on the part of Buyer. In addition, Buyer agrees to indemnify, defend and hold the Seller Indemnitees harmless from and against any Damages arising from or relating to (v) all employment-related claims arising with respect to any Business Employee under federal, state or local Law (including but not limited to discrimination and harassment claims and any claims alleging joint employer liability), (w) tortious conduct alleged by any Business Employee, including allegations of negligence, defamation and intentional or negligent infliction of emotional distress, (x) any matter relating to the Buyer’s use of any Business Employee or involving the use by Business Employee of the Buyer’s machinery, facilities, equipment and/or vehicles, (y) any employee-related fines, penalties or sanctions related to any Business Employee; and (z) any increase in Seller’s workers’ compensation rate as a result of claims or work classification of Business Employees, in each case to the extent arising from facts and circumstances occurring during the term of this Agreement. For clarification and without limiting the generality of the foregoing, Seller shall not be responsible for any act or omission of any Business Employee, and any such act or omission shall not constitute willful misconduct, willful omission or negligence of Seller.

4

(b) The Seller agrees to indemnify and hold Buyer and its Affiliates and persons serving as officers, directors, partners or employees thereof harmless from and against any Damages (including, without limitation, reasonable fees of counsel) of any kind or nature whatsoever (whether or not arising out of third-party claims and including all amounts paid in investigation, defense or settlement of the foregoing) which may be sustained or suffered by any of them arising out of or based upon any gross negligence, violation of Law, or willful misconduct in each case on the part of Seller.

(c) No right of indemnification shall exist under this Agreement with respect to matters for which indemnification may reasonably be claimed under the Purchase Agreement, it being the intent of the parties that claims that are addressed under the Purchase Agreement shall be governed solely by the Purchase Agreement. No right of indemnification shall exist under the Purchase Agreement for claims arising out of the performance of this Agreement, it being the intent of the Parties that such claims shall be solely governed by the provisions of this Agreement. Notwithstanding the foregoing, no claim for indemnification made under this Agreement shall be denied solely based on the preceding two sentences if such claim was initially brought under the Purchase Agreement and denied because the subject matter of such claim was reasonably believed to be covered under the indemnification provisions of this Agreement.

5. GENERAL

5.1 Impracticability; Force Majeure.

(a) Notwithstanding any other provision of this Agreement, no Service Provider shall be required to provide any Service to the extent the performance of such Service would require such Service Provider to violate any applicable Laws or any contracts to which the Service Provider is a party.

(b) The obligations of Seller under this Agreement with respect to any Service shall be suspended during the period and to the extent that the applicable Service Provider is prevented or hindered from providing such Service, or Buyer is prevented or hindered from receiving such Service, due to any of the following causes beyond such party’s reasonable control (such causes, "Force Majeure Events”): (i) acts of God, (ii) flood, fire or explosion, (iii) war, invasion, riot or other civil unrest, (iv) governmental order or Law, (v) actions, embargoes or blockades in effect on or after the date of this Agreement, (vi) action by any Governmental Authority, (vii) national or regional emergency, (viii) strikes, labor stoppages or slowdowns or other industrial disturbances, (ix) shortage of adequate power or transportation facilities, or (x) any other event which is beyond the reasonable control of such party. The party suffering a Force Majeure Event shall give notice of suspension as soon as reasonably practicable to the other party stating the date and extent of such suspension and the cause thereof, and Seller shall resume the performance of its obligations as soon as reasonably practicable after the removal of the cause. If such suspension of Services has a negative impact on Buyer’s business operations, at Buyer’s request, Seller shall use commercially reasonable efforts, at Buyer’s sole cost and expense to assist Buyer in securing alternative services to minimize such negative impact on Buyer. Neither Buyer nor Seller shall be liable for the nonperformance or delay in performance of its respective obligations (other than payment obligations) under this Agreement when such failure is due to a Force Majeure Event. The applicable end date for any Service so suspended shall be automatically extended for a period of time equal to the time lost by reason of the suspension.

5

5.2 Relationship of the Parties. Seller (including, as applicable, its Affiliates) shall for all purposes be considered independent contractors with respect to Buyer, and Seller (including, as applicable, its Affiliates) shall not be considered an employee, employer, agent, principal, partner or joint venturer of Buyer. For purposes of this Agreement, neither Seller nor any employee, representative or agent of Seller shall have any claim, right, or entitlement under this Agreement or otherwise against the Buyer for workers’ compensation, unemployment compensation, sick leave, vacation pay, pension or retirement benefits, Social Security benefits, or any other employee benefits with respect to employees of Seller that provide Services to Buyer. Nothing contained in this Agreement shall be deemed or construed to create any liability whatsoever of any party with respect to the indebtedness, liabilities, obligations or actions of the other party or any of its respective representatives, or any other Person.

5.3 Intellectual Property. To the extent Seller becomes aware, Seller shall disclose to the Buyer any improvements, inventions, formulas, ideas, works of authorship, processes, computer programs, know-how and trade secrets, whether or not patentable, made or conceived or reduced to practice or developed by Seller, either alone or jointly with others, during the term of this Agreement and related to the Seller’s provision of Services to the Buyer through any Business Employee hereunder ("Inventions”). The parties agree that all Inventions and Intellectual Property rights therein shall be the sole property of the Buyer and shall be "works made for hire.” Seller hereby assigns to the Buyer any rights Seller may have, had or acquire in all Inventions and agrees to perform, during and after the term of this Agreement, at the Buyer’s expense (including payment of the Seller’s fully burdened costs) all acts deemed reasonably necessary by the Buyer in obtaining and enforcing Intellectual Property rights with respect to such Inventions. Subject to the foregoing, nothing in this Agreement shall be interpreted to, or shall, assign, transfer or license any Intellectual Property rights between the parties hereto, and each party shall retain all right, title and interest in and to their respective Intellectual Property rights and any and all improvements, modifications and derivative works thereof or thereto.

5.4 Insurance. Buyer shall maintain at its sole cost, with insurers reasonably satisfactory to Seller, insurance policies, including General Liability and Umbrella Coverage with coverages, limits and deductibles at least equal to those set forth in the insurance policies maintained by Seller for the Business as of the Closing Date; provided that immaterial differences shall be ignored. On or before the Effective Date, Buyer shall furnish to Seller evidence to Seller confirming to Seller the insurance at the time in force pursuant to this Section specifying the amount and character of coverage, identifying the insurers and certifying as to no default in the payment of current premiums thereon and will furnish Seller with copies of all such policies.

5.5 Compliance with Laws. Each party hereto shall be responsible for its and its Affiliates’ own compliance with any and all applicable Laws in connection to their performance and receipt of Services under this Agreement. No party or its Affiliates will take any action in violation of any such applicable Law that would reasonably be likely to result in liability being imposed on the other party or its Affiliates, as the case may be, as a result of a violation of applicable Law. Each Service Provider shall notify the other parties of any material compliance problems in connection with the Services of which the Service Provider becomes aware.

5.6 General Provisions. Section 8.02 (Notices), Section 8.04 (Severability), Section 8.05 (Entire Agreement), Section 8.06 (Successors and Assigns), Section 8.07 (No Third-Party Beneficiaries), Section 8.08 (Amendment and Modification), Section 8.09 (Waiver), Section 8.10 (Governing Law), Section 8.11 (Submission to Jurisdiction), Section 8.12 (Waiver of Jury Trial), Section 8.13 (Specific Performance), and Section 8.14 (Counterparts) of the Purchase Agreement are each hereby incorporated by reference mutatis mutandis.

5.7 Conflict. This Agreement is being executed and delivered pursuant to the terms and conditions of the Purchase Agreement. In the event of any inconsistency between the terms of this Agreement and the Purchase Agreement, the terms of the Purchase Agreement shall control.

Signature Page Follows

6

IN WITNESS WHEREOF, Seller and Buyer have duly executed this Agreement as of the day, month and year first above written.

SELLER:

CURE PHARMACEUTICAL CORPORATION

a California corporation

By: /s/ Robert Davidson

Name:

Robert Davidson
Title: CEO

BUYER:

TF TECH VENTURES, INC.

a Delaware corporation

By:

/s/ C.A. Preston

Name:

C.A. Preston

Title:

CEO & President

7

SCHEDULE A

Services

Service Item

Description of Service

Termination Dates

Fees

Operations

All actions and services necessary to operate the Business in the ordinary course of business consistent with the manner in which Seller conducted the Business prior to the Closing Date, as if the sale of the Purchased Assets pursuant to the Purchase Agreement had not occurred.

For the avoidance of doubt, during the Term, the Business Employees will continue to provide and perform all services and functions as they performed for the Business prior to Closing.

The date on which Buyer has provided written notice to Seller that Buyer has obtained each of the Permits set forth on Exhibit 1, attached hereto, or has determined in its reasonable discretion that any Permits that it has not obtained are not required for the operation of the Business by the Buyer (such date, the "Notice Date”).

Actual cost.

Payroll & Benefits

Provide payroll processing, payment and tax filing services and employee benefits coverage (to the extent such benefits were provided as of the Closing Date) for the Business Employees (so long as they are employees of Seller) through the Seller’s PEO provider as of the Closing Date.

The Termination Date, which shall be no later than 45 days following the Closing Date.

Actual costs – paid in accordance with Section 1.5 and Section 1.6 of the Agreement.

Accounting and Finance Transition

At Buyer’s direction and cost, the appropriate Business Employees will, as part of their regular job duties, take such actions as reasonably required for Buyer’s operation of the Business as a stand-alone entity, including setting up Buyer’s accounting and finance systems.

The Notice Date.

Actual costs – including the costs of any software licenses.

IT

Provide Buyer access to IT services and software licenses to the extent needed for Buyer to operate the Business.

6 months after the Closing Date.

Actual cost; provided, that Seller shall not be responsible for obtaining any additional software licenses or to renew any software licenses.

Permits & Licenses

At Buyer’s direction, provide all applicable information, documents, cooperation and support to properly transition each of the Permits set forth on Exhibit 1, attached hereto (excluding those which Buyer determines are not necessary for the operation of the Business).

The date on which Buyer has provided written notice to Seller that Buyer has obtained each of the Permits set forth on Exhibit 1, attached hereto, or has determined in its reasonable discretion that any Permits that it has not obtained are not required for the operation of the Business by the Buyer.

Actual cost.

Facilities

Seller shall make payment of the utilities for the Leased Real Property.

On the date when Buyer has opened all necessary utilities accounts for the Leased Real Property in its own name, which shall occur no later than 60 days following the Closing Date.

At cost; provided, that Seller shall not be required to include such charges on the monthly Invoice and shall instead invoice Buyer when payment is made and Buyer shall reimburse Seller in full no later than three (3) Business Days following receipt of the applicable invoice.

8

EXHIBIT 1 TO SCHEDULE A

PERMITS

Description

License Number

Issuance Date

Expiration Date

Issuing Authority

Oxnard Business License

23-00105063

8/16/2021

7/31/2022

City of Oxnard, License Services

DEA: Schedule 1 & 3N Manufacturing License

RC0545701

8/24/2021

8/31/2022

United States Department of Justice, Drug Enforcement Administration

CDPH Drug Manufacturing License

58961

10/11/2021

9/12/2022

State of California, Department of Public Health, Food and Drug Branch

CDPH Process Food Registration

58961

9/12/2022

State of California, Department of Public Health, Food and Drug Branch

Storm Water Permit

NEC: 456NEC004719

11/14/2018

N/A

The State Water Resources Control Board

US FDA Facility Establishment Identifier (FEI)

3009940880

N/A

State of California, Department of Public Health, Food and Drug Branch

US FDA Registration

19835250384

12/31/2022

U.S. Food & Drug Administration

IND relating to Collaboration Agreement

Operation of Allopathic Pharmacy or Homeopathic Pharmacy (Without Preparation of Pharmaceutical Specialties) or Apothecary

COFEPRIS-05-007-D

3/3/2022

Comisión Federal para la Protección contra Riesgos Sanitarios

9

SCHEDULE B

BUSINESS EMPLOYEES

1. Robert Davidson

2. Michael Redard

3. Mark Udell

4. Courtney Lasley

5. Adrienne Grashaw

6. Katherin Landas

7. Tim Habeck

8. Cheryl Baumgart

9. Lina Galeano

10. Sarahi Zuniga

11. Karina Sierra

12. Sandy Garate

13. Jose Bernardo

10

EXHIBIT 10.6

TRADEMARK LICENSE AGREEMENT

This Trademark License Agreement ("Agreement”) is made and entered into as of July 22, 2022 (the "Effective Date”) by and between TF Tech Ventures, Inc., a Delaware corporation ("Buyer” or "Licensor”) and CURE Pharmaceutical Corporation, a California corporation ("Seller”), and CURE Pharmaceutical Holding Corp., a Delaware corporation ("Parent”, together with Seller, "Licensees”, and each a "Licensee”) (Licensor and Licensees each a "Party” and collectively, the "Parties”). Capitalized terms not defined in this Agreement will have the meaning specified in the Purchase Agreement (defined below).

RECITALS

WHEREAS, Licensor and Seller are Parties to an Asset Purchase Agreement, dated as of the date hereof (the "Purchase Agreement”), whereby Licensor purchased from Seller certain trademarks, tradenames and brand names and logos ("Purchased Marks”) related to the Business;

WHEREAS, under Section 5.04 of the Purchase Agreement, Buyer agreed to allow Seller, Parent, and their Affiliates to continue to use the Purchased Marks during the Transitional Period to allow for both the performance of the services to be performed by Seller pursuant to the Transition Services Agreement and for an orderly wind-down of use of the Purchased Marks and rebranding by Seller, Parent, and their Affiliates;

WHEREAS, Licensees desire to obtain from Licensor and Licensor desires to grant to Licensees a license to use the Purchased Marks for a limited period of time under the terms and conditions of this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of mutual covenants and agreements set forth below, and for other good and valuable consideration as set forth in the Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

1. License. Licensor hereby grants to Licensees and their Affiliates as of the Effective Date a fully paid-up, non-assignable, non-transferrable, non-sublicensable, and limited license ("License”) to use the Purchased Marks ("Licensed Marks”) during the Transitional Period. A list of the Licensed Marks is set forth on Exhibit A to this Agreement. Domain names that reference the Purchased Marks may remain active for a period of time in accordance with Section 5.04(c) of the Purchase Agreement.

2. Use of Licensed Marks. Licensees agree to use, and shall ensure their Affiliates use, the Licensed Marks only in connection with: the corporate and business names and tradenames of Seller, Parent, and their Affiliates; and Business Materials that are not associated with product packaging, labeling, promotional, or marketing materials except for purposes of providing the Services (as defined in the Transition Services Agreement). Licensees and their Affiliates shall use the Licensed Marks (a) only in the same form and manner as they were used in the Business immediately prior to Closing, (b) shall not modify the Licensed Marks or any Business Materials containing the Licensed Marks in any respect, and (c) at Licensor’s reasonable request, shall provide appropriate documentation to confirm compliance with the foregoing. Except to the extent necessary to perform the Services pursuant to the Transition Services Agreement, Licensees and their Affiliates shall not use the Licensed Marks in connection with the distribution, sale, promotion, marketing, or advertising of any product. Licensees shall not use, and shall ensure their Affiliates do not use, the Licensed Marks in any manner that tarnishes, degrades, disparages, or reflects adversely on the Licensed Marks. Licensees shall ensure that all uses by Licensees and their Affiliates comply with applicable laws and regulations. Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement or the Purchase Agreement shall restrict Licensees and their Affiliates’ (i) sale, promotion, marketing, or advertising of their inventory that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure”, or (ii) use of packaging that was in their possession prior to Closing and remains in their possession after Closing that bears the Purchased Mark "Powered By Cure” on future products that they might purchase form Buyer in accordance with the relevant terms of such purchase(s).

3. Effect of Termination. Except as set forth in Section 2 with respect to Inventory, upon the expiration of the Transitional Period, Licensees and their Affiliates shall immediately cease all use of the Licensed Marks.

4. Enforcement. Licensees shall promptly notify Licensor in writing of any actual, suspected, or threatened infringement, dilution, or other conflicting use of the Licensed Marks by any third party of which it becomes aware. Licensor has the sole right, in its discretion, to bring any action or proceeding with respect to any such infringement, dilution, or other conflict and to control the conduct of, and retain any monetary recovery resulting from, any such action or proceeding (including any settlement). Licensees shall provide Licensor with all assistance that Licensor may reasonably request, at Licensor’s expense, in connection with any such action or proceeding.

5. Confidentiality. Each Party acknowledges that in connection with this Agreement it may gain access to information that is treated as confidential by the other Party, including information about the other Party’s business operations and strategies, goods and services, customers, pricing, marketing, and other sensitive and proprietary information ("Confidential Information”). Each Party shall not disclose or use any Confidential Information of the other Party for any purpose other than as reasonably necessary to exercise its rights or perform its obligations under this Agreement; provided that each Party may disclose Confidential Information to the limited extent required to comply with the order of a court or other governmental body, or as otherwise necessary to comply with applicable law, provided that the Party making the disclosure pursuant to the order shall first have given written notice to the other Party and made a reasonable effort to obtain a protective order.

2

6. Warranties and Indemnification.

6.1 Warranties. Licensor makes no representations or warranties of any kind, either express or implied, and assumes no responsibilities whatsoever with respect to the use of Licensed Marks by Licensees.

6.2 Indemnification. Licensees shall, jointly and severally, fully indemnify, defend, and hold harmless Licensor and its Affiliates and their respective directors, officers, agents, representatives, employees, dealers, licensees, licensing agents, and distributors ("Licensor Indemnified Parties”), from any and all losses, damages, expenses, liabilities, judgments, penalties, and costs (including reasonable attorneys’ fees and costs) asserted against or incurred by the Licensor Indemnified Parties with respect to any and all third party claims, actions or suits against them arising out of: (i) any breach of any term of this Agreement by Licensees; or (ii) Licensees’ use of Licensed Marks.

6. General Provisions

6.1 Amendments and Waiver. This Agreement may be amended only by a written instrument executed by the Parties or their respective successors or permitted assigns. The failure of any Party hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of such Party thereafter to enforce each and every such provision. No waiver of any breach of or non-compliance with this Agreement shall be held to be a waiver of any other or subsequent breach or non-compliance.

6.2 Severability. If any provision of this Agreement (or any portion hereof) or the application of any such provision (or any portion thereof) or circumstance shall be held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision hereof (or the remaining portion thereof). Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated in this Agreement are fulfilled to the extent possible. Notwithstanding this Section, in the event that any restriction in this Agreement is too broad to permit enforcement of such restriction to its fullest extent, each Party agrees that a court of competent jurisdiction may enforce such restriction to the maximum extent permitted by law, and each Party hereby consents and agrees that the scope of such restriction may be judicially modified accordingly in any proceeding brought to enforce such restriction.

3

6.3 Notices. All correspondence or notices required or permitted to be given under this Agreement must be in writing, and addressed to the other Party at its address set out on the signature page to this Agreement (or to any other address that the receiving Party may designate from time to time). Each Party shall deliver all notices by personal delivery, nationally recognized overnight courier (with all fees prepaid), facsimile or email (with confirmation of transmission), or certified or registered mail (in each case, return receipt requested, postage prepaid).

6.4 Counterparts. This Agreement may be executed in one or more counterparts (including by facsimile signature or by other electronic means, such as portable document format (.pdf) file) and each counterpart shall be deemed to be an original.

6.5 Construction. This Agreement was negotiated by the Parties with the benefit of legal representation and any rule of construction or interpretation otherwise requiring this Agreement to be construed or interpreted against any Party shall not apply to any construction or interpretation hereof.

6.6 Entire Agreement. The Recitals set forth at the beginning of this Agreement are incorporated by reference and made a part of this Agreement. This Agreement, the Purchase Agreement, the Letter Agreement, dated as of the date hereof, by and between Parent and Buyer, and the Transition Services Agreement constitutes the entire agreement among the Parties to this Agreement and supersedes all other prior agreements and understandings, both written and oral, among or between the Parties with respect to the subject matter hereof and thereof.

6.7 Remedies Not Exclusive. All remedies specified herein shall be cumulative and not exclusive and shall be in addition to any other remedies which any Party may have under this Agreement or otherwise.

[signature page follows]

4

IN WITNESS THEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives who are authorized to bind the respective Parties.

TF Tech Ventures, Inc.

CURE Pharmaceutical Corporation

By:

/s/ C.A. Preston By: /s/ Robert Davidson

Name:

C.A. Preston Name: Robert Davidson

Title:

CEO and President Title: CEO

Address for Notices:

Address for Notices:

1620 Beacon Place

5805 Sepulveda Blvd., #801

Oxnard, CA 93033

Van Nuys, CA 91411

CURE Pharmaceutical Holding Corp.

By:

/s/ Robert Davidson

Name:

Robert Davidson

Title:

CEO

Address for Notices:

5805 Sepulveda Blvd., #801

Van Nuys, CA 91411

5

EXHIBIT A

Licensed Marks

Trademark

Registration No.

C CURE PHARMACEUTICAL

View Filing Data for SEC filing 0001477932-22-005454 (3)

The mark consists of the word "C CURE PHARMACEUTICAL” in a stylized font with the letter "C” connected by varying shades to form a circle.

U.S. Registration No. 5708591

Logo

View Filing Data for SEC filing 0001477932-22-005454 (4)

The mark consists of a stylized letter "C.” The two ends of the "C” are connected by varying shades to form a circle.

U.S. Registration No. 5708589

CUREFILM

The mark consists of standard characters, without claim to any particular font style, size, or color.

U.S. Registration No. 5690125

DELIVERING THE PROMISE OF HEALTHIER LIVES

The mark consists of standard characters, without claim to any particular font style, size, or color.

U.S. Registration No. 6008699

CURE PHARMACEUTICAL

The mark consists of standard characters, without claim to any particular font style, size, or color.

U.S. Registration No. 5708588

6

And the following unregistered trademarks:

1. Powered by CURE

2. CUREdots

3. CUREcream

4. CUREpods

5. CUREdrops

7

EXHIBIT 10.7

EMPLOYMENT AGREEMENT

This Employment Agreement (this "Agreement”), effective as of July 22, 2022 (the "Effective Date”), is made by and between Cure Pharmaceutical Holding Corp., a Delaware corporation (together with its affiliates and any successor thereto, the "Company”), and Joel Bennett (the "Executive”) (collectively referred to herein as the "Parties”).

WHEREAS, the Parties mutually desire to set forth the terms and conditions upon which the Company will compensate Executive for his services as an employee following the Effective Date.

NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows:

1. Employment.

(a) General. From and after the Effective Date, the Company shall employ Executive for the period and in the position set forth in this Section 1, subject to the terms and conditions herein provided.

(b) Employment Term. The term of employment under this Agreement (the "Term”) shall commence on the Effective Date and continue for a period of two years, unless terminated in accordance with Section 3. Following the expiration of the initial Term, the Term shall be extended by one year unless terminated by one of the Parties.

(c) Position and Duties. Executive shall serve as the Chief Financial Officer (CFO) of the Company, with such customary responsibilities, duties and authority normally associated with such position and as may, from time to time, be assigned to Executive consistent with such position. In the performance of such duties, Executive shall report to the Chief Executive Officer. Executive shall devote substantially all of Executive’s working time and efforts to the business and affairs of the Company, provided however, that the Company acknowledges and agrees that Executive shall be permitted to engage in and pursue such contemporaneous activities and interests as Executive may desire personally such as charitable or philanthropic endeavors or otherwise, provided such activities that do not materially interfere with Executive’s performance of his duties and obligations to the Company under this Agreement. Executive agrees to observe and comply with the rules and policies of the Company as adopted by the Company from time to time, in each case as amended from time to time, and as delivered or made available to Executive (each, a "Policy”).

2. Compensation and Related Matters.

(a) Annual Base Salary. Executive shall receive a base salary at a rate of Two Hundred and Twenty Thousand Dollars ($220,000.00) per annum (such annual base salary, as it may be adjusted from time to time, the "Annual Base Salary”). The Annual Base Salary shall be paid in equal installments in accordance with the customary payroll practices of the Company, but no less frequently than monthly, less any withholdings required by law and less any deductions agreed upon by the Company and Executive. The Company’s CEO shall review Executive’s salary at least once a year and with Board approval increase Executive’s salary if an increase is warranted. In Addition, Executive shall be eligible to participate in any and all employee and health benefit plans, including, but not limited to, health, medical, dental, alternative care, chiropractic, and mental health plans; and other employee benefit plans, including, but not limited to, life insurance, disability insurance, savings plans, qualified pension plans, fringe benefits, perquisites, and bonus plans that may be established by the Company from time to time for the benefit of other Company employees of comparable status. The Employee shall be required to comply with the conditions attendant to coverage by such preceding plans and policies and shall comply with and be eligible for benefits only in accordance with the terms and conditions of such plans as they may be amended from time to time.

(b) Expenses. During the Term, the Company shall reimburse Executive for all reasonable travel and other business expenses incurred by Executive in the performance of Executive’s duties to the Company in accordance with the Company’s expense reimbursement Policy.

(c) Options. The Company shall award two hundred thousand (200,000) Options to Executive pursuant to the Company’s 2017 Equity Incentive Plan (the "2017 Plan”) as adopted.

(d) Personal Time Off. Executive shall be entitled to fifteen (15) days of personal time off ("PTO”) per year, which shall accrue weekly. Executive shall take PTO at such time or times as shall be approved by the CEO which approval shall not be unreasonably withheld.

3. Termination.

(a) At-Will Employment. The Parties acknowledge that Executive’s employment during the Term will be at-will, as defined under applicable law, and that Executive’s employment with the Company during the Term may be terminated with or without cause by either party, as applicable under the following circumstances, provided that, in all cases, the termination is subject to all of the severance and equity acceleration terms in this Agreement.

(b) Notice of Termination. Any termination of Executive’s employment by the Company or by Executive under this Section 3 shall be communicated to the other party by a written notice which, if submitted by Executive, shall be no less than thirty (30) days following the date of such notice (a "Notice of Termination”), and shall be deemed to effect termination from all positions held by Executive with the Company and the Subsidiary notwithstanding anything to the contrary in the Notice of Termination; provided, however, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date following the date of Company’s receipt of such Notice of Termination that is prior to the date specified in such Notice of Termination. A Notice of Termination submitted by the Company may provide for a Date of Termination (defined as the last day of Executive’s employment at the Company) on the date Executive receives the Notice of Termination, or any date thereafter elected by the Company in its sole discretion.

(c) No Other Compensation. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided in this Section 3, all of Executive’s rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder, if any, shall cease upon the termination of Executive’s employment hereunder.

(d) Termination Without Cause or Voluntary Termination for Good Reason. In the event the Company terminates Executive’s employment during the Term without Cause (as defined in Section 3(g) below), or in the event of Executive’s voluntary termination of his employment with the Company for Good Reason (as defined in Section 3(d) below), the Executive shall receive Severance Compensation (defined in Section 3(f) below).

2

(e) Good Reason to Resign. Executive has the right to voluntarily terminate employment and collect Severance Compensation if: (i) there is a material diminution in duties, responsibility or authority; (ii) there is a material diminution in the Executive’s Annual Base Salary and/or bonus potential, other than in conjunction with a reduction in salaries or bonus potential affecting all officers of the Company, provided that the percentage of reduction in Executive’s Annual Base Salary and/or bonus potential shall be no larger than the percentage reduction of the officer of the Company receiving the least reduction in base salary and/or bonus potential; (iii) in the event of a change of control there is a relocation of Executive’s principal place of employment that increases Executive’s one-way commute by more than thirty-five (35) miles; or (iv) there is any material breach by the Company of any material provision of this Agreement which shall remain uncured for a period of thirty (30) days following receipt by the Company of notice from Executive within ninety (90) days of the breach, of his intention to resign because of such breach.

(f) Change of Control. Change of Control shall mean the consummation by Company of any transaction (or series of related transactions) of the following events: (a) any third party (or group of third parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock or other ownership interests (as applicable) then outstanding shares normally entitled to vote in elections of directors or equivalent governing body; or (b) the consolidation with or merger into another entity, or any entity consolidating with or merging into Company, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the stock or other ownership interests (as applicable) outstanding of the surviving entity normally entitled to vote in elections of directors or equivalent governing body is not held by the parties holding at least fifty percent (50%) of the outstanding stock or other ownership interests (as applicable) of Company immediately preceding such consolidation or merger, (c) any other arrangement whereby a third party controls or has the right to control the board of directors or equivalent governing body that has the ability to cause the direction of the management or policies of Company or (d) Company shall dissolve, transfer, sell, assign, mortgage, encumber, pledge, or otherwise dispose of (i) all or substantially all of its assets, or (ii) any controlling interest in its business (whether in the form of stock or otherwise).

(g) Severance Compensation. In the event Executive’s employment is terminated by the Company without Cause or by the Executive for Good Reason, (i) Company shall pay Executive and Executive shall accept as severance compensation for the termination of Executive’s services, an amount equal to one (1) weeks’ salary for every month Executive has been employed by Company from the Effective Date up to the Date of Termination for a maximum total severance compensation equal to six (6) months’ salary (at the highest rate of compensation Executive received in the year immediately prior to termination), less applicable deductions. The severance amount shall be paid in equal semi-monthly installments, at the Executive’s current salary rate as of the date of termination, beginning on the first pay period following termination and continuing until the severance amount is paid in full; (ii) Executive’s equity shall be subject to accelerated vesting, 100% immediate vesting in the event of a Change of Control of the Company and one (1) year’s accelerated vesting in the event of involuntary termination without Cause or voluntary termination for Good Reason; (iii) Executive will be granted a post- termination exercise period (the "Exercise Period”) for vested stock options of one (1) year from the anniversary of the Date of Termination; provided that, in the event Company is unable to legally issue stock and/or Executive is unable to legally sell Company stock, then the Exercise Period commences only after such barriers to such purchase and/or sale are removed; (iv) provided Executive timely elects COBRA coverage, the Company shall pay o n e ( 1 ) m o n t h o f Executive’s COBRA premiums directly to the COBRA administrator for every four (4) months that Executive has been employed by Company from the Effective Date up to the Date of Termination for a maximum of three (3) months of Executive’s COBRA premiums, and (v) Executive shall be entitled to continue participating in employee welfare benefit plans described in Section 2(a) in accordance with their terms for the shorter of six (6) months or until such time as Executive becomes eligible to participate in a benefit plan offered by another employer.

3

(h) Cause. For purposes of this Agreement, "Cause” shall mean only the Executive’s: (i) willful, substantial, and repeated refusal to follow a lawful and reasonable directive of the Company’s Board; (ii) willful, substantial, and repeated gross neglect of his obligations to the Company which causes a material economic loss to the Company other than such failure resulting from Employee’s incapacity due to physical or mental illness; or (iii) conviction of a felony crime involving moral turpitude. Executive shall not be terminated for Cause under and (ii) above unless the Board delivers to the Executive a written statement identifying all the ways in which the Board believes Cause exists under (i) and/or (ii), as applicable, and Executive is given thirty (30) days to cure, providing that if Executive cures, Cause shall not exist under (i) and/or (ii), as applicable. Termination of this Agreement in connection with a change in control shall not constitute termination for Cause.

(i) Specified Employee. Notwithstanding any other term in this Agreement, if, at the time of Executive’s "separation from service” within the meaning of Treasury Regulation § 1.409A-1(h) ("Separation”), Executive is a "specified employee,” as defined in Treasury Regulation § 1.409A-1(i), to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under 26 U.S.C. § 409A(a)(2)(B)(i), that portion of Executive’s benefits shall not be provided to Executive before the earlier of (a) six (6) months and one day after Executive’s Separation from the Company, or (b) the date of Executive’s death. All payments deferred pursuant to this section shall be paid in a lump sum to Executive on the date which is six (6) months and one day after Executive’s Separation, or the date of Executive’s death, as applicable, and any remaining payments due under this Agreement shall be paid as required by this Agreement.

4. Restrictive Covenants.

(a) General. Executive acknowledges that the Company has provided, and during the Term, the Company from time to time will continue to provide, Executive with access to its proprietary information. Ancillary to the rights provided to Executive as set forth in this Agreement, the Company’s provision on Confidential Information, and Executive’s agreements regarding the use of same, to protect the value of any Confidential Information, the Parties agree to the provisions (A) against unfair competition, (B) respecting Executive’s use of proprietary information and the protection of such information, and (C) the ownership of inventions developed by Executive in the course of Executive’s engagement or employment by or relationship with the Company, which Executive acknowledges represent a fair balance of the Company’s rights to protect its business and Executive’s right to pursue employment.

(b) Non-competition; Non-solicitation.

(i) Non-competition. Executive shall not, at any time during the Term, directly or indirectly engage in, have any equity interest in, manage or provide services to or operate any person, firm, corporation, partnership or business (whether as director, officer, employee, agent, representative, partner, security holder, consultant or otherwise) that engages in any business that competes with any portion of the Company’s Business (defined below), anywhere in the world.

(ii) Non-solicitation. Executive shall not, at any time during the Restriction Period (as defined below), directly or indirectly, recruit or otherwise solicit or induce any customer, subscriber or supplier of the Company to (A) terminate or reduce its arrangement or business with the Company, or (B) otherwise change its relationship with the Company. Executive shall not, at any time during the Restriction Period, directly or indirectly, either for Executive or for any other person or entity, (x) solicit any employee or independent contractor of the Company to terminate his or her employment or arrangement with the Company, or (y) employ any such individual during his or her employment or engagement with the Company and for a period of twelve months after such individual terminates his or her employment or engagement with the Company.

(iii) Blue Penciling. In the event that the terms of this S ection 4(b) are determined, by a court of competent jurisdiction, to be unenforceable by reason of its duration, geographical scope, breadth or for any other respect, it shall be interpreted to extend only over the maximum period of time for which it may be enforceable, over the maximum geographical area as to which it may be enforceable, or to the maximum extent in all other respects as to which it may be enforceable, all as determined by such court in such action.

4

(c) Proprietary Information and Inventions Agreement. The Parties have executed the Company’s standard Proprietary Information and Inventions Agreement, which agreement is incorporated herein by reference (the "Proprietary Information and Inventions Agreement”). Executive agrees to perform each and every obligation of hers therein contained.

(d) Return of Property. Upon termination of Executive’s employment with the Company for any reason, Executive shall promptly deliver to the Company all correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial documents, or any other documents or property concerning the Company’s customers, business plans, marketing strategies, products, property or processes.

(e) Non-Disparagement. Each party agrees, during the Term and following the Date of Termination, to refrain from Disparaging (as defined below) the other party and its affiliates, including, in the case of the Company, any of its services, technologies or practices, or any of its directors, officers, agents, representatives or stockholders, either orally or in writing. Nothing in this paragraph shall preclude either party from making truthful statements that are reasonably necessary to comply with applicable law, regulation or legal process, or to defend or enforce a Party’s rights under this Agreement. For purposes of this Agreement, "Disparaging” shall mean remarks, comments, or statements, whether written or oral, that impugn the character, integrity, reputation or abilities of the person or entity being disparaged.

(f) Definitions. As used in Section 4, (i) the term "Company” shall include the Company and its direct and indirect parents and subsidiaries; (ii) the term "Business” shall mean the business of the Company, specifically, drug delivery, as such business may be expanded or altered by the Company during the Term; and

(iii) the term "Restriction Period” shall mean the period beginning on the Effective Date and ending on the date that is twelve (12) months following the Date of Termination.

(g) Rights and Remedies Upon Breach. It is recognized and acknowledged by Executive that a breach of the covenants contained in this Section 4 will cause irreparable damage to Company and its goodwill, the exact amount of which will be difficult or impossible to ascertain, and that the remedies at law for any such breach will be inadequate. Accordingly, Executive agrees that in the event of a breach of any of the covenants contained in this Section 4, in addition to any other remedy which may be available at law or in equity, the Company shall be entitled to seek specific performance and injunctive relief. In addition, in the event Executive breaches any of the provisions of this Section 4, the Company shall be entitled to immediately cease all payments under Section 2 above.

(h) Acknowledgment by Executive. Executive has carefully read and considered the provisions of this Section 4, and, having done so, acknowledges and agrees that the restrictions set forth in this Section 4, including, but not limited to, the Restriction Period, are fair and reasonable and are reasonably required for the protection of the interests of the Company and its parent or subsidiary corporations, officers, directors, shareholders, and all other employees of the Company.

5. Assignment and Successors.

The Company may assign its rights and obligations under this Agreement to any affiliate or successor, all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributors, devisees, and legatees, as applicable. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only by will or operation of law.

5

6. Miscellaneous Provisions.

(a) Governing Law; Venue. This Agreement shall be governed, construed, interpreted, and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of California without reference to the principles of conflicts of law of the State of California or any other jurisdiction, and where applicable, the laws of the United States. Any suit brought hereon shall be brought in the state or federal courts sitting in Los Angeles, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. The Parties hereby agree that any such court shall have in person jurisdiction over it and consents to service of process in any manner authorized by California law.

(b) Validity. The invalidity or unenforceability of any provision(s) of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

(c) Notices. Any notice, request, claim, demand, document and other communication hereunder to either party shall be effective upon receipt (or refusal of receipt), and shall be in writing and delivered personally or sent by email, facsimile or certified or registered mail, postage prepaid, as follows:

(i) If to the Company:

Cure Pharmaceutical Holding Corp.

5805 Sepulveda Blvd., Suite #801, Van Nuys, California 91411

Attention: Chief Executive Officer

(ii) If to Executive, at the last address that the Company has in its personnel records for Executive.

(d) Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile shall be deemed effective for all purposes.

(e) Entire Agreement. The terms of this Agreement, together with the Proprietary Information and Inventions Agreement and any other agreements referenced in this Agreement (i.e., the 2017 Plan and the Bonus Plan), which are all incorporated by reference, are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including, without limitation, any offer letter, employment or consulting agreement between the Company and Executive; however, Executive hereby reaffirms his obligations under any previous confidentiality, assignment of inventions or noncompetition agreement with the Company and agrees that this Agreement does not supersede or modify any continuing obligations thereunder. The Company shall be entitled to enforce any and all such agreements against Executive to ensure that the Company receives the benefit of all such agreements. To the extent any provisions of any other agreement between the parties conflicts with the terms of this Employment Agreement, the terms of this Agreement shall prevail. The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. This Agreement shall be interpreted to comply with the requirements of I.R.C. § 409A, and, if necessary, the parties will work in good faith to amend the Agreement to comply with § 409A.

6

(f) Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.

(g) No Inconsistent Actions. The Parties hereto shall not voluntarily undertake or fail to undertake any action or course of action inconsistent with the provisions or essential intent of this Agreement. Furthermore, it is the intent of the Parties hereto to act in a fair and reasonable manner with respect to the interpretation and application of the provisions of this Agreement.

(h) Arbitration. The Parties agree to submit any and all disputes, controversies, or claims based upon, relating to, or arising from Executive’s employment with the Company (other than workers’ compensation claims) or the terms, interpretation, performance, breach, or arbitrability of this Agreement to final and binding arbitration before a single neutral arbitrator in Los Angeles County, California. Subject to the terms of this paragraph, the arbitration proceedings shall be initiated in accordance with, and governed by, the National Rules for the Resolution of Employment Disputes ("Rules”) of the American Arbitration Association ("AAA”). The arbitrator shall be appointed by agreement of the Parties hereto or, if no agreement can be reached, by the AAA pursuant to its Rules. Notwithstanding the Rules, the Parties may take discovery in accordance with Sections 1283.05(a)-(d) of the California Code of Civil Procedure, and prior to the arbitration hearing the Parties may file, and the arbitrator shall rule on, pre-trial motions such as demurrers and motions for summary judgment (applying the procedural standard embodied in Rule 56 of the Federal Rules of Civil Procedure). The time for filing such motions shall be determined by the arbitrator. The arbitrator will rule on all pre-trial motions at least ten (10) business days prior to the scheduled hearing date. Arbitration may be compelled, the arbitration award shall be enforced, and judgment thereon shall be entered, pursuant to the California Arbitration Act (Code of Civil Procedure §§ 1280 e t seq.). Each party shall bear his, her or its own attorneys’ fees and costs (including expert witness fees) incurred in connection with the arbitration, unless the arbitrator finds that a statutory award of attorneys’ fees is appropriate. The Company shall bear AAA’s administrative fees and the arbitrator’s fees and costs. If either party is required to compel arbitration of a dispute governed by this paragraph, the prevailing party shall be entitled to recover from the other party reasonable costs and attorneys’ fees incurred to compel arbitration. This Section 6(i) is intended to be the exclusive method for resolving any and all claims of the Parties against each other for payment of damages under this Agreement or relating to Executive’s employment or service.

(j) Enforcement. If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws effective during the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be legally possible, valid and enforceable.

7

(k) Withholding. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding arise.

(l) Survival. This Section 6(l) and the covenants, agreements, representations and warranties contained in or made in Sections 2(c), 3(c), 4 and 6, and in the last sentence of Section 3(e), shall survive the expiration or any termination of this Agreement for any reason.

(m) Indemnification. Company shall indemnify Executive to the fullest extent permitted by law for all claims, allegations, investigations, or settlements of any kind brought or alleged to be brought against Executive, at any time, for any act or omission in any way related to Executive’s service to the Company, and in connection with this obligation, the Company shall immediately advance all costs and expenses, including attorneys’ fees, to Executive at any time Executive demands an advancement of costs and/or expenses. The Company’s obligation to indemnify Executive shall be construed as broadly as possible.

(n) Insurance. Executive’s position shall be specifically covered by all of the Company’s directors and officers, employment liability, and errors and omissions insurance policies (and all substantially similar insurance policies) so that Executive is fully covered by all policies at all times during and after Executive’s employment.

(o) Mitigation. Executive shall have no duty to mitigate any breach by the Company of this Agreement.

7. Executive Acknowledgement.

Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has freely entered into this Agreement based on Executive’s own judgment.

[Signature Page Follows]

8

IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have duly executed this Agreement as of the Effective Date.

Cure Pharmaceutical Holding Corp.

Company

Joel Bennett

Executive

/s/ Nancy Duitch /s/ Joel Bennett
Nancy Duitch Joel Bennett
Chief Executive Officer
9

EXHIBIT 99.1

CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million

Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology

OXNARD, Calif. – PR NEWSWIRE – July 28, 2022 – CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 million in total consideration. CURE used a portion of the cash proceeds to pay down certain debt obligations and the balance will be used to grow its intellectual property portfolio and its wellness and beauty brands. In addition, CURE retained its remaining proprietary platform technology that it intends to monetize through the commercialization of the technology or through the licensing or sale of the technology.

CURE will host a conference call on August 3, 2022 to provide a full corporate update to shareholders. Details of the conference call will be made available on August 1, 2022 in a follow-up press release.

For additional information, see the Current Report on Form 8-K relating to the transactions described above, which will be filed with the Securities and Exchange Commission and available on CURE’s corporate website at: www.curepharmaceutical.com/investors/sec-filings/.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the United States, China, Mexico, Canada, Israel, and other markets in Europe.

About The Sera Labs, Inc.

The Sera Labs, Inc. ("Sera Labs”), a wholly-owned subsidiary of CURE, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology.SeraLabscreates high quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™ SeraLabs™, and Nutri-Strips™.SeraLabssells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, and health & wellness,SeraLabsproducts are sold in major national drug, grocery chains, convenience stores and mass retailers. CURE and Sera Labs also sell products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow Sera Labs on Instagram at @seratopical, as well as Twitter and Facebook.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information

Contacts

Investor Relations

Jim Hock

(818) 516-3432

investor@curepharmaceutical.com

2

FAQs

How many copies should be submitted to SEC? ›

All applications and supporting documents must be in four (4) copies and in A4 size bond paper with a cover sheets.

How do I save a SEC file as a PDF? ›

From respective application select the File menu –> Print – this not the same as the "Save to PDF" option 2. Select "Adobe PDF" as the printer 3. You will be prompted to save the file 4.

Can you download from EDGAR? ›

All companies, foreign and domestic, are required to file registration statements, periodic reports, and other forms electronically through EDGAR. Anyone can access and download this information for free.

Where can I download SEC forms? ›

SEC.gov | Forms List.

How long does SEC approval take? ›

reviews a company's registration statement to ensure compliance with SEC disclosure rules and federal securities laws, and to elicit clear and balanced disclosure to investors. The typical timeframe for the SEC review is between 90 to 150 days.

How many copies of audited financial statements are submitted to the SEC? ›

Corporations shall submit three (3) copies of each report or four (4) copies if they wish to receive a return copy. The SEC advised the public to submit their reports through couruer or registered mail only upon easing or lifting of travel restrictions.

Does SEC EDGAR have filings in PDF format? ›

EDGAR supports fillings with attached unofficial Portable Document Format (pdf) documents.

How do I download a 10k? ›

Downloading a 10-K into an Excel File from SEC.gov - YouTube

How do you EDGARize a document? ›

EDGARize a PDF
  1. Open the filing you want to add your PDFs to and go to the Collect step.
  2. Click Upload to add a PDF from your computer. ...
  3. After you add or upload your PDF, select the "File this PDF as an exhibit" option in the dialog and click Add.
  4. Use the generate as drop-down menu to select EDGAR PDF.
22 Dec 2021

How do you download EDGAR filings as Excel? ›

Export a single filing table
  1. Look up your filing through the SEC filing search or the list of filings on each company page. Click the 'Notable SEC filings ...' if you're looking for filings other than 10-K, 10-Q, and 8-K.
  2. Find the table you would like to export.
  3. Click the XLSX button.
  4. Your table is downloaded.

How do I get access to EDGAR? ›

Individuals or companies requesting access to EDGAR must complete online on the EDGAR Filer Management website a form known as the Uniform Application for Access Codes or Form ID.

Are SEC filings public information? ›

Yes, SEC filings are public information and can be retrieved for free via the EDGAR system online.

How do I get a general information sheet from the SEC? ›

The public may call Hotline Number 737-8888 for requests, mode of payment and courier delivery of the requested documents/s nationwide. The public may schedule an appointment when to go to SEC to make their request for document/s. The request shall then be accompanied at the appointed date and time.

What is SEC file number? ›

Reporting File Number. This is a number with an 811- prefix assigned to filers registered under the Investment Company Act of 1940. CIK. The Central Index Key (CIK) is a ten digit number assigned by the SEC to each entity that submits filings.

How do you check if the business is registered in SEC? ›

For Primary SEC Registration, you may visit the Philippine Securities and Exchange Commission (SEC) official website at www.sec.gov.ph. Proceed to Online Services, then Search Registered Names.

How long is the validity of SEC registration? ›

The five-year period shall commence from the date of the aforesaid approval by the Securities and Exchange Commission.

How long does it take for a company to go public after filing? ›

Once a privately held company is prepared to go public, the formal process typically takes six months.

How long does it take for a startup to go public? ›

High fiscal impact IPOs tend to happen within a dozen years of a firm's founding. The most common time frame for high-impact IPOs is 8 to 10 years from founding. The amount of time from founding to IPO has increased somewhat in recent years.

Does the SEC require audited financial statements? ›

The federal securities laws require publicly held companies that file reports with the SEC to submit financial statements that are accurate, truthful, and complete and prepared according to a set of accounting standards called "Generally Accepted Accounting Principles" (or "GAAP").

Who are not required to file audited financial statements? ›

As long as your annual gross revenues do not exceed P3 million, you are qualified for optional 8% income tax and required to use BIR Form 1701A in filing your annual income tax return. If you are qualified for optional 8% income tax, you are not required to submit a financial statement.

Where can I find financial data for a company? ›

Financial information can be found on the company's web page in Investor Relations where Securities and Exchange Commission (SEC) and other company reports are often kept. The SEC has financial filings electronically available beginning in 1993/1994 free on their website. See EDGAR: Company Filings.

What does it mean to Edgarize a document? ›

What exactly does EDGARization mean? EDGARization is the process of converting parent documents - MS Word, MS Excel, PDF, Word Perfect, etc - into acceptable SEC EDGAR ASCII or HTML format. Once EDGARized, the documents can be submitted to the SEC via the EDGAR system.

What is an invalid PDF tag? ›

One of the most common reasons for a suspended Form ID or Passphrase Update is an “Invalid PDF tag”. This means that a PDF had underlying text, active JavaScript or form fields that couldn't be read by the EDGAR system.

Does the SEC have an API? ›

The SEC announced an API (Application Programming Interface) is now available on data.sec.gov, making corporate disclosures quicker and easier to access.

Where can I find a company's 10-K report? ›

To find a particular company's Form 10-K filings, use the Company Search for the SEC's EDGAR database.

What is included in a 10-K report? ›

Information in the 10-K includes corporate history, financial statements, earnings per share, and any other relevant data. The 10-K is a useful tool for investors to make important decisions about their investments.

Is EDGAR Online Free? ›

Who has access to EDGAR's information? Access to EDGAR's public database is free—allowing you to research, for example, a public company's financial information and operations by reviewing the filings the company makes with the SEC.

How do I upload a PDF to Wdesk? ›

Go to Files in Home and choose the Upload button next to the search bar. To upload to a specific folder, right-click on a folder. Hover over Create and choose Upload. Browse for your PDF and use the drop-down to choose where to put the file.

How do I convert XBRL to Excel? ›

How to convert xbrl files
  1. Click inside the file drop area to upload a xbrl file or drag & drop a xbrl file.
  2. Your xbrl file will be uploaded and will be converted to other format.
  3. Download link of result file will be available instantly after conversion.
  4. You can also send a link to the xbrl file to your email address.

What is the EDGAR database? ›

EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system, performs automated collection, validation, indexing, acceptance, and forwarding of submissions by companies and others who are required by law to file forms with the U.S. Securities and Exchange Commission (SEC).

How do I extract financial statements in Excel? ›

Moving your financial statements into Excel Follow
  1. Export your plan to Word.
  2. Navigate to the tables in the Word document that you wish to convert into a spreadsheet, and select all of the rows you want to include.
  3. Copy the selection:
  4. Open an Excel spreadsheet, select any cell, and paste the selection from your clipboard.
25 Aug 2022

What are EDGAR access codes? ›

EDGAR access codes are generated by the SEC upon acceptance of the Form ID. These codes are used to identify a company or individual and also enable a filer to access the EDGAR system and submit filings.

Do EDGAR codes expire? ›

The EDGAR password expires annually, 12 months after it was created or last changed, and must be changed before the expiration date.

How do I find my EDGAR EIN number? ›

If you are a business owner, you can call the IRS at 800-829-4933, Monday through Friday. You'll be required to complete the telephonic verification to receive the EIN details. If you are an employee or a contractor or have some other legal right to receive the EIN details, you can call your local IRS service.

What is SEC I view? ›

The SEC i-View is an online pay-per-use facility that gives the public the convenience of getting copies of documents (Annual Financial Statement, General Information Sheet, and others). The facility allows the general public, other government and private entities to view and print company reports for a fee.

What is included in SEC filings? ›

SEC Filings Form 10-K

It includes a detailed summary of the company's results, management discussions, and audited financial statements. Companies are required to submit this filing within 90 days after the end of their fiscal year.

Do private companies have to report to the SEC? ›

Unlike public companies, private companies are not required to file with the Securities and Exchange Commission (SEC), so the type of information and the depth of information that can be found in those documents is not necessarily going to be available for private companies.

What are SEC reporting requirements? ›

SEC rules require your company to file annual reports on Form 10-K and quarterly reports on Form 10-Q with the SEC on an ongoing basis. These reports require much of the same information about the company as is required in a registration statement for a public offering.

What are the requirements for SEC? ›

Register with the Securities and Exchange Commission (SEC)

Name Reservation and Payment Form. Notarized Articles of Incorporation and By-laws. Treasurer's Affidavit. Bank Certificate of Deposit or Proof of Inward Remittance.

What disclosures are required by the SEC? ›

SEC regulations require that annual reports to stockholders contain certified financial statements and other specific items. The certified financial statement must include a two-year audited balance sheet and a three-year audited statement of income and cash flows.

Do all companies need to file with the SEC? ›

Even if a company doesn't have to register its securities for an offering, it still may have to file reports with the SEC if the company lists its securities on an exchange or has more than $10 million in assets and a class of equity securities with either 2,000 or more record holders or 500 or more record holders that ...

Are SEC filings public information? ›

Yes, SEC filings are public information and can be retrieved for free via the EDGAR system online.

Why are SEC filings important? ›

SEC filings are useful as they provide updates from companies, as well as key financials. The "Financial Statements and Supplementary Data" section represents the meat and potatoes of the 10-Q and 10-K, providing a comprehensive financial overview.

What information is required to be disclosed to investors? ›

Both federal and state laws require companies conducting a securities offering to tell each potential investor all material information about the company, its principals, and the investment opportunity (including the risks of the investment) that a reasonable person would want to know in order to make an informed ...

How long is the validity of SEC registration? ›

The five-year period shall commence from the date of the aforesaid approval by the Securities and Exchange Commission.

How do I check my SEC registration status? ›

The facility is available 24/7, accessible from any device – desktop, phone or tablet, anytime and anywhere. Simply access the CRS Application Status Online Inquiry with URL: http://crsquery.sec.gov.ph/ and log in using the email address for CRS and transaction number.

Does the SEC require audited financial statements? ›

The federal securities laws require publicly held companies that file reports with the SEC to submit financial statements that are accurate, truthful, and complete and prepared according to a set of accounting standards called "Generally Accepted Accounting Principles" (or "GAAP").

What fact would be considered a material defect that must be disclosed? ›

Examples of material facts that must be disclosed include structural problems with the house, soil problems, a leaking roof, unpermitted construction, neighborhood noise problems, and anything else that a buyer would deem to be important.

What is the disclosure rule? ›

The Disclosure Rule asks if you would be comfortable with all your family and friends knowing about the action you propose to take. Would you be comfortable reading about what you are about to do on the front page of The Wall Street Journal or the local paper, or seeing it on Facebook?

Which three reports are mandatory for every public company to file? ›

Companies subject to Public Company SEC Reporting Requirements must file Annual Reports on Form 10-K, Quarterly Reports on Form 10Q's and Current Reports on Form 8-K.

Do private companies have to register with SEC? ›

Registration of securities under the Securities Exchange Act of 1934 is something that many private companies have put out of their minds until the market improves. However, for private companies with over 500 stockholders or option holders, registration under the Exchange Act is a requirement, not a choice.

Which types of companies must register with the SEC? ›

In general, all securities offered in the United States must be registered with the SEC or must qualify for an exemption from the registration requirements.

Top Articles

You might also like

Latest Posts

Article information

Author: Catherine Tremblay

Last Updated: 10/07/2022

Views: 6068

Rating: 4.7 / 5 (67 voted)

Reviews: 90% of readers found this page helpful

Author information

Name: Catherine Tremblay

Birthday: 1999-09-23

Address: Suite 461 73643 Sherril Loaf, Dickinsonland, AZ 47941-2379

Phone: +2678139151039

Job: International Administration Supervisor

Hobby: Dowsing, Snowboarding, Rowing, Beekeeping, Calligraphy, Shooting, Air sports

Introduction: My name is Catherine Tremblay, I am a precious, perfect, tasty, enthusiastic, inexpensive, vast, kind person who loves writing and wants to share my knowledge and understanding with you.